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Abstract 
Nickel-Catalyzed Oxidative Decarboxylative 
(Hetero)Arylation Reactions 
Aaron Honeycutt 
  Transition-metal-catalyzed decarboxylative coupling reactions have gained 
considerable attention over the past decade as an efficient route to form heterobiaryls. 
However, current methods for oxidative decarboxylative (hetero)arylation with 
unactivated CH bonds have been limited by poor substrate scope, control of 
regioselectivity, and chemospecificity. This thesis describes the development of a new 
nickel-catalyzed oxidative decarboxylative coupling (ODC) with unactivated CH bonds.  
The first chapter discusses the development of the new nickel-catalyzed ODC reaction to 
enable the coupling of a N,Nbidentate directing group with a broad scope of 
heteroaromatic carboxylates and ortho-substituted benzoates, a scope that has not been 
achieved in previous oxidative decarboxylative coupling transformations. The following 
chapter is an extension of the nickel-catalyzed ODC reaction for the synthesis of 
heterocycle-containing phenanthridinones. This chapter details an oxidative 
decarboxylative annulation with heteroaromatic carboxylates and ortho-fluorobenzoates. 
The final chapter describes the investigation and attempted synthesis of a proposed Ni(II) 
metallacycle from our catalytic cycles in the previous chapters. Synthesis of a Ni(II) 
metallacycle by denitrogenation of 3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin 
‐4‐one led to an interesting azanickelacycle dimer. However, decarbonylation of a 2-
(quinolin-8-yl)-2,3-dihydro-1H-isoindole-1,3-dione led to the desired five-membered 
metallacycle. Each of these chapters represents the challenges to developing an oxidative 
decarboxylative arylation with unactivated CH bonds with a first-row transition metal. 
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C h a p t e r  1 :  I n t r o d u c t i o n  
1.1.  Traditional Cross-Coupling Systems for Unsymmetrical Biaryls  
  Transition-metal-catalyzed cross-coupling reactions have gained considerable attention 
over the past thirty years for the construction of unsymmetrical biaryls.
1 
These well-
known reactions such as the Suzuki-Miyaura,
 2
 Kumada, Negishi,
3
 and Mizoroki-Heck
4
 
coupling reactions were developed for building various unsymmetrical biaryls (Scheme 
1).
5
 These reactions have allowed chemists to  construct complex pharmaceutical building 
blocks, increase industrial process development, and advance material sciences. 
However, these traditional cross-coupling methods require prefunctionalized aryl halide 
or pseudohalide coupling partners thereby resulting in poor atom- and step-economy. On 
the contrary, decarboxylative coupling reactions for biaryl formation would eliminate the 
need for prefunctionalized aryl halide or pseudohalide coupling partners because, 
carboxylic acids are ubiquitous in nature, commercially available in a large scope, and 
easy to handle. 
  2 
Scheme 1. Traditional transition-metal-catalyzed cross-coupling for the synthesis of 
biaryls. 
1.2. Decarboxylative Coupling Reactions for the Synthesis of Biaryls 
  The first reported decarboxylative Ullmann-type coupling for the synthesis of biaryls 
was from Nilsson in 1966.
6
 Nilsson found that benzoic acids undergo decarboxylative 
coupling in the presence of stoichiometric amounts of copper and aryl iodides (Scheme 
2). However, the reaction was limited to only ortho-nitrobenzoic acids and product yields 
were low due to harsh reaction conditions. However, this new method demonstrated the 
viability of using benzoic acids as nucleophilic coupling partners.  
  3 
 
Scheme 2. Decarboxylative Ullmann coupling for the synthesis of biaryls with copper. 
  The first catalytic decarboxylative cross-coupling reaction was not reported until forty 
years later. In 2006, Goossen and co-workers reported the first example of a bimetallic 
palladium/copper-catalyzed redox neutral decarboxylative cross-coupling of aromatic 
carboxylic acids with aryl halides (Scheme 3).
7
 This new method afforded unsymmetrical 
biaryls in good yields. However, this system is limited to ortho-substituted benzoic acids 
such as the 2-nitro, 2-fluoro, 2-methoxy, and 2-acetylbenzoic acids, for example. 
 
Scheme 3. A bimetallic redox-neutral decarboxylative coupling of aryl halides with 
benzoic acids. 
  4 
  Though Goossen and co-workers disclosed the first catalytic redox-neutral 
decarboxylative coupling, this reaction still requires the use of prefunctionalized aryl 
halides and pseudohalides as coupling partners. Efforts that are more recent have led to 
oxidative variants of these coupling reactions which would enable the coupling of arene 
CH bonds thereby eliminating prefuntionalized coupling partners. In 2008, Crabtree and 
co-workers reported the first Pd-catalyzed intermolecular and intramolecular 
decarboxylative arylation of CH bonds.8 Following this seminal work, other groups 
such as Larrosa
9
, Tan
10
, and Su
11
 have developed related oxidative decarboxylative 
coupling (ODC) reactions with CH bonds (Scheme 4) and have found that the strategies 
are typically limited in their substrate scope. 
 
Scheme 4. Oxidative decarboxylative couplings with activated CH bonds. 
  The majority of oxidative decarboxylative couplings employ Pd catalysts. However, 
most of these catalyst systems are limited to ortho-substituted benzoic acids. The 
  5 
decarboxylative coupling of heteroaromatic carboxylic acids would be attractive as 
heterobiaryl structures are common motifs in pharmaceutically relevant compounds,
12
 
and the corresponding esters are the direct products of traditional heterocycle syntheses.
13
 
Notably, Greaney
14
 and Su
15
 reported the first ODC reactions of heteroaromatic acids; 
yet, they were limited to reactions with activated CH bonds such as oxazoles and 
thiophenes. A silver-mediated oxidative decarboxylative CH arylation that enables the 
coupling of pyridine carboxylic acids through a radical pathway has also been reported 
by Su, but shows poor regioselectivity (Scheme 5).
16
 
Scheme 5. Selected examples of oxidative decarboxylative coupling reactions of 
heteroaromatic carboxylic acids. 
  Recently, there has been interest in replacing noble-metal catalysts with base-metals in 
ODC reactions. However, many of these reactions that use copper-
17
 or nickel-
42
 catalysts 
are again limited to the coupling of 2-nitrobenzoic acids and pentafluorobenzoic acids 
with arenes bearing activated CH bonds. The one exception is a recent report of a 
copper-catalyzed ODC reaction from Shi and co-workers.
18
 They found their reaction 
  6 
method would couple 2-thiophene carboxylic acids. However, during their mechanistic 
studies they found the reaction proceeded through a protodecarboxylation and 
dehydrogenative coupling with complete loss of chemospecificity. Overall, these reaction 
methods that enable the oxidative decarboxylative heteroarylation of CH bonds with a 
base metal are limited to a specific class of heteroaromatics such as thiophene, azoles, 
and nicotinic carboxylic acids (Scheme 6). 
Scheme 6. Oxidative decarboxylative coupling with base metal catalysts. 
  Decarboxylative arylation reactions have similar limitations with respect to the CH 
coupling partner. As mentioned earlier, these reactions are often specific  to couplings of 
electronically activated CH bonds such as oxazoles and thiazoles. Efforts to enable the 
decarboxylative arylation of unactivated CH bonds are limited. The Crabtree group8 and 
Glorius
19
 group reported early examples of oxidative decarboxylative coupling reactions 
with unactivated CH bonds; yet, both of these transformations form regioisomeric 
product mixtures. It was not until 2009 that Yu and co-workers reported the first Pd-
catalyzed decarboxylative arylation of arenes using 2-phenylpyridine and electron-
  7 
deficient aryl acylperoxides (Scheme 7).
20
 Although this reaction allowed the installation 
of a broader scope of arenes not seen in previous ODC systems, the required aryl acyl 
peroxides are commercially limited and potentially dangerous.  
 
Scheme 7. Oxidative decarboxylative coupling with unactivated CH bonds. 
  Two copper systems have been reported recently that enable the decarboxylative 
coupling with arenes bearing benzamide directing groups. The  first, from Shi
18
 and co-
workers (Scheme 6), is specific to the coupling of 2-thiophene carboxylic acids through a 
tandem protodecarboxylation-dehydrogenative coupling pathway resulting in the loss of 
regiospecificity of the acids. More recently, Miura and co-workers have reported a 
copper-mediated ODC reaction of benzamides, however, their reaction suffers from 
limitations in the acid coupling partner, and efficient coupling is only achieved with 2-
nitrobenzoic acids (Scheme 8).
65
 
  8 
Scheme 8. Copper-mediated ODC reaction with unactivated CH bonds and 2-
nitrobenzoic acids. 
  There are currently no examples of a catalytic oxidative decarboxylative arylation of 
unactivated CH bonds capable of coupling a broad scope of (hetero)aromatic carboxylic 
acids. However, this thesis will later discuss the development of a new reaction method 
that overcomes these limitations by paring a base metal with a silver oxidant that will be 
discussed in Chapters 2 and 3. 
1.3. Transition-Metal Catalyzed Directing Group Assisted CH Activation 
  During the last decade, CH functionalization has been used as an invaluable 
technique for the installation of a plethora of functional groups in complex molecules.
21
 
Due to the high bond-dissociation energy of a CH bond (110 kcal mol-1), transition 
metals are commonly used. The activation and functionalization of inert CH bonds with 
a transition metal offers an atom- and step-economical path towards building new 
methodologies in cross-coupling reactions. Recently, research groups have used the 
directing group (DG) approach for the activation of these inert CH bonds. In this 
approach, the transitional metal catalyst coordinates to the monodentate directing group, 
increasing the reactivity due to precoordination and facilitates the formation of a 
thermodynamically stable metallacycle (Scheme 9).
22
 This method has been applied not 
only to the formation of carbon-carbon bonds, but also carbon-heteroatom bonds. 
  9 
Scheme 9. CH activation and functionalization with directing groups and a transition 
metal. 
  Early development of a directed cyclometalation of CH bonds with a group 10 metal 
was reported by Kleiman and Dubeck.
23
 They found that when NiCp2 as treated with 
azobenzene the formation of the cyclometalated complex cyclopentadienyl [o-
(phenylazo)phenyl]nickel resulted (Scheme 10, Cp = cyclopentadienyl). Following this 
work, Cope and co-workers reported a related cyclometalation of azo compounds using 
PdCl2.
24
  
 
Scheme 10. First reported nickel metallacycle by CH activation. 
 Building on these early pioneering works, many groups have focused on developing 
new methodologies for CH functionalization using more sustainable and cost-effective 
first-row transition metals, such as Co, Ni, Fe, and Cu. However, there are fundamental 
challenges that first row transition metals face compared to their second and third row 
counter parts. First row transition metals have weaker M-C bonds making the catalytic 
system difficult to control upon CH activation.25 In addition, CH activation with first 
row-metals can be more complicated since these metals are prone to single electron 
oxidations.  
  To overcome these issues, many groups have used tethered bidentate directing groups 
made from benzoic acid derivatives with first row-metals. These bidentate directing 
  10 
groups allow for improved CH activation because: 1) they increase the reactivity 
because of the higher effective concentration of the catalyst at the site of interest 2) 
facilitate the formation of a thermodynamically stable metallacycle upon CH activation 
and 3) the metallacycle intermediate is stabilized in higher oxidation states after CH 
activation (Scheme 11).
26, 27
  
 
Scheme 11. Bidentate CH activation and functionalization with a transition metal. 
  Recently, nickel catalysis has received increasing attention due to its promising 
reactivity with CH bonds. This evidence has been shown in several examples in 
literature for forming CC32, CN28, and CS29 bonds utilizing a directing group.  Initial 
progress in CH functionalization reactions catalyzed by nickel are limited to the 
activation and coupling of specific activated CH bonds such as polyfluorinated benzene, 
azoles, and pyridine derivatives.
30
 However, examples of nickel-catalyzed activation of 
unactivated CH bonds are limited. In 2011, Chatani and co-workers reported the first 
nickel-catalyzed functionalization of unactivated CH bonds using a N,N-bidentate 
directing group.
31
 This led to the development of a variety of different transformations 
such as, arylation,
32
 alkynylation,
33
 alkylation,
34
 halogenation,
35
 dehydrogenative 
coupling,
36
 and allylation (Scheme 12).
37
 
  11 
Scheme 12. Selected examples of nickel-catalyzed directed CH functionalization 
reactions. 
  We envisioned using a base metal in the presence of a N,N-bidentate directing group 
to help facilitate the functionalization of inert CH bonds for decarboxylative coupling. 
After many attempts, we finally succeed in developing a new method for the oxidative 
decarboxylative (hetero)arylation of unactivated CH bonds later discussed in the 
following chapters. 
 
Scheme 13. The targeted ODC reaction of unactivated CH bonds with (hetero)aromatic 
acids and first-row transition metal catalyst. 
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C h a p t e r  2 :  ( H e t e r o ) A r y l a t i o n  o f  U n a c t i v a t e d  C - H  
B o n d s  b y  O x i d a t i v e  D e c a r b o x y l a t i v e  C o u p l i n g  
2.1. Overview 
 As seen in Chapter 1, oxidative decarboxylative couplings are becoming an attractive 
alternative to their redox-neutral counter parts. We initially set our goal of achieving an 
oxidative decarboxylative (hetero)arylation with unactivated CH bonds with 
heteroaromatic carboxylic acids, since, heterobiaryls can be found in many 
pharmaceuticals, agrochemicals, and material sciences.
38
 We hypothesized that an 
unactivated CH bond could be functionalized with a heteroaromatic carboxylic acid in 
the presence of a base metal catalyst and oxidant (Scheme 14). 
 
Scheme 14. Targeted goal of achieving an oxidative decarboxylative arylation with 
unactivated CH bonds. 
2.2. Results 
2.2.1. Condition Optimization for Nickel-Catalyzed Oxidative Decarboxylative 
(Hetero)Arylation 
 We initially designed our reaction using 2-methyl-N-(quinolin-8-yl)benzamide (1a) and 
4-methyl-2-phenyl-1,3-thiazole-5-carboxylate (2a) in the presence of a catalyst and 
oxidant. We began using a copper catalyst since copper salts have been shown to undergo 
a directed CH arylation39 and enable the decarboxylation of a broad scope of benzoic 
acids.
40
 However, all attempts to use copper for this transformation were unsuccessful 
(Table 2.1 entry 1). Surprisingly, Ni salts were found to generate the desired ODC 
product in high yield when compared to copper (Table 2.1 entry 2). The use of 
Ni(OAc)2•4H2O was found to be the most effective pre-catalyst which generated the 
desired ODC product in 45% yield (Table 2.1 entry 3). We then found that using pivalic 
acid as an additive increased the yield from 45% to 64% (Table 2.1 entry 5). Finally, 
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when the loading of 4-methyl-2-phenyl-1,3-thiazole-5-carboxylate (2a) was lowered 
from 5 equiv to 3 equiv we were able to achieve quantitative yields of the desired ODC 
product. In contrast, when there is no nickel or silver present in the reaction, no desired 
product is formed (Table 2.1 entry 7 and 8). Therefore, our final optimized conditions 
consisted of 20 mol% of Ni(OAc)2•4H2O, Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), and 
PivOH (1.5 equiv) in DMA at 110 C for 24 h. This finding was quite interesting because 
nickel salts have been shown to be effective catalyst for directed CH activation.41 
However, their use in oxidative decarboxylative arylations have been shown in only two 
previous examples, both of which are limited to the reactions of 2-nitro- and 
pentafluorobenzoic acids with activated CH bonds.42 
Table 2.1. Optimization for oxidative decarboxylative (hetero)arylation
a
 
 
entry catalyst oxidant additive yield (%)
b
 
1 Cu(OAc)2 Ag2CO3 - 17 
2 NiBr2•H2O Ag2CO3 - 29 
3 Ni(OAc)2•4H2O Ag2CO3 - 45 
4 Ni(OAc)2•4H2O AgOAc - 11 
5
c 
Ni(OAc)2•4H2O Ag2CO3 PivOH 64 
6
d 
Ni(OAc)2•4H2O Ag2CO3 PivOH > 95 (93)
e 
7
d 
- Ag2CO3 PivOH 0 
8
d 
Ni(OAc)2•4H2O - PivOH 0 
a
Reaction conditions: Benzamide 1a (0.2 mmol), heteroaromatic carboxylate 2a (1.0 mmol) in 
DMA (2 mL). 
b1
H NMR yield with 1,3,5-trimethoxybenzene as an internal standard. 
c
Pivalic acid 
(0.3 mmol) 
d
Heteroaromatic carboxylate 2a (0.6 mmol) 
e
Isolated yield 
2.2.2. Exploration of the Nickel-Catalyzed Oxidative Decarboxylative 
(Hetero)Arylation Substrate Scope 
 Since heteroaromatic carboxylates were successfully coupled using this new Ni-catalyst 
system, we examined the scope of this new reactivity (Table 2.2). Thiazole derivatives 
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bearing electron-withdrawing groups (3a, 3b, and 3d) gave higher yields than those 
bearing electron-donating groups (3c). Not only do thiazole carboxylates undergo 
oxidative decarboxylative coupling but also oxazoles in 74% yield (3e). The 
unsubstituted thiazole-5-carboxylate (3f) also undergoes coupling with complete 
chemoselectivity at the C5 position in 90% yield. We were encouraged to see this new 
method could also be extended to pyrazoles (3g and 3h), triazole (3i), benzoazoles (3j 
and 3k), and ortho-fluoro pyridine (3l).  
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Table 2.2. Heteroaromatic carboxylate scope of the nickel-catalyzed oxidative 
decarboxylative (hetero)arylation
a 
 
a
Isolated yields. Reaction conditions: Benzamide 1a (0.2 mmol), heteroaromatic 
carboxylate 2 (0.6 mmol), Ni(OAc)2•4H2O (20 mol %), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 
equiv), and PivOH (1.5 equiv) in DMA (2 mL) for 24 h at 110 °C under a N2 atmosphere. 
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 However, other pyridine carboxylates such as picolinic carboxylate, picolonic 
carboxylate N-oxide, and 1-isoquinoline carboxylate did not undergo decarboxylative 
coupling (Table 2.3). This could be due to the thermal instability of the pyridine 
derivatives, which are known to undergo thermal decarboxylation at lower temperature 
than our reaction conditions.
43
 These data show pyridine derivatives with ortho-
carboxylates were not able to undergo cross-coupling. 
Table 2.3. Heteroaromatic carboxylates that do not undergo oxidative decarboxylative 
coupling
a, b 
 
a
Reaction conditions: Benzamide 1a (0.2 mmol), heteroaromatic carboxylate 2 (0.6 mmol), 
Ni(OAc)2•4H2O (20 mol %), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), and PivOH (1.5 
equiv) in DMA (2 mL) for 24 h at 110 °C under a N2 atmosphere.
 b
ND = None detected 
by
 1
H NMR with 1,3,5-trimethoxybenzene as an internal standard.
 
 Next, we wanted to demonstrate that our new Ni-catalyst system was not limited to 
only coupling heteroaromatic carboxylates. We then investigated the reactivity of 
benzoates under the optimized reaction conditions, (Table 2.4). Decarboxylative arylation 
of the ortho-substituted benzoates proceeded cleanly with electron-donating and electron-
withdrawing substitutes in varying positions. As shown in Table 2.4, 2-fluorobenzoates 
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provided the highest yields (3r, 3s, 3t, and 3u) over other ortho-substituted benzoates. It 
should be noted that arylbromides and chlorides are tolerated under these reaction 
conditions allowing for further functionalization. 
Table 2.4. Benzoate scope of the nickel-catalyzed oxidative decarboxylative 
(hetero)arylation
a
 
 
a
Isolated yields. Reaction conditions: Benzamide 1a (0.2 mmol), benzoate 2 (0.6 mmol), 
Ni(OAc)2•4H2O (20 mol %), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), and PivOH (1.5 
equiv) in DMA (2 mL) for 24 h at 110 °C under a N2 atmosphere. 
b1
H NMR yield with 
1,3,5-trimethoxybenzene as an internal standard. 
 
 
 Lastly, we explored the scope of the substituted benzamides (Table 2.5). Benzamides 
with different substituents were explored first. When the unsubstituted benzamide is 
submitted to the standard reaction conditions, both mono- and diarylation products were 
formed. Benzamides with meta- substituents (3aa – 3ad) showed regioselective arylation 
at the less-hindered ortho-CH bond. This new catalyst system again tolerates aryl 
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halides (3ac and 3ad) as seen in Table 2.4. Other benzamides such as naphthyl (3ae) and 
N-methylpyrrole (3af) also undergo arylation in good yields. 
Table 2.5. Benzamide scope of the nickel-catalyzed oxidative decarboxylative 
(hetero)arylation
a
 
 
a
Isolated yields. Reaction conditions: Benzamide 1 (0.2 mmol), heteroaromatic carboxylate 
2a (0.6 mmol), Ni(OAc)2•4H2O (20 mol %), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), 
and PivOH (1.5 equiv) in DMA (2 mL) for 24 h at 110 °C under a N2 atmosphere. 
2.2.3. Preliminary Mechanistic Experiments of the Nickel-Catalyzed Oxidative 
Decarboxylative (Hetero)Arylation 
 To gain insight into the reaction pathway of this new reaction, we conducted a series of 
experiments. As mentioned earlier in the optimization of the reaction conditions, when 
there is no nickel or silver present no product is formed (Table 2.6). When the standard 
reaction was conducted only in the presence of silver no product 3a was formed, 
however, 85 % of the protodecarboxylated 4-methyl-2-phenyl-1,3-thiazole was recovered 
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(Table 2.6 entry 2). In contrast, when the experiment is conducted in the presence of only 
nickel there is quantitative recovery of the heteroaromatic carboxylic acid (2a, entry 3). 
These data show that silver could be responsible for decarboxylation, while nickel is 
needed for the CC bond formation. 
Table 2.6. Control experiments of the nickel-catalyzed oxidative decarboxylative 
(hetero)arylation
a
 
 
entry catalyst oxidant yield (%)
b
 yield (%)
b
 yield (%)
b 
1 Ni(OAc)2 
. 
4H2O  Ag2CO3 > 95 65 0 
2 - Ag2CO3 0 85 0 
3 Ni(OAc)2 
. 
4H2O  - 0 0 > 95 
a
Reaction conditions: Benzamide 1a (0.2 mmol), heteroaromatic carboxylate 2a (0.6 
mmol), Ni(OAc)2•4H2O (20 mol %), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), and 
PivOH (1.5 equiv) in DMA (2 mL) for 24 h at 110 °C under a N2 atmosphere.
 b1
H NMR 
yield with 1,3,5-trimethoxybenzene as an internal standard. 
  As previously mentioned in Chapter 1, it is known that silver salts can promote the 
decarboxylation of benzoic acids to generate silver-aryl or radical intermediates.
16
 We 
first probed our reaction conditions with radical trapping reagents such as TEMPO and 
DHA (Table 2.7). In the presence of 1 equiv of either radical scavenger, there were no 
trappable radical intermediates and no decrease in the yield of the desired product 3a. 
These data suggest there could be a silver-aryl intermediate that plays a key role in this 
reaction.  
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Table 2.7. Radical scavengers with the nickel-catalyzed oxidative decarboxylative 
(hetero)arylation
 a
 
 
entry Radical scav. (1 equiv) yield (%)
b
 
1 none >95 
2 TEMPO >95 
3 DHA >95 
a
Reaction conditions: Benzamide 1a (0.2 mmol), heteroaromatic carboxylate 2a (0.6 
mmol), Ni(OAc)2•4H2O (20 mol %), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), radical 
scavenger (1.0 equiv) and PivOH (1.5 equiv) in DMA (2 mL) for 24 h at 110 °C under a 
N2 atmosphere.
 b1
H NMR yield with 1,3,5-trimethoxybenzene as an internal standard. 
  Next, we explored the CH activation step of our new reaction method. The kinetic 
isotope effect obtained from the intermolecular competition (Scheme 15a) experiment 
reveled kH/kD =  4.3. The deuterium-exchange of 1a-d7 under our standard reaction 
conditions showed no proton incorporation of the ortho-CD bond in the recovered 
starting material (Scheme 15b) by 
1
H NMR spectroscopy. These data suggest that the 
CH activation step is irreversible and consistent with a primary isotope effect.44 If this is 
the case, we might be able to isolate a stable nickel metallacycle; this will be discussed 
later in Chapter 4. 
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Scheme 15. Kinetic isotope effect of the nickel-catalyzed oxidative decarboxylative 
(hetero)arylation.
a 
 
a
Reaction conditions: Benzamide 1a (0.1 mmol), 1a-d7 (0.1 mmol), heteroaromatic 
carboxylate 2a (0.6 mmol), Ni(OAc)2•4H2O (20 mol %), Ag2CO3 (2.0 equiv), Na2CO3 
(4.0 equiv), and PivOH (1.5 equiv) in DMA (2 mL) for 2 h at 110 °C under a N2 
atmosphere.
 b
Benzamide 1a-d7 (0.2 mmol), Heteroaromatic carboxylate 2a (0.6 mmol), 
Ni(OAc)2•4H2O (20 mol %), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), and PivOH (1.5 
equiv) in DMA (2 mL) for 2 h at 110 °C under a N2 atmosphere. 
c1
H NMR yield with 
1,3,5-trimethoxybenzene as an internal standard. 
2.2.4. Proposed Reaction Mechanism of the Nickel-Catalyzed Oxidative 
Decarboxylative (Hetero)Arylation Reaction 
  From the results of the control experiments and kinetic isotope effect experiments 
mentioned above, we have proposed a mechanism for our new catalytic reaction (Scheme 
16). The pre-catalyst enters the reaction pathway and becomes the active catalyst 
followed by ligand exchange with the amide A and then forming the nickel(II) 
metallacycle B. During this time, silver(I) carboxylate is formed and undergoes 
decarboxylation to form a silver(I)-aryl. The silver(I)-aryl undergoes transmetallation 
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with nickel complex B along with concomitant oxidation to form the nickel(III) 
metallacycle C. Reductive elimination from intermediate C generates the new CC bond 
to form D. Intermediate D undergoes protonation and reoxidation of nickel(I) to close the 
catalytic cycle. We believe the remarkable efficiency of this new catalyst system is due to 
the cooperation of both nickel and silver together. 
Scheme 16. Proposed reaction mechanism of the nickel-catalyzed oxidative 
decarboxylative (hetero)arylation. 
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2.3.  Conclusion 
  In summary, we have developed the first nickel-catalyzed oxidative decarboxylative 
(hetero)arylation of unactivated CH bonds. This method employs the use of 
Ni(OAc)2•4H2O as the catalyst,  Ag2CO3 as the oxidant, Na2CO3 as the base and PivOH 
as an additive to enable the efficient coupling of a broad scope of heteroaromatic 
carboxylates and ortho-substituted benzoates. The data from our control experiments 
show there could be cooperation between both nickel and silver. Silver could be 
responsible for decarboxylation and generation of a silver(I)-aryl, while nickel is needed 
for formation of the CC bond. 
2.4. Experimental  
  General Information. All manipulations were performed using standard Schlenk or 
glovebox techniques under a nitrogen atmosphere. All solvents (including dry DMA) 
were bought from Alfa-Aesar, Fisher, and Cambridge Isotope and used as received. All 
other reagents were purchased from Maybridge, Oakwood, Acros, Alfa-Aesar, Astatech, 
Strem and CDN Isotopes and used without further purification. All NMR spectra were 
recorded at ambient temperature using Agilent 400 MHz (
1
H, 400 MHz; 
13
C{
1
H}, 100 
MHz; 
19
F, 376 MHz) spectrometer. Chemical shifts are referenced to the residual solvent 
signals (CDCl3, 
1
H: 7.26 ppm, 
13
C: 77.2 ppm) and (DMSO-d6, 
1
H: 2.50 ppm, 
13
C: 39.5 
ppm).
45
 High resolution mass spectra were obtained on a Thermo Finnigan Linear 
Trapping Quadrupole mass spectrometer. IR spectra were recorded on a PerkinElmer 
(Spectrum 100) FT-IR spectrometer. Column chromatography was performed using 
Silicycle Silia Flash P60 silica gel. 
General Procedure for the Optimization of the Oxidative Decarboxylative Arylation 
Reaction. An oven-dried 50 mL Schlenk tube with a stirring bar was charged with 4-
methy-2-phenyl-1,3-thiazole-5-carboxylic acid 2a (131 mg, 0.600 mmol), sodium 
carbonate (63 mg, 0.60 mmol), and dry DMA (1 mL). The reaction vessel was placed in a 
pre-heated oil bath and stirred for 0.5 h at 130 °C. The solvent was removed under 
reduced pressure until dry and the carboxylate salt was used without further purification. 
2-methyl-N-(quinolin-8-yl) benzamide 1a (52.4 mg, 0.200 mmol), Ni(OAc)2•4H2O (9.9 
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mg, 0.040 mmol), Ag2CO3 (110 mg, 0.400 mmol), Na2CO3 (83 mg, 0.80 mmol), and 
PivOH (30.6 mg, 0.300 mmol) were added and the tube was evacuated and backfilled 
with nitrogen three times after which DMA (2 mL) was added via syringe. The reaction 
mixture was stirred at 110 °C for 24 h. Upon completion, the reaction tube was cooled to 
room temperature. The solution was diluted with ethyl acetate (25 mL) and poured into a 
250 mL separatory funnel. To the solution, water (25 mL), Na2EDTA (500 mg), aqueous 
HCl (1N, 10 mL) were added and extracted with ethyl acetate (2 x 30 mL). The combined 
organic layers were washed with water (100 mL) and brine (25 mL), dried over Na2SO4, 
filtered and concentrated under vacuum. Then 1,3,5-trimethoxybenzene (5.00 mg) was 
added to the residue and the crude mixture was dissolved in CDCl3 for 
1
H analysis. 
 
Optimization of the Pre-catalyst
a 
  
entry catalyst yield 3a (%)
b 
1 Ni(OAc)2•4H2O 45 
2 Cu(OAc)2 17 
3
 
Ni(HCO2)2•2H2O 15 
4 NiBr2•H2O 29 
5 Ni(acac)2 19 
6 NiCl2 15 
7 NiI2 32 
8 Ni(OTf)2 21 
9
c 
Ni(OAc)2•4H2O 8 
a
Reaction conditions: 1a (0.200 mmol), 2a (1.00 mmol) in solvent (2 mL). 
b1
H NMR 
yield with 1,3,5-trimethoxybenzene as an internal standard. 
c
10 mol% 
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Optimization of the Oxidant
a
  
 
entry oxidant yield 3a (%)
b 
1 Ag2CO3  45 
2 AgNO3 16 
3
 
AgOAc 11 
4 AgOTf 19 
5 Ag2O 9 
6 O2 0 
a
Reaction conditions: 1a (0.200 mmol), 2a (1.00 mmol) in solvent (2 mL). 
b1
H NMR 
yield with 1,3,5-trimethoxybenzene as an internal standard.  
 
Optimization of the Solvent
a
  
 
entry solvent yield 3a (%)
b 
1 DMA 45 
2 DMF 13 
3
 
NMP 35 
4 Diglyme 0 
5 PhCH3 0 
a
Reaction conditions: 1a (0.200 mmol), 2a (1.00 mmol) in solvent (2 mL). 
b1
H NMR 
yield with 1,3,5-trimethoxybenzene as an internal standard.  
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Optimization of the Base
a
  
 
entry [base] yield 3a (%)
b 
1 Na2CO3 45 
2 Li2CO3 20 
3
 
K2CO3 0 
4 NaOAc 25 
5 pyridine 15 
a
Reaction conditions: 1a (0.200 mmol), 2a (1.00 mmol) in solvent (2 mL). 
b1
H NMR 
yield with 1,3,5-trimethoxybenzene as an internal standard.  
 
Optimization of the Additives
a
  
 
entry [additive] yield 3a (%)
b 
1 Pivalic Acid 64 
2 Acetic Acid 42 
3
 
Trifluoroacetic acid 34 
a
Reaction conditions: 1a (0.200 mmol), 2a (1.00 mmol) in solvent (2 mL). 
b1
H NMR 
yield with 1,3,5-trimethoxybenzene as an internal standard. 
General Procedure for the NiCatalyzed Oxidative Decarboxylative Arylation. 
Procedure A (Generation of Sodium Salts at 130 °C): An oven-dried 50 mL Schlenk 
tube with a stirring bar was charged with carboxylic acid 2 (0.600 mmol), Na2CO3 (63 
mg, 0.60 mmol), and dry DMA (1 mL). The reaction vessel was placed in a pre-heated oil 
bath and stirred for 0.5 h at 130 °C. The solvent was removed under reduced pressure 
until dry and the carboxylate salt was used without further purification. N-(quinolin-8-yl) 
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benzamide 1 (0.200 mmol), Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), Ag2CO3 (110 mg, 
0.400 mmol), Na2CO3 (83 mg, 0.80 mmol), and PivOH (30.6 mg, 0.300 mmol) were 
added and the tube was evacuated and backfilled with nitrogen three times after which 
DMA (2 mL) was added via syringe. The reaction mixture was stirred at 110 °C for 24 h. 
Upon completion, the reaction tube was cooled to room temperature. The solution was 
diluted with ethyl acetate (25 mL) and poured into a 250 mL separatory funnel. To the 
solution, water (25 mL), Na2EDTA (500 mg), aqueous HCl (1N, 10 mL) were added and 
the mixture was extracted with ethyl acetate (2 x 30 mL). The combined organic layers 
were washed with water (100 mL) and brine (25 mL), dried over Na2SO4, filtered and 
concentrated under vacuum. The residue was purified by silica gel column 
chromatography (gradient elution, hexanes : ethyl acetate (19:1, v/v) to (1:1, v/v)), to 
yield the corresponding product. 
 
Procedure B (Generation of Sodium Salts at 110 °C): An oven-dried 50 mL Schlenk 
tube with a stirring bar was charged with carboxylic acid 2 (0.600 mmol), Na2CO3 (63 
mg, 0.60 mmol), and dry DMA (1 mL). The reaction vessel was placed in a pre-heated oil 
bath and stirred for 0.5 h at 110 °C. The solvent was removed under reduced pressure 
until dry and the carboxylate salt was used without further purification. N-(quinolin-8-yl) 
benzamide 1 (0.200 mmol), Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), Ag2CO3 (110 mg, 
0.400 mmol), Na2CO3 (83 mg, 0.80 mmol), and PivOH (30.6 mg, 0.300 mmol) were 
added and the tube was evacuated and backfilled with nitrogen three times after which 
DMA (2 mL) was added via syringe. The reaction mixture was stirred at 110 °C for 24 h. 
Upon completion, the reaction tube was cooled to room temperature. The solution was 
diluted with ethyl acetate (25 mL) and poured into a 250 mL separatory funnel. To the 
solution, water (25 mL), Na2EDTA (500 mg), aqueous HCl (1N, 10 mL) were added and 
the mixture was extracted with ethyl acetate (2 x 30 mL). The combined organic layers 
were washed with water (100 mL) and brine (25 mL), dried Na2SO4, filtered and 
concentrated in vacuo. The residue was purified by silica gel column chromatography 
(gradient elution, hexanes:ethyl acetate (19:1, v/v) to (1:1, v/v)), yielding the 
corresponding product. 
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Reactions with Radical Scavengers.  
An oven-dried 50 mL Schlenk tube with a stirring bar was charged with 4-methy-2-
phenyl-1,3-thiazole-5-carboxylic acid 2a (131 mg, 0.600 mmol), sodium carbonate (63 
mg, 0.60 mmol), and dry DMA (1 mL). The reaction vessel was placed in a pre-heated oil 
bath and stirred for 0.5 h at 130 °C. The solvent was removed under reduced pressure 
until dry and the resulting carboxylate salt was used without further purification. 2-
methyl-N-(quinolin-8-yl) benzamide 1a (52.4 mg, 0.200 mmol), Ni(OAc)2•4H2O (9.9 
mg, 0.040 mmol), Ag2CO3 (110 mg, 0.400 mmol), Na2CO3 (83 mg, 0.80 mmol), TEMPO 
(31.2 mg, 0.200 mmol) or DHA (36.0, 0.200 mmol), and PivOH (30.6 mg, 0.300 mmol) 
were added and the tube was evacuated and backfilled with nitrogen three times after 
which DMA (2 mL) was added via syringe. The reaction mixture was stirred at 110 °C 
for 24 h. Upon completion, the reaction tube was cooled to room temperature. The 
solution was diluted with ethyl acetate (25 mL) and poured into a 250 mL separatory 
funnel. To the solution, water (25 mL), Na2EDTA (500 mg), aqueous HCl (1N, 10 mL) 
were added and extracted with ethyl acetate (2 x 30 mL). The combined organic layers 
were washed with water (100 mL) and brine (25 mL), dried over Na2SO4, filtered and 
concentrated under vacuum. Then 1,3,5-trimethoxybenzene (5.00 mg) was added to the 
residue and the crude mixture was dissolved in CDCl3 for 
1
H analysis. 
 
Procedure for the Intermolecular Competition Experiment. An oven-dried 50 mL 
Schlenk tube with a stirring bar was charged with carboxylic acid 2 (0.600 mmol), 
sodium carbonate (63 mg, 0.60 mmol), and dry DMA (1 mL). The reaction vessel was 
placed in a pre-heated oil bath and stirred for 0.5 h at 130 °C. Solvent was removed under 
reduced pressure until dry and the resulting carboxylate salt was used without further 
purification. 1a (26.2 mg, 0.100 mmol), 1a-d7 (26.9 mg, 0.100 mmol), Ni(OAc)2•4H2O 
(9.9 mg, 0.040 mmol), Ag2CO3 (110 mg, 0.400 mmol), Na2CO3 (83 mg, 0.80 mmol), 
PivOH (30.6 mg, 0.300 mmol) were added, the tube was evacuated and backfilled with 
nitrogen three times after which DMA (2 mL) was added via syringe. The reaction 
mixture was stirred at 110 °C for 2 h. Upon completion, the reaction tube was cooled to 
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room temperature. The solution was diluted with ethyl acetate (25 mL) and poured into a 
250 mL separatory funnel. To the solution, water (25 mL), Na2EDTA (500 mg), aqueous 
HCl (1N, 10 mL) were added and extracted with ethyl acetate (2 x 30 mL). The combined 
organic layers were washed with water (100 mL) and brine (25 mL), dried Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by silica gel column 
chromatography (gradient elution, hexanes:ethyl acetate (19:1, v/v) to (4:1, v/v)), 
yielding the corresponding product of 3a and 3a-d6 in 17% and 4% yields respectively, 
giving a KIE of 4.3 by 
1
H NMR spectroscopy. 
  
1
H NMR spectrum of the reaction mixture of 3a and 3a-d6 
 
Procedure for the Isotopic Exchange Experiment. An oven-dried 50 mL Schlenk tube 
with a stirring bar was charged with carboxylic acid 2 (0.600 mmol), sodium carbonate 
(63 mg, 0.60 mmol), and dry DMA (1 mL). The reaction vessel was placed in a pre-
heated oil bath and stirred for 0.5 h at 130 °C. Solvent was removed under reduced 
pressure until dry and the resulting carboxylate salt was used without further purification. 
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1a-d7 (53.8 mg, 0.200 mmol), Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), Ag2CO3 (110 mg, 
0.400 mmol), Na2CO3 (83 mg, 0.80 mmol), PivOH (30.6 mg, 0.300 mmol) were added, 
the tube was evacuated and backfilled with nitrogen three times after which DMA (2 mL) 
was added via syringe. The reaction mixture was stirred at 110 °C for 2 h. Upon 
completion, the reaction tube was cooled to room temperature. The solution was diluted 
with ethyl acetate (25 mL) and poured into a 250 mL separatory funnel. To the solution, 
water (25 mL), Na2EDTA (500 mg), aqueous HCl (1N, 10 mL) were added and extracted 
with ethyl acetate (2 x 30 mL). The combined organic layers were washed with water and 
brine, dried Na2SO4, filtered and concentrated in vacuo. The residue was purified by 
silica gel column chromatography (gradient elution, hexanes:ethyl acetate (19:1, v/v) to 
(4:1, v/v)), yielding the corresponding product. The extent of proton incorporation was 
determined by 
1
H NMR spectroscopy. 
 
1
H NMR spectrum of the reaction mixture 3a-d6  
 
 
 
 
No H incorporation 
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General Procedure for the Synthesis of (Hetero)Aryl Benzamides (1) 
Procedure A: Synthesis from the benzoyl chloride. A 100 mL two-neck round bottom 
flask was charged with 8-aminoquinoline (1.44 g, 10.0 mmol), Et3N (1.56 mL, 12.0 
mmol), and methylene chloride (20 mL) under a N2 atmosphere. The corresponding acid 
chloride was added dropwise at room temperature over 10 minutes. The mixture was 
stirred for 6 h at room temperature. The reaction was quenched with 10 mL of saturated 
NaHCO3 and extracted with methylene chloride (3 x 25 mL). The combined organic layer 
was washed with brine (15 mL) and dried over anhydrous Na2SO4. The solvent was 
removed under reduced pressure and the residue was purified via silica gel column 
chromatography (gradient elution, hexanes : ethyl acetate (19:1, v/v) to (4:1, v/v)). 
Procedure B: Synthesis from the carboxylic acid. A 50 mL two-neck round bottom 
flask was charged with the corresponding carboxylic acid (1.70 mmol), N,N-
dimethylformamide (2 drops), and methylene chloride (2 mL) under a N2 atmosphere at 0 
°C. Oxalyl chloride (0.17 mL, 2.0 mmol) was then added dropwise and the reaction 
mixture was allowed to stir for 3 h at room temperature. The solvent was removed under 
reduced pressure and the acid chloride was used without further purification. A 100 mL 
two-neck round bottom flask was charged with 8-aminoquinoline (255 mg, 1.70 mmol), 
Et3N (0.278 mL, 2.00 mmol), and methylene chloride (10 mL) under q N2 atmosphere at 
0 °C. The corresponding acid chloride was added dropwise to the reaction and stirred for 
3 h. The reaction was quenched with 5 mL of saturated NaHCO3 and extracted with 
methylene chloride three times (3 x 25 mL). The combined organic layer was washed 
with brine (15 mL) and dried over anhydrous Na2SO4. The solvent was removed under 
reduced pressure and the residue was purified via silica gel column chromatography 
(gradient elution, hexanes : ethyl acetate (19:1, v/v) to (9:1, v/v)). 
 
 
General Procedure for the Synthesis of Thiazole Carboxylic Acids (2) 
A mixture of thiobenzamide (3.77 g, 27.5 mmol) and ethyl 2-chloroacetoacetate (3.45 
mL, 25.0 mmol) in methanol was refluxed for 5-6 h in a 100 mL round bottom flask. The 
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solvent was removed under reduced pressure to yield the corresponding crude ethyl 
carboxylate. A 250 mL round bottom flask was charged with the crude ethyl carboxylate, 
THF/EtOH/H2O (1:1:1, 165 mL, v/v), and KOH (4 equiv) and the mixture was allowed to 
stir at room temperature overnight. The reaction was quenched with HCl (2 N) until a pH 
of 2 was reached. The solid was filtered and dried under reduced pressure to yield the 
corresponding carboxylic acid. 
 
Characterization of (Hetero)Aryl Benzamides (1) 
 
2-methyl-N-(quinolin-8-yl) benzamide (1a): The following compound was synthesized 
following General Procedure A. 
1
H NMR (400 MHz, CDCl3) δ 10.21 (s, 1H), 8.95 (dd, J 
= 7.5, 1.5 Hz, 1H), 8.78 (dd, J = 4.2, 1.7 Hz, 1H), 8.19 (dd, J = 8.3, 1.7 Hz, 1H), 7.69 (dd, 
J = 7.9, 1.4 Hz, 1H), 7.64 – 7.53 (m, 2H), 7.50 – 7.37 (m, 3H), 7.33 (tt, J = 7.7, 0.8 Hz, 
2H), 2.61 (s, 3H).
13
C{
1
H} NMR (100 MHz, CDCl3) δ 168.17, 148.28, 138.60, 136.70, 
136.64, 136.35, 134.76, 131.41, 130.36, 128.00, 127.40, 127.27, 126.05, 121.81, 121.69, 
116.49, 20.27. The spectral data are consistent with those reported in the literature.
46 
 
N-(quinolin-8-yl) benzamide (1z): The following compound was synthesized following 
General Procedure A. 
1
H NMR (400 MHz, CDCl3) δ 10.73 (s, 1H), 8.95 (dd, J = 7.5, 1.4 
Hz, 1H), 8.82 (dd, J = 4.2, 1.7 Hz, 1H), 8.14 (dd, J = 8.3, 1.7 Hz, 1H), 8.12 – 8.06 (m, 
2H), 7.62 – 7.48 (m, 5H), 7.44 (dd, J = 8.3, 4.2 Hz, 1H). 13C{1H} NMR (100 MHz, 
CDCl3) δ 165.47, 148.33, 138.81, 136.43, 135.21, 134.64, 131.90, 128.86, 128.04, 
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127.49, 127.35, 121.76, 121.74, 116.59. The spectral data are consistent with those 
reported in the literature.
46 
 
3-methyl-N-(quinolin-8-yl) benzamide (1aa): The following compound was 
synthesized following General Procedure A. 
1
H NMR (400 MHz, CDCl3) δ 10.67 (s, 1H), 
8.94 (dd, J = 7.6, 1.2 Hz, 1H), 8.79 (dd, J = 4.2, 3.7, 1.7 Hz, 1H), 8.08 (dd, J = 8.2, 4.5, 
1.7 Hz, 1H), 7.90 – 7.82 (m, 2H), 7.54 (td, J = 7.9, 2.8 Hz, 1H), 7.46 (ddd, J = 8.3, 3.5, 
1.4 Hz, 1H), 7.44 – 7.32 (m, 3H), 2.45 (d, J = 2.3 Hz, 3H).13C{1H} NMR (100 MHz, 
CDCl3) δ 165.50, 148.19, 138.66, 138.58, 136.26, 135.07, 134.57, 132.55, 128.59, 
127.99, 127.89, 127.33, 124.16, 121.59, 116.43, 21.45. The spectral data are consistent 
with those reported in the literature.
47
 
 
3-methoxy-N-(quinolin-8-yl) benzamide (1ab): The following compound was 
synthesized following General Procedure A. 
1
H NMR (400 MHz, CDCl3) δ 10.73 (s, 1H), 
8.93 (dd, J = 7.5, 1.1 Hz, 1H), 8.83 (dd, J = 4.2, 2.1 Hz, 1H), 8.16 (dd, 1H), 7.64 (tdd, J = 
3.3, 1.7, 1.0 Hz, 2H), 7.62 – 7.56 (m, 1H), 7.56 – 7.51 (m, 1H), 7.50 – 7.41 (m, 2H), 7.12 
(dd, J = 8.2, 2.5, 1.0 Hz, 1H), 3.91 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3) δ 165.08, 
159.96, 148.26, 148.24, 138.63, 136.54, 136.29, 136.26, 134.48, 129.74, 127.89, 127.35, 
127.31, 121.69, 121.64, 119.01, 118.99, 117.90, 117.84, 116.45, 116.41, 112.72, 112.71, 
55.43. The spectral data are consistent with those reported in the literature.
48
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3-chloro-N-(quinolin-8-yl) benzamide (1ac): The following compound was synthesized 
following General Procedure A. 
1
H NMR (400 MHz, CDCl3) δ 10.67 (s, 1H), 8.89 (dd, J 
= 7.3, 1.8 Hz, 1H), 8.83 (dd, J = 4.1, 2.0 Hz, 1H), 8.16 (dd, J = 8.3, 3.5, 1.6 Hz, 1H), 8.05 
(d, J = 2.0 Hz, 1H), 7.93 (dd, J = 7.7, 1.6 Hz, 1H), 7.61 – 7.50 (m, 3H), 7.46 (td, J = 7.4, 
2.8 Hz, 2H). 
13
C{
1
H} NMR (100 MHz, CDCl3) δ 163.08, 147.93, 138.12, 136.33, 135.88, 
134.59, 133.75, 131.40, 129.63, 127.46, 127.34, 126.85, 124.71, 121.63, 121.35, 116.17. 
The spectral data are consistent with those reported in the literature.
47
 
 
 
3-bromo-N-(quinolin-8-yl) benzamide (1ad): The following compound was 
synthesized following General Procedure A. 
1
H NMR (400 MHz, CDCl3) δ 10.60 (s, 1H), 
8.84 (dd, J = 7.4, 1.6 Hz, 1H), 8.78 (dd, J = 4.2, 1.7 Hz, 1H), 8.16 (t, J = 1.8 Hz, 1H), 
8.09 (dd, J = 8.3, 1.7 Hz, 1H), 7.92 (ddd, J = 7.8, 1.7, 1.0 Hz, 1H), 7.63 (ddd, J = 8.0, 2.0, 
1.0 Hz, 1H), 7.56 – 7.43 (m, 2H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H). 
13
C{
1
H} NMR (100 MHz, CDCl3) δ 163.72, 148.38, 138.65, 137.06, 136.38, 134.77, 
134.21, 130.64, 130.29, 127.94, 127.36, 125.65, 123.07, 122.03, 121.77, 116.67. The 
spectral data are consistent with those reported in the literature.
47 
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N-(quinolin-8-yl)naphthalene-1-carboxamide (1ae): The following compound was 
synthesized following General Procedure A. 
1
H NMR (400 MHz, CDCl3) δ 10.45 (s, 1H), 
9.09 (dd, J = 7.7, 1.3 Hz, 1H), 8.74 (dd, J = 4.2, 1.7 Hz, 1H), 8.61 – 8.55 (m, 1H), 8.16 
(dd, J = 8.3, 1.7 Hz, 1H), 8.00 (dt, J = 8.2, 1.1 Hz, 1H), 7.93 (ddd, J = 7.3, 5.5, 1.6 Hz, 
2H), 7.65 (t, J = 7.9 Hz, 1H), 7.63 – 7.53 (m, 4H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H). 13C{1H} 
NMR (100 MHz, CDCl3) δ 167.78, 148.37, 138.68, 136.41, 134.90, 133.96, 131.21, 
130.43, 128.47, 128.08, 127.49, 127.39, 127.38, 126.59, 125.66, 125.59, 124.94, 122.03, 
121.76, 116.78. The spectral data are consistent with those reported in the literature.
47
 
 
1-methyl-N-(quinolin-8-yl)-1H-pyrrole-2-carboxamide (1af): The following 
compound was synthesized following General Procedure B. 
1
H NMR (400 MHz, CDCl3) 
δ 10.43 (s, 1H), 8.86 – 8.74 (m, 2H), 8.13 (dd, J = 8.3, 1.7 Hz, 1H), 7.55 (t, J = 7.9 Hz, 
1H), 7.47 (dd, J = 8.3, 1.4 Hz, 1H), 7.43 (dd, J = 8.2, 4.2 Hz, 1H), 7.02 (dd, J = 4.0, 1.7 
Hz, 1H), 6.81 (t, J = 2.1 Hz, 1H), 6.21 (dd, J = 4.0, 2.5 Hz, 1H), 4.06 (s, 3H). 
13
C{
1
H} 
NMR (100 MHz, CDCl3) δ 160.11, 148.21, 138.65, 136.34, 135.13, 128.90, 127.47, 
126.34, 121.65, 121.00, 115.86, 115.85, 113.09, 107.67, 37.03. The spectral data are 
consistent with those reported in the literature.
47
 
 
 
Characterization of Thizaole Carboxylic Acids (2). 
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4-methyl-2-phenyl-1,3-thiazole-5-carboxylic acid (2a). 
1
H NMR (400 MHz, DMSO-d6) 
δ 13.30 (s, 1H), 7.93 (d, J = 8.0 Hz, 2H), 7.63 – 7.39 (m, 3H), 2.67 (s, 3H). 13C{1H} 
NMR (100 MHz, DMSO-d6) δ 168.44, 162.92, 159.61, 132.36, 131.18, 129.29, 126.47, 
122.91, 17.14. The spectral data are consistent with those reported in the literature.
49 
 
2-(4-chlorophenyl)-4-methyl-1,3-thiazole-5-carboxylic acid (2b). 
1
H NMR (400 MHz, 
DMSO-d6) δ 13.42 (s, 1H), 7.94 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.5 Hz, 2H), 2.66 (s, 
3H). 
13
C{
1
H} NMR (100 MHz, DMSO-d6) δ 166.86, 162.70, 159.51, 135.73, 131.04, 
129.15, 127.94, 123.23, 16.96. The spectral data are consistent with those reported in the 
literature.
49
 
 
2-(4-methoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid (2c). 
1
H NMR (400 
MHz, DMSO-d6) δ 13.26 (s, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.05 (d, J = 8.6 Hz, 2H), 3.83 
(s, 3H), 2.64 (s, 3H). 
13
C{
1
H} NMR (100 MHz, DMSO-d6) δ 168.44, 163.07, 161.63, 
159.61, 128.14, 125.16, 121.69, 114.56, 55.40, 17.13. The spectral data are consistent 
with those reported in the literature.
50 
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4-methyl-2-(naphthalene-1-yl)-1,3-thiazole-5-carboxylic acid (2d): White solid, mp = 
207 – 209 °C. 1H NMR (400 MHz, DMSO-d6) δ 13.44 (s, 1H), 8.81 (d, 1H), 8.08 (dd, J = 
8.4, 2.1, 1.0 Hz, 1H), 8.01 (d, 1H), 7.90 (dt, J = 7.2, 1.7 Hz, 1H), 7.66 – 7.55 (m, 3H), 
2.76 (s, 3H). 
13
C{
1
H} NMR (100 MHz, DMSO-d6) δ 168.48, 163.05, 159.35, 133.67, 
131.22, 129.62, 129.36, 128.92, 128.53, 127.62, 126.56, 125.49, 125.34, 123.60, 17.32. 
FTIR (ATR, cm
-1
): 3330, 3156, 1690, 1614, 1421, 1258, 911. HRMS (ESI-MS) m/z 
calcd for C15H12NO2S [M + H]
+
 270.0589 found 270.0595. 
 
 
Characterization of Ni-Catalyzed Oxidative Decarboxylative (Hetero) Arylation 
Products. 
 
 
2-methyl-6-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)benzamide (3a): 
The title compound was synthesized following General Procedure A. Light yellow solid 
in 93 % (81.0 mg, 0.18 mmol), mp = 146 – 148 °C. 1H NMR (400 MHz, CDCl3): δ 9.83 
(s, 1H), 8.80 (dd, J = 7.3, 1.7 Hz, 1H), 8.67 (dd, J = 4.2, 1.7 Hz, 1H), 8.05 (dd, J = 8.3, 
1.7 Hz, 1H), 7.77 – 7.69 (m, 2H), 7.52 – 7.39 (m, 3H), 7.39 – 7.27 (m, 6H), 2.55 (s, 3H), 
2.46 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 167.11, 166.18, 150.90, 148.02, 
138.68, 138.30, 136.18, 134.14, 133.45, 130.89, 129.63, 129.20, 129.18, 129.17, 129.02, 
128.65, 127.84, 127.23, 126.23, 121.91, 121.52, 116.59, 19.82, 15.97. FTIR (ATR, cm
-1
): 
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3339, 3061, 2921, 1670, 1580, 1520, 1483, 1384, 1325, 905, 726. HRMS (ESI-MS) m/z 
calcd for C27H22N3OS [M + H]
+
 436.1484 found 436.1497. 
 
 
 
2-[2-(4-chlorophenyl)-4-methyl-1,3-thiazol-5-yl]-6-methyl-N-(quinolin-8-
yl)benzamide (3b): The title compound was synthesized following General Procedure A. 
Light yellow solid in 89 % (83.7 mg, 0.17 mmol), mp = 80 – 82 °C. 1H NMR (400 MHz, 
CDCl3): δ 9.82 (s, 1H), 8.77 (dd, J = 6.9, 2.1 Hz, 1H), 8.68 (dd, J = 4.2, 1.7 Hz, 1H), 8.10 
(dd, J = 8.3, 1.7 Hz, 1H), 7.69 – 7.63 (m, 2H), 7.53 – 7.45 (m, 2H), 7.42 (d, J = 7.6 Hz, 
1H), 7.41 – 7.35 (m, 2H), 7.33 – 7.24 (m, 3H), 2.54 (s, 3H), 2.44 (s, 3H). 13C{1H} NMR 
(100 MHz, CDCl3): δ 167.22, 165.04, 151.11, 148.13, 138.82, 138.35, 136.54, 136.39, 
135.81, 134.18, 131.91, 131.21, 129.59, 129.39, 129.29, 129.07, 129.00, 128.04, 127.63, 
127.47, 122.16, 121.71, 116.94, 19.95, 15.99. FTIR (ATR, cm
-1
): 3343, 3188, 2943, 
1674, 1523, 1483, 1424, 1326, 826, 789. HRMS (ESI-MS) m/z calcd for C27H21ClN3OS 
[M + H]
+
 470.1094 found 470.0925. 
 
 
2-[2-(4-methoxyphenyl)-4-methyl-1,3-thiazol-5-yl]-6-methyl-N-(quinolin-8-
yl)benzamide (3c): The title compound was synthesized following General Procedure A. 
Light yellow solid in 72 % (67.0 mg, 0.14 mmol), mp = 85 – 87 °C. 1H NMR (400 MHz, 
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CDCl3): δ 9.82 (s, 1H), 8.79 (dt, J = 7.4, 1.3 Hz, 1H), 8.66 (ddd, J = 4.1, 1.7, 0.7 Hz, 1H), 
8.09 – 7.99 (m, 1H), 7.71 – 7.61 (m, 2H), 7.53 – 7.38 (m, 3H), 7.38 – 7.28 (m, 3H), 6.86 
– 6.75 (m, 2H), 3.77 (s, 3H), 2.54 (s, 3H), 2.44 (s, 3H). 13C{1H} NMR (100 MHz, 
CDCl3): δ 167.28, 166.22, 160.93, 150.64, 148.12, 138.78, 138.41, 136.27, 136.25, 
134.28, 130.88, 129.44, 129.35, 129.25, 128.09, 127.94, 127.79, 127.33, 126.54, 121.98, 
121.61, 116.68, 114.10, 55.38, 19.92, 16.06. FTIR (ATR, cm
-1
): 3333, 3062, 2926, 1671, 
1518, 1482, 1460, 1423, 1325, 1252, 1171, 905, 726. HRMS (ESI-MS) m/z calcd for 
C28H24N3O2S [M + H]
+
 466.1589 found 466.1578. 
 
 
 
2-methyl-6-[4-methyl-2-(naphthalene-1-yl)-1,3-thiazol-5-yl]-N-(quinolin-8-
yl)benzamide (3d): The title compound was synthesized following General Procedure A. 
Light yellow solid in 93 % (90.3 mg, 0.18 mmol), mp = 208 – 210 °C. 1H NMR (400 
MHz, CDCl3): δ 9.87 (s, 1H), 8.87 (dd, J = 7.5, 1.5 Hz, 1H), 8.68 (dd, J = 4.2, 1.7 Hz, 
1H), 8.07 (ddd, J = 8.3, 6.8, 1.3 Hz, 2H), 7.79 (ddt, J = 9.2, 8.1, 1.0 Hz, 2H), 7.57 – 7.30 
(m, 9H), 7.21 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 2.60 (s, 3H), 2.59 (s, 3H). 
13
C{
1
H} NMR 
(100 MHz, CDCl3): δ 167.27, 165.41, 150.73, 148.17, 138.70, 138.34, 136.69, 136.32, 
134.34, 133.80, 131.09, 130.79, 130.65, 130.19, 130.05, 129.43, 129.30, 129.15, 128.18, 
128.15, 127.96, 127.44, 127.03, 126.12, 125.51, 124.89, 122.01, 121.72, 116.59, 20.03, 
16.19. FTIR (ATR, cm
-1
): 3339, 3057, 2919, 1672, 1519, 1482, 1423, 1325, 1263, 906, 
729. HRMS (ESI-MS) m/z calcd for C31H24N3OS [M + H]
+
 486.1640 found 486.1650. 
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2-methyl-6-(4-methyl-2-phenyl-1,3-oxazol-5-yl)-N-(quinolin-8-yl)benzamide (3e): 
The title compound was synthesized following General Procedure A. White solid in 74 % 
(62.0 mg, 0.14 mmol), mp = 148 – 150 °C. 1H NMR (400 MHz, CDCl3): δ 9.92 (s, 1H), 
8.87 (dd, J = 7.2, 1.8 Hz, 1H), 8.62 (dd, J = 4.2, 1.7 Hz, 1H), 8.08 (dd, J = 8.3, 1.7 Hz, 
1H), 7.65 – 7.58 (m, 2H), 7.52 – 7.39 (m, 4H), 7.38 – 7.30 (m, 2H), 7.21 – 7.15 (m, 1H), 
7.05 – 6.98 (m, 2H), 2.56 (s, 3H), 2.39 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3): δ 
167.98, 160.09, 148.33, 144.30, 138.54, 136.77, 136.33, 136.23, 135.24, 134.47, 130.84, 
129.90, 129.43, 128.33, 128.01, 127.39, 126.99, 126.30, 126.28, 126.12, 122.01, 121.71, 
117.06, 19.86, 13.10. FTIR (ATR, cm
-1
): 3346, 3079, 2924, 1677, 1519, 1482, 1424, 
1325, 1264, 1028, 898, 711. HRMS (ESI-MS) m/z calcd for C27H22N3O2 [M + H]
+
 
420.1712 found 420.1728. 
 
 
2-methyl-N-(quinolin-8-yl)-6-(1,3-thiazol-5-yl)benzamide (3f): The title compound 
was synthesized following General Procedure B. Bright yellow solid in 90 % (62.1 mg, 
0.18 mmol), mp = 56 – 58 °C. 1H NMR (400 MHz, CDCl3): δ 9.86 (s, 1H), 8.86 (dd, J = 
7.1, 1.9 Hz, 1H), 8.67 (dd, J = 4.2, 1.7 Hz, 1H), 8.62 (d, J = 0.6 Hz, 1H), 8.13 (dd, J = 
8.3, 1.7 Hz, 1H), 8.02 (t, J = 0.5 Hz, 1H), 7.59 – 7.49 (m, 2H), 7.44 – 7.37 (m, 3H), 7.36 
– 7.31 (m, 1H), 2.52 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3): δ 167.64, 153.37, 
148.35, 141.91, 138.50, 137.32, 136.46, 136.33, 136.17, 134.16, 130.90, 129.56, 128.40, 
128.25, 128.05, 127.46, 122.34, 121.77, 117.13, 19.75. FTIR (ATR, cm
-1
): 3339, 3003, 
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2916, 1672, 1519, 1483, 1424, 1386, 1325, 874, 789, 754. HRMS (ESI-MS) m/z calcd 
for C20H16N3OS [M + H]
+
 346.1014 found 346.1028. 
 
 
2-methyl-6-(1-methyl-1H-pyrazol-5-yl)-N-(quinolin-8-yl)benzamide (3g): The title 
compound was synthesized following General Procedure B. Light yellow solid in 74 % 
(50.6 mg, 0.14 mmol), mp = 140 – 142 °C. 1H NMR (400 MHz, CDCl3): δ 9.69 (s, 1H), 
8.74 (dd, J = 6.3, 2.7 Hz, 1H), 8.69 (dd, J = 4.2, 1.7 Hz, 1H), 8.13 (dd, J = 8.3, 1.7 Hz, 
1H), 7.55 – 7.47 (m, 2H), 7.47 – 7.36 (m, 3H), 7.28 – 7.20 (m, 2H), 6.33 (d, J = 1.9 Hz, 
1H), 3.84 (s, 3H), 2.54 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 167.13, 148.15, 
140.83, 138.45, 138.33, 136.42, 136.21, 134.10, 131.26, 129.22, 128.44, 127.99, 127.97, 
127.37, 122.07, 121.72, 116.66, 107.38, 37.24, 19.77. FTIR (ATR, cm
-1
): 3326, 3067, 
2922, 1675, 1523, 1483, 1424, 1326, 826, 753. HRMS (ESI-MS) m/z calcd for 
C21H19N4O [M + H]
+
 343.1559 found 343.1570. 
 
 
2-methyl-6-(1-methyl-3-phenyl-1H-pyrazol-5-yl)-N-(quinolin-8-yl)benzamide (3h): 
The title compound was synthesized following General Procedure B. Light yellow solid 
in 70 % (58.5 mg, 0.14 mmol), mp = 92 – 93 °C. 1H NMR (400 MHz, CDCl3): δ 9.78 (s, 
1H), 8.76 (dd, J = 7.2, 1.6 Hz, 1H), 8.67 (dd, J = 4.3, 1.6 Hz, 1H), 8.06 (dt, J = 8.3, 1.6 
Hz, 1H), 7.55 – 7.37 (m, 6H), 7.34 (ddd, J = 8.2, 4.3, 1.4 Hz, 1H), 7.31 – 7.14 (m, 4H), 
6.68 (d, J = 1.5 Hz, 1H), 3.86 (s, 3H), 2.57 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 
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167.15, 150.49, 148.17, 142.38, 138.42, 138.39, 136.42, 134.15, 133.46, 131.44, 129.32, 
128.44, 128.43, 128.33, 128.10, 128.02, 127.41, 127.40, 125.53, 122.15, 121.64, 116.81, 
104.92, 37.43, 19.88. FTIR (ATR, cm
-1
): 3337, 3134, 2929, 1672, 1520, 1483, 1424, 
1325, 906, 723. HRMS (ESI-MS) m/z calcd for C27H23N4O [M + H]
+
 419.1872 found 
419.1889. 
 
 
2-methyl-6-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)-N-(quinolin-8-yl)benzamide 
(3i): The title compound was synthesized following General Procedure A. Yellow solid 
in 40 % (33.5 mg, 0.08 mmol), mp = 140 – 142 °C. 1H NMR (400 MHz, CDCl3): δ 9.95 
(s, 1H), 8.85 (dd, J = 7.3, 1.7 Hz, 1H), 8.60 (dd, J = 4.2, 1.7 Hz, 1H), 8.09 (dd, J = 8.3, 
1.7 Hz, 1H), 7.67 – 7.60 (m, 2H), 7.54 – 7.41 (m, 4H), 7.41 – 7.36 (m, 1H), 7.33 (dd, J = 
8.3, 4.2 Hz, 1H), 7.15 – 7.08 (m, 3H), 2.60 (s, 3H), 2.44 (s, 3H). 13C{1H} NMR (100 
MHz, CDCl3): δ 167.98, 148.26, 145.67, 143.89, 139.56, 138.59, 137.65, 136.70, 136.22, 
134.59, 131.05, 129.31, 128.85, 128.16, 128.00, 127.41, 126.70, 121.84, 121.58, 118.26, 
116.86, 19.98, 11.21. FTIR (ATR, cm
-1
): 3344, 3059, 2923 1673, 1595, 1519, 1482, 
1325, 907, 729. HRMS (ESI-MS) m/z calcd for C26H22N5O [M + H]
+
 420.1824 found 
420.1839. 
 
 
2-methyl-6-(3-methyl-1-benzothiophen-2-yl)-N-(quinolin-8-yl)benzamide (3j): The 
title compound was synthesized following General Procedure B. Light yellow solid in 70 
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% ( 57.1 mg, 0.14 mmol), mp = 211 – 212 °C. 1H NMR (400 MHz, CDCl3): δ 9.81 (s, 
1H), 8.75 (dd, J = 7.4, 1.6 Hz, 1H), 8.63 (dd, J = 4.2, 1.7 Hz, 1H), 8.02 (dd, J = 8.3, 1.7 
Hz, 1H), 7.62 (dt, J = 7.9, 0.9 Hz, 1H), 7.56 (dt, J = 8.2, 0.9 Hz, 1H), 7.47 – 7.40 (m, 
3H), 7.39 – 7.36 (m, 1H), 7.36 – 7.30 (m, 2H), 7.27 – 7.21 (m, 1H), 7.17 (ddd, J = 8.3, 
7.0, 1.3 Hz, 1H), 2.56 (s, 3H), 2.38 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 167.42, 
147.97, 140.35, 139.67, 138.72, 138.42, 136.23, 136.19, 135.60, 134.45, 132.05, 130.87, 
130.03, 129.46, 129.06, 127.89, 127.34, 124.14, 123.88, 122.06, 122.05, 121.78, 121.51, 
116.64, 20.03, 12.76. FTIR (ATR, cm
-1
): 3340, 3061, 2919, 1671, 1520, 1482, 1325, 905, 
727. HRMS (ESI-MS) m/z calcd for C26H21N2OS [M + H]
+
 409.1375 found 409.1383. 
 
 
 
2-methyl-6-(3-methyl-1-benzofuran-2-yl)-N-(quinolin-8-yl)benzamide (3k): The title 
compound was synthesized following General Procedure B. Light yellow solid in 36 % 
(28.2 mg, 0.07 mmol), mp = 135 – 137 °C. 1H NMR (400 MHz, CDCl3): δ 9.87 (s, 1H), 
8.83 (dd, J = 7.6, 1.0 Hz, 1H), 8.60 (dd, J = 4.3, 1.7, 0.7 Hz, 1H), 8.09 – 8.01 (m, 1H), 
7.55 – 7.41 (m, 4H), 7.41 – 7.28 (m, 3H), 7.08 – 6.97 (m, 3H), 2.60 (s, 3H), 2.36 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 167.90, 154.28, 149.95, 148.03, 138.50, 137.35, 
136.68, 136.15, 134.72, 131.14, 130.38, 129.21, 128.68, 127.91, 127.70, 127.36, 124.17, 
122.11, 121.73, 121.49, 119.28, 116.65, 113.51, 110.86, 20.00, 9.16. FTIR (ATR, cm
-1
): 
3342, 3052, 2986, 1673, 1519, 1482, 1384, 1325, 1079, 1263, 905, 728. HRMS (ESI-
MS) m/z calcd for C26H21N2O2 [M + H]
+
 393.1603 found 393.1618. 
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2-(3-fluoropyridin-4-yl)-6-methyl-N-(quinolin-8-yl)benzamide (3l): The title 
compound was synthesized following General Procedure B. Yellow solid in 35 % (25.0 
mg, 0.07 mmol), mp = 154 – 155 °C. 1H NMR (400 MHz, CDCl3): δ 9.78 (s, 1H), 8.72 – 
8.65 (m, 2H), 8.34 (d, J = 1.7 Hz, 1H), 8.25 (dd, J = 4.9, 0.9 Hz, 1H), 8.11 (dd, J = 8.3, 
1.7 Hz, 1H), 7.51 – 7.48 (m, 2H), 7.46 (d, J = 7.6 Hz, 1H), 7.43 – 7.37 (m, 3H), 7.32 – 
7.28 (m, 1H), 2.57 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 166.95, 148.30, 145.49, 
145.44, 138.61, 138.46, 138.36, 137.35, 136.52, 136.40, 135.74, 135.61, 134.04, 131.54, 
130.79, 129.44, 127.98, 127.91, 127.89, 127.35, 125.53, 122.26, 121.80, 116.75, 20.03. 
19
F NMR (376 MHz, CDCl3) δ -130.14 (d, J = 6.5 Hz). FTIR (ATR, cm
-1
): 3333, 3132, 
1675, 1523, 1484, 1424, 1326, 827, 722. HRMS (ESI-MS) m/z calcd for C22H17FN3O [M 
+ H]
+
 358.1356 found 358.1370. 
 
 
 
2'-fluoro-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (3r): The title 
compound was synthesized following General Procedure A. White solid in 70 % (49.8 
mg, 0.14 mmol), mp = 78 – 80 °C. 1H NMR (400 MHz, CDCl3): δ 9.77 (s, 1H), 8.72 (dd, 
J = 6.8, 2.2 Hz, 1H), 8.67 (dd, J = 4.2, 1.7 Hz, 1H), 8.09 (dd, J = 8.3, 1.7 Hz, 1H), 7.53 – 
7.36 (m, 5H), 7.34 (dd, J = 7.6, 1.3 Hz, 1H), 7.30 (dd, J = 7.6, 1.4 Hz, 1H), 7.12 – 7.04 
(m, 1H), 6.99 (td, J = 7.5, 1.3 Hz, 1H), 6.93 (ddd, J = 9.7, 8.1, 1.3 Hz, 1H), 2.55 (s, 3H). 
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13
C{
1
H} NMR (100 MHz, CDCl3): δ 167.73, 159.75 (d), 148.17, 138.52, 137.77, 136.19, 
136.01, 134.45, 133.54, 131.60 (d), 130.35, 129.48 (d), 129.08, 128.47, 128.46, 127.89, 
127.73, 127.36, 123.91 (d), 121.71 (d), 116.54, 115.60 (d), 20.04. 
19
F NMR (376 MHz, 
CDCl3) δ -115.43 (td, J = 8.7, 5.3 Hz). FTIR (ATR, cm
-1
): 3337, 2925, 1673, 1519, 1482, 
1423, 1325, 1233, 1026, 826, 753. HRMS (ESI-MS) m/z calcd for C23H18FN2O [M + H]
+
 
357.1403 found 357.1407. 
 
 
 
4'-bromo-2'-fluoro-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (3s): 
The title compound was synthesized following General Procedure A. White solid in 58 % 
(50.4 mg, 0.11 mmol), mp = 67 – 68 °C. 1H NMR (400 MHz, CDCl3): δ 9.78 (s, 1H), 
8.73 (dd, J = 6.0, 3.0 Hz, 1H), 8.68 (dd, J = 4.2, 1.7 Hz, 1H), 8.12 (dd, J = 8.3, 1.7 Hz, 
1H), 7.54 – 7.48 (m, 2H), 7.45 – 7.38 (m, 2H), 7.35 (ddd, J = 7.6, 1.4, 0.7 Hz, 1H), 7.31 
(d, J = 7.8 Hz, 1H), 7.27 – 7.23 (m, 1H), 7.19 – 7.10 (m, 2H), 2.55 (s, 3H). 13C{1H} 
NMR (100 MHz, CDCl3): δ 167.47, 159.54 (d), 148.24, 138.51, 137.63, 136.34, 136.12, 
134.26, 132.61 (d), 132.44, 130.70, 129.20, 128.33, 127.98, 127.38, 127.31 (d), 127.01 
(d), 122.06, 121.91 (d), 121.73, 119.32 (d), 116.75, 20.04. 
19
F NMR (376 MHz, CDCl3) δ 
-112.36 (t, J = 8.6 Hz). FTIR (ATR, cm
-1
): 3343, 3064, 1675, 1523, 1483, 1424, 1386, 
1326, 892, 790. HRMS (ESI-MS) m/z calcd for C23H17BrFN2O [M + H]
+
 435.0508 found 
435.0505. 
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2',4'-difluoro-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (3t): The 
title compound was synthesized following General Procedure A. White solid in 55 % 
(41.1 mg, 0.10 mmol). mp = 136 – 138 °C. 1H NMR (400 MHz, CDCl3): δ 9.77 (s, 1H), 
8.72 (dd, J = 6.1, 2.9 Hz, 1H), 8.68 (dd, J = 4.2, 1.7 Hz, 1H), 8.12 (dd, J = 8.3, 1.7 Hz, 
1H), 7.54 – 7.47 (m, 2H), 7.45 – 7.37 (m, 3H), 7.37 – 7.32 (m, 1H), 7.29 – 7.22 (m, 1H), 
6.79 – 6.65 (m, 2H), 2.54 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3): δ 167.61, 162.24 
(dd), 159.42 (dd), 148.20, 138.48, 137.89, 136.36, 136.07, 134.29, 132.61, 132.33 (dd), 
130.53, 129.16, 128.50, 127.97, 127.40, 123.97 (dd), 121.99, 121.72, 116.67, 111.18(dd), 
104.01 (dd), 20.01. 
19
F NMR (376 MHz, CDCl3) δ -110.75 – -110.93 (m). FTIR (ATR, 
cm
-1
): 3342, 3059, 1673, 1519, 1482, 1423, 1385, 1326, 1266, 966, 791. HRMS (ESI-
MS) m/z calcd for C23H17F2N2O [M + H]
+
 375.1309 found 375.1318. 
 
 
 
2'-fluoro-3,5'-dimethyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (3u): The 
title compound was synthesized following General Procedure A. White solid in 60 % 
(44.4 mg, 0.12 mmol), mp = 132 – 134 °C. 1H NMR (400 MHz, CDCl3) δ 9.78 (s, 1H), 
8.74 (dd, J = 7.0, 1.9 Hz, 1H), 8.68 (dd, J = 4.2, 1.7 Hz, 1H), 8.09 (dd, J = 8.3, 1.7 Hz, 
1H), 7.52 – 7.44 (m, 2H), 7.44 – 7.36 (m, 2H), 7.32 (dt, J = 7.6, 1.0 Hz, 1H), 7.30 – 7.25 
(m, 1H), 7.23 (dd, J = 7.3, 2.2 Hz, 1H), 6.86 – 6.74 (m, 2H), 2.55 (s, 3H), 2.14 (s, 
3H).
13
C{
1
H} NMR (100 MHz, CDCl3): δ 167.81, 157.91 (d), 148.11, 138.51, 137.72, 
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136.22, 135.96, 134.52, 133.80, 133.22 (d), 131.95 (d), 130.25, 129.87, 129.79, 129.08, 
128.41, 127.90, 127.37, 127.35 (d), 121.66 (d), 116.49, 115.18 (d), 20.57, 20.05. 
19
F 
NMR (376 MHz, CDCl3) δ -120.81 (q, J = 7.3 Hz). FTIR (ATR, cm
-1
): 3344, 3061, 1677, 
1522, 1483, 1424, 1385, 1326, 826, 760. HRMS (ESI-MS) m/z calcd for C24H20FN2O [M 
+ H]
+
 371.1560 found 371.1572. 
 
 
2'-chloro-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (3v): The title 
compound was synthesized following General Procedure A. White solid in 42 % (31.3 
mg, 0.08 mmol), mp = 181 – 183 °C. 1H NMR (400 MHz, CDCl3) δ 9.78 (s, 1H), 8.70 
(dd, J = 4.1, 1.9 Hz, 1H), 8.68 – 8.62 (m, 1H), 8.08 (dq, J = 8.4, 1.4 Hz, 1H), 7.43 (td, J = 
5.1, 1.5 Hz, 2H), 7.41 – 7.35 (m, 3H), 7.32 (d, J = 7.7 Hz, 1H), 7.26 – 7.20 (m, 2H), 7.13 
– 7.06 (m, 1H), 7.05 – 6.98 (m, 1H), 2.52 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3) δ 
167.55, 148.07, 138.89, 138.46, 137.49, 137.03, 136.16, 135.83, 134.43, 133.27, 131.43, 
130.21, 129.46, 128.96, 128.81, 128.17, 127.86, 127.32, 126.44, 121.75, 121.66, 116.46, 
19.95. FTIR (ATR, cm
-1
): 3339, 3127, 2915, 1676, 1522, 1483, 1425, 1326, 900, 730. 
HRMS (ESI-MS) m/z calcd for C23H18ClN2O [M + H]
+
 373.1108 found 373.1113. 
 
 
 
2'-chloro-5'-methoxy-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide 
(3w): The title compound was synthesized following General Procedure A. Yellow solid 
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in 40 % (32.2 mg, 0.08 mmol), mp = 52 – 53 °C. 1H NMR (400 MHz, CDCl3): δ 9.81 (s, 
1H), 8.73 – 8.68 (m, 2H), 8.08 (dd, J = 8.3, 1.7 Hz, 1H), 7.49 – 7.43 (m, 2H), 7.42 – 7.36 
(m, 2H), 7.34 (ddd, J = 7.7, 1.4, 0.7 Hz, 1H), 7.27 – 7.22 (m, 1H), 7.11 (d, J = 8.8 Hz, 
1H), 6.96 (d, J = 3.0 Hz, 1H), 6.57 (dd, J = 8.8, 3.1 Hz, 1H), 3.64 (s, 3H), 2.55 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 167.55, 157.79, 148.03, 139.57, 138.43, 137.35, 
137.08, 136.17, 135.90, 134.48, 130.27, 130.13, 128.85, 128.06, 127.86, 127.32, 124.58, 
121.77, 121.64, 116.43, 115.94, 115.73, 55.61, 19.94. FTIR (ATR, cm
-1
): 3333, 3063, 
2958, 1671, 1519, 1482, 1423, 1324, 1228, 905, 728. HRMS (ESI-MS) m/z calcd for 
C24H20ClN2O2 [M + H]
+
 403.1213 found 403.1226. 
 
 
 
2-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)benzamide (3z): The title 
compound was synthesized following General Procedure A. Yellow solid in 45 % (37.9 
mg, 0.09 mmol), mp = 138 – 140 °C. 1H NMR (400 MHz, CDCl3): δ 10.20 (s, 1H), 8.85 
(dd, J = 7.6, 1.4 Hz, 1H), 8.49 (dd, J = 4.2, 1.7 Hz, 1H), 8.11 – 8.05 (m, 1H), 8.03 (dd, J 
= 8.3, 1.7 Hz, 1H), 7.85 – 7.76 (m, 2H), 7.62 – 7.55 (m, 2H), 7.55 – 7.48 (m, 2H), 7.45 
(dd, J = 8.3, 1.4 Hz, 1H), 7.36 (ddd, J = 4.9, 2.9, 1.6 Hz, 3H), 7.27 – 7.21 (m, 1H), 2.41 
(s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 166.87, 166.32, 151.47, 148.04, 138.58, 
137.11, 136.14, 134.60, 133.66, 132.54, 130.88, 130.17, 129.98, 129.59, 129.24, 129.17, 
128.94, 127.92, 127.38, 126.40, 121.90, 121.56, 116.52, 15.93. FTIR (ATR, cm
-1
): 3315, 
2927, 1665, 1524, 1484, 1423, 1325, 755, 688. HRMS (ESI-MS) m/z calcd for 
C26H20N3OS [M + H]
+
 422.1327 found 422.1342. 
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2,6-bis(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)benzamide (3z’): The 
title compound was synthesized following General Procedure A. Yellow solid in 26 % 
(30.8 mg, 0.05 mmol), mp = 155 – 157 °C. 1H NMR (400 MHz, CDCl3): δ 9.81 (s, 1H), 
8.64 (dd, J = 4.2, 1.7 Hz, 1H), 8.56 (dd, J = 5.0, 4.0 Hz, 1H), 8.02 (dd, J = 8.3, 1.7 Hz, 
1H), 7.81 – 7.73 (m, 4H), 7.61 (dd, J = 8.9, 6.1 Hz, 1H), 7.58 – 7.53 (m, 2H), 7.41 – 7.37 
(m, 2H), 7.37 – 7.28 (m, 7H), 2.48 (s, 6H). 13C{1H} NMR (100 MHz, CDCl3): δ 166.70, 
165.50, 151.35, 148.05, 139.88, 138.31, 136.30, 133.99, 133.52, 132.37, 130.70, 129.92, 
129.45, 128.87, 128.48, 127.90, 127.36, 126.45, 122.07, 121.58, 116.86, 16.19. FTIR 
(ATR, cm
-1
): 3329, 3056, 1672, 1521, 1484, 1424, 1384, 1326, 905, 726. HRMS (ESI-
MS) m/z calcd for C36H27N4OS2 [M + H]
+
 595.1626 found 595.1646. 
 
 
 
5-methyl-2-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)benzamide (3aa): 
The title compound was synthesized following General Procedure A. Yellow solid in 86 
% (74.9 mg, 0.17 mmol), mp = 147 – 148 °C. 1H NMR (400 MHz, CDCl3): δ 10.18 (s, 
1H), 8.85 (dd, J = 7.6, 1.4 Hz, 1H), 8.48 (dd, J = 4.2, 1.7 Hz, 1H), 8.01 (dd, J = 8.3, 1.7 
Hz, 1H), 7.90 (q, J = 1.0 Hz, 1H), 7.85 – 7.76 (m, 2H), 7.51 (t, J = 7.9 Hz, 1H), 7.44 (dd, 
J = 8.3, 1.4 Hz, 1H), 7.40 – 7.31 (m, 5H), 7.23 (dd, J = 8.3, 4.2 Hz, 1H), 2.49 (s, 3H), 
2.40 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3): δ 166.65, 166.51, 151.34, 148.01, 
139.35, 138.57, 136.83, 136.10, 134.63, 133.70, 132.45, 131.66, 130.73, 129.91, 129.33, 
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128.92, 127.90, 127.37, 126.49, 126.37, 121.84, 121.53, 116.50, 21.35, 15.89. FTIR 
(ATR, cm
-1
): 3316, 3051, 2926, 1662, 1522, 1483, 1424, 1383, 1325, 906, 698. HRMS 
(ESI-MS) m/z calcd for C27H22N3OS [M + H]
+
 436.1484 found 436.1501. 
 
 
5-methoxy-2-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)benzamide (3ab): 
The title compound was synthesized following General Procedure A. Light pink solid in 
80 % (72.1 mg, 0.16 mmol), mp = 162 – 164 °C.  1H NMR (400 MHz, CDCl3): δ 10.21 
(s, 1H), 8.83 (dd, J = 7.6, 1.4 Hz, 1H), 8.45 (dd, J = 4.2, 1.6 Hz, 1H), 7.98 (dt, J = 8.4, 
1.8 Hz, 1H), 7.78 (dd, J = 6.7, 2.9 Hz, 2H), 7.61 (d, J = 2.7 Hz, 1H), 7.49 (t, J = 7.9 Hz, 
1H), 7.45 – 7.36 (m, 2H), 7.36 – 7.30 (m, 3H), 7.20 (ddd, J = 8.1, 4.1, 1.9 Hz, 1H), 7.13 – 
7.05 (m, 1H), 3.91 (s, 3H), 2.38 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 166.56, 
166.02, 160.17, 151.48, 148.03, 148.02, 138.59, 138.14, 136.07, 134.56, 133.88, 133.77, 
129.86, 129.14, 128.91, 127.89, 127.33, 126.33, 121.92, 121.54, 121.46, 117.57, 116.51, 
114.57, 114.55, 55.77, 15.88. FTIR (ATR, cm
-1
): 3317, 3052, 2960, 1661, 1523, 1483, 
1424, 1385, 1326, 1038, 906, 727. HRMS (ESI-MS) m/z calcd for C27H22N3O2S [M + 
H]
+
 452.1433 found 452.1449. 
 
 
 
5-chloro-2-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)benzamide (3ac): 
The title compound was synthesized following General Procedure A. Yellow solid in 61 
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% (55.6 mg, 0.12 mmol), mp = 166 – 168 °C. 1H NMR (400 MHz, CDCl3): δ 10.21 (s, 
1H), 8.82 (dd, J = 7.5, 1.5 Hz, 1H), 8.48 (dd, J = 4.2, 1.7 Hz, 1H), 8.09 (d, J = 2.3 Hz, 
1H), 8.03 (dd, J = 8.3, 1.7 Hz, 1H), 7.84 – 7.76 (m, 2H), 7.55 (dd, J = 8.3, 2.4 Hz, 1H), 
7.51 (d, J = 7.6 Hz, 1H), 7.49 – 7.42 (m, 2H), 7.40 – 7.33 (m, 3H), 7.28 – 7.22 (m, 1H), 
2.39 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 167.27, 164.77, 151.92, 148.13, 
138.56, 138.39, 136.18, 135.47, 134.32, 133.84, 133.54, 130.99, 130.38, 130.14, 128.99, 
128.00, 127.93, 127.92, 127.37, 126.43, 122.20, 121.64, 116.70, 15.95. FTIR (ATR, cm
-
1
): 3310, 3061, 2924, 1663, 1522, 1484, 1424, 1326, 908, 761, 728. HRMS (ESI-MS) m/z 
calcd for C26H19ClN3OS [M + H]
+
 456.0937 found 456.0955. 
 
 
 
 
5-bromo-2-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)benzamide (3ad): 
The title compound was synthesized following General Procedure A. Yellow solid in 55 
% (55.0 mg, 0.11 mmol), mp = 156 – 158 °C. 1H NMR (400 MHz, CDCl3): δ 10.19 (s, 
1H), 8.81 (dd, J = 7.5, 1.5 Hz, 1H), 8.47 (dd, J = 4.2, 1.7 Hz, 1H), 8.24 (d, J = 2.1 Hz, 
1H), 8.03 (dd, J = 8.3, 1.7 Hz, 1H), 7.84 – 7.76 (m, 2H), 7.70 (dd, J = 8.2, 2.2 Hz, 1H), 
7.55 – 7.43 (m, 2H), 7.40 – 7.33 (m, 4H), 7.27 – 7.21 (m, 1H), 2.39 (s, 3H). 13C{1H} 
NMR (100 MHz, CDCl3): δ 167.29, 164.65, 151.88, 148.12, 138.54, 136.16, 134.29, 
133.98, 133.94, 133.52, 133.27, 130.14, 128.99, 128.47, 127.95, 127.35, 126.42, 123.45, 
122.19, 121.63, 116.69, 15.95. FTIR (ATR, cm
-1
): 3308, 3065, 1662, 1523, 1484, 1424, 
1326, 905, 824, 726.  HRMS (ESI-MS) m/z calcd for C26H19BrN3OS [M + H]
+
 500.0432 
found 500.0452. 
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2-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)naphthalene-1-carboxamide 
(3ae): The title compound was synthesized following General Procedure A. Light yellow 
solid in 80 % (75.4 mg, 0.16 mmol), mp = 98 – 100 °C. 1H NMR (400 MHz, CDCl3): δ 
10.04 (s, 1H), 8.94 (dd, J = 7.6, 1.5 Hz, 1H), 8.61 (dd, J = 4.2, 1.7 Hz, 1H), 8.29 – 8.21 
(m, 1H), 8.07 (dd, J = 8.3, 1.7 Hz, 1H), 8.04 – 7.99 (m, 1H), 7.98 – 7.93 (m, 1H), 7.80 – 
7.72 (m, 2H), 7.63 – 7.51 (m, 4H), 7.48 (dd, J = 8.3, 1.5 Hz, 1H), 7.36 – 7.28 (m, 4H), 
2.51 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 166.78, 166.77, 151.42, 148.17, 
138.44, 136.41, 136.29, 134.41, 133.54, 133.32, 130.49, 129.87, 129.85, 129.15, 128.83, 
128.55, 128.26, 127.99, 127.89, 127.39, 127.27, 126.93, 126.41, 125.92, 122.21, 121.68, 
116.85, 16.23. HRMS (ESI-MS) m/z calcd for C30H22N3OS [M + H]
+
 472.1484 found 
472.1504. 
 
 
1-methyl-3-(4-methyl-2-phenyl-1,3-thiazol-5-yl)-N-(quinolin-8-yl)-1H-pyrrole-2-
carboxamide (3af): The title compound was synthesized following General Procedure 
A. Yellow solid in 74 % (62.8 mg, 0.15 mmol), mp = 75 – 77 °C. 1H NMR (400 MHz, 
CDCl3): δ 10.34 (s, 1H), 8.83 (dd, J = 7.7, 1.3 Hz, 1H), 8.30 (dd, J = 4.2, 1.7 Hz, 1H), 
7.97 (dd, J = 8.3, 1.7 Hz, 1H), 7.95 – 7.88 (m, 2H), 7.49 (t, J = 8.0 Hz, 1H), 7.46 – 7.36 
(m, 4H), 7.15 (dd, J = 8.3, 4.2 Hz, 1H), 6.85 (d, J = 2.6 Hz, 1H), 6.27 – 6.22 (m, 1H), 
4.12 (s, 3H), 2.37 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 166.73, 159.79, 152.40, 
148.00, 138.61, 135.83, 135.15, 133.98, 129.86, 129.03, 127.91, 127.89, 127.25, 126.38, 
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124.94, 124.91, 121.50, 121.22, 117.17, 115.82, 111.50, 38.17, 15.92. FTIR (ATR, cm
-1
): 
3293, 2954, 1656, 1525, 1484, 1424, 1326, 824, 760.  HRMS (ESI-MS) m/z calcd for 
C25H21N4OS [M + H]
+
 425.1436 found 425.1454. 
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C h a p t e r  3 :  A  N i c k e l - C a t a l y z e d  S e q u e n t i a l  
O x i d a t i v e  D e c a r b o x y l a t i v e  ( H e t e r o ) A r y l a t i o n  a n d  
C y c l i z a t i o n  f o r  t h e  S y n t h e s i s  o f  P h e n a n t h r i d i n o n e s  
3.1. Overview 
  As our work in Chapter 2 shows, we were able to achieve a new nickel-catalyzed 
oxidative decarboxylative (hetero)arylation of unactivated C H bonds. During the 
optimization of the reaction conditions for the Ni-catalyzed ODC reaction, we noticed the 
formation of a small amount of byproduct, which we later characterized to be the 
phenanthridinone products. We found that phenanthridinones that contain heterocycles 
are limited under oxidative conditions as coupling partners. Knowing our new catalyst 
system works with heteroaromatic carboxylates, we should be able to achieve a 
sequential heteroarylation and cyclization to form heterocycle-containing 
phenanthridinones. 
  Phenanthridinones are key structures found in a variety of natural products and 
biologically active molecules
51
 such as, anticancer therapeutics,
52
 polymerase (PARP),
53
 
aurora kinase inhibitors,
54
 antimalarial,
55
 anti-HIV,
56
 and antituberculosis activities
57
 to 
name a few. In addition, phenanthridinone derivatives are also utilized in material 
sciences because of the planar heterocycle-containing system providing effective 
photoconducting and photovoltaic properties in optoelectronics and electroluminescence 
(Figure 1).
58
 
  Heterocycle-containing phenanthridinones, however, are less explored than their non-
heterocycle-containing counterparts. The ability to synthesize a library of different 
heterocycle-containing phenanthridinones could prove valuable in a world of evolving 
diseases, since heterocycles are sometimes more potent than non-heterocycle drugs.12  
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Figure 1. Phenanthridinones in medicine and natural products. 
  Phenanthridinones are typically synthesized from traditional cross-coupling reactions 
such as the Suzuki-Miyaura coupling or Buchwald-Hartwig amination reaction.
59
 
However, because of the inherent drawbacks associated with the required 
prefunctionalized starting materials, more recent efforts have led to oxidative variants 
with transition metals employing dehydrogenative coupling, yet these examples are 
limited to the use of simple arenes as coupling partners.
60
 However, Baidya and co-
workers recently reported a copper-mediated dehydrogenative annulation of benzamides 
with 3,5-difluorpyridine (Scheme 17).
61
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Scheme 17. Examples of heterocycle containing phenanthridinone syntheses. 
  Oxidative decarboxylative coupling reactions have been applied to the synthesis of 
phenanthridinones (Scheme 18). In 2014, Wang and co-workers reported the first 
synthesis of phenanthridinones utilizing a  Pd-catalyzed ODC strategy with aryl 
acylperoxides and N-methoxybenzamides.
62
 However, despite the fair reaction yields, the 
method was limited to aryl acylperoxides, which are commercially limited. Similarly, 
Miura and co-workers reported an analogous copper-mediated ODC reaction for the 
synthesis of phenanthridinones from ortho-nitrobenzoates.65 While the work from Miura 
had advantages over Wang’s (i.e. commercially available and shelf stable benzoates) both 
of their catalyst systems were limited to only 2-nitrobenzoates and aryl acylperoxides, 
heteroaryl carboxylates were ineffective coupling partners. 
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Scheme 18. Oxidative decarboxylative phenanthridinone syntheses. 
  At this time, there were no examples of a catalytic oxidative decarboxylative arylation 
and cyclization for the synthesis of heterocycle-containing phenanthridinones. From our 
studies in Chapter 2, we looked to extend our new methodology to couple heteroaromatic 
carboxylates with unactivated CH bonds (Scheme 19).  
 
Scheme 19. Targeted goal of achieving a sequential oxidative decarboxylative 
heteroarylation and cyclization with unactivated CH bonds. 
3.2. Results 
3.2.1. Optimization of the Sequential Oxidative Decarboxylative (Hetero)arylation 
and Cyclization Reaction 
  We designed our reaction using 2-methyl-N-(quinolin-8-yl)benzamide and 2-
fluoronicotinic carboxylate in the presence of nickel and silver. We begin by using 
Ni(OAc)2•4H2O as our pre-catalyst in the presence of Ag2CO3 as our oxidant which 
generated the desired product 5a in 25% yield (Table 3.1 entry 1). All other nickel salts 
tested provided low yields of the desired product in (<10%). AgNO3 was the best oxidant 
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for this transformation when the loading was increased to 4.0 equivalents, while other 
oxidants explored (AgOPiv and AgOAc) gave lower yields (Table 3.1 entry 3 and 4). 
Finally, when we increased the loading of 5a from 1.5 equivalents to 2.0 equivalents, the 
yield of the desired product increased to 81% (Table 3.1 entry 6). Therefore, the final 
optimized conditions employ 20 mol% of Ni(OAc)2•4H2O, AgNO3 (4.0 equiv), and 
Na2CO3 (4.0 equiv) in DMA at 130 C for 24 h.  
Table 3.1. Optimization of the nickel-catalyzed sequential oxidative decarboxylative 
(hetero)arylation
a 
 
entry catalyst oxidant yield (%)
b 
1 Ni(OAc)2•4H2O Ag2CO3 25 
2 Ni(acac)2 Ag2CO3 4 
3
c 
Ni(OAc)2•4H2O AgOPiv 63 
4
c 
Ni(OAc)2•4H2O AgOAc 51 
5
 d
 Ni(OAc)2•4H2O Ag3PO4 35 
6
c,e 
Ni(OAc)2•4H2O AgNO3  81 (80)
f 
7
c,e 
- AgNO3 0 
8
e 
Ni(OAc)2•4H2O - 0 
a
Reaction conditions: 1a (0.2 mmol), 4a (0.3 mmol) in DMA (2 mL). 
b1
H NMR yield 
with 1,3,5-trimethoxybenzene as an internal standard. 
c
Ag (4.0 equiv). 
d
1.3 equiv Ag3PO4 
(4.0 equiv of Ag)
 e
4a (0.4 mmol). 
f
Isolated yield. 
3.2.2. Scope of the Sequential Oxidative Decarboxylative (Hetero)arylation and 
Cyclization Reaction  
 With the optimized conditions in hand, we turned our attention to the heteroaromatic 
carboxylate scope (Table 3.2). The reaction is compatible with both electron-withdrawing 
(5d, 5e, and 5g), and electron-donating (5b, 5c, and 5f) substituents on the nicotinic 
carboxylate. We found that substituents in the C6 position of the nicotinate resulted in 
lower yields (4c – 4e) than their unsubstituted counterpart (4a). Analogous to the ODC 
reaction described in Chapter 2, this new catalyst system also tolerates bromo- and 
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chloro-substitution (5e and 5g) allowing for further functionalization in subsequent cross-
coupling reactions. This new catalyst method could also be conducted on a 1 mmol scale 
without a significant reduction in yield (75% of 5a). To our delight, we found that other 
heteroaromatic carboxylates also couple under this new reaction system. Quinoline and 
thiophenes are found in pharmacologically active compounds
63
 and material sciences
64
 
and the corresponding carboxylates (5h-5j) also proved to be competent coupling 
partners under these catalytic conditions. 
Table 3.2. Ni-catalyzed oxidative decarboxylative arylation and cyclization 
heteroaromatic carboxylate scope
a
 
 
a
Isolated yields. Reaction conditions: 1a (0.2 mmol), 4 (0.4 mmol) in DMA (2 mL). 
b
130 
C for 8 h then 170 C for 16 h c170 C. 
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  This new catalyst system also worked with substituted benzoates as seen in our 
previous ODC reaction (Table 3.3). To our surprise, the sequential oxidative 
decarboxylative arylation proceeded smoothly at 170 C. A variety of different electron-
donating (5l and 5o) and electron-withdrawing groups (5k, 5m, and 5n) were tolerated on 
the benzoates. However, we did notice di-ortho-substituted 2-fluoro-6-methylbenzaote 
(4p) was an ineffective coupling partner under these reaction conditions. This new 
method illustrates the ability to couple and cyclize not only heteroaromatic carboxylates 
but also ortho-fluorobenzoates. 
Table 3.3. Ni-catalyzed oxidative decarboxylative arylation and cyclization benzoate 
scope
a
 
 
 a
Isolated yields. Reaction conditions: 1a (0.2 mmol), 4 (0.4 mmol) in DMA (2 mL). 
  Finally, we explored the scope of the substituted benzamides with the 2-fluoronicotinic 
carboxylate (Table 3.4). Benzamide substrates with electron-donating groups para to the 
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benzamide moiety (5q and 5r) gave higher yields than the electron-withdrawing group 
(5s). In addition, substrates bearing electron-donating groups in the meta-position (5t and 
5u) gave higher yields (54% and 70%) than those with electron-withdrawing groups (5v, 
31%). We did notice that in the absence of an ortho-substituent on the benzamide, 
product formation was reduced (5w). This new catalyst method also tolerates heterocyclic 
benzamides (5x) opening the potential to build a vast library of substituted 
phenanthridinones.  
Table 3.4. Ni-catalyzed oxidative decarboxylative arylation and cyclization benzamide 
scope
a
 
 
a
Isolated yields. Reaction conditions: 1 (0.2 mmol), 4a (0.4 mmol) in DMA (2 mL). 
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3.2.3. Preliminary Mechanistic Studies of the Sequential Oxidative Decarboxylative 
(Hetero)Arylation and Cyclization Reaction 
 First, we conducted a series of radical trapping experiments under our reaction 
conditions to explore the possible formation of free radical intermediates. The reaction of 
1a and 4a in the presence of 1.0 equiv of either TEMPO or DHA only slightly decreased 
the yield of the desired product 5a (Table 3.5, entry 2 and 3). These data suggest there 
could be a well-defined silver-aryl intermediate in this reaction, analogous to the ODC 
reaction reported above (Chapter 2). 
Table 3.5. Radical scavengers with the nickel-catalyzed sequential oxidative 
decarboxylative (hetero)arylation and cyclization reaction
a
 
 
entry Radical scav. (1 equiv) yield (%)
b
 
1 none 81 
2 TEMPO 74 
3 DHA 78 
a
Reaction conditions: Benzamide 1a (0.2 mmol), heteroaromatic carboxylate 4a (0.4 
mmol), Ni(OAc)2•4H2O (20 mol %), AgNO3 (4.0 equiv), Na2CO3 (4.0 equiv), radical 
scavenger (1.0 equiv) in DMA (2 mL) for 24 h at 130 °C under a N2 atmosphere.
 b1
H 
NMR yield with 1,3,5-trimethoxybenzene as an internal standard. 
 In order to gain insight into the CH activation step, we carried out a 
deuterium/hydrogen exchange experiment. We measured the KIE from an intermolecular 
competition experiment with an equimolar mixture of 1a and 1a-d7 under our standard 
reaction conditions for 30 minutes. The KIE determined from the resulting mixture of 5a 
and 5a-d7 products is 4.5 (Scheme 20). Next, we carried out the deuterium/hydrogen 
exchange experiment of 1a-d7 under the standard conditions for 30 min., the D content 
only dropped by >1%. These data indicate a primary isotope effect and that the CH 
activation is irreversible. 
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Scheme 20. Kinetic isotope effect of the nickel-catalyzed sequential oxidative 
decarboxylative. 
 
a
Reaction conditions: Benzamide 1a (0.1 mmol), 1a-d7 (0.1 mmol), heteroaromatic 
carboxylate 4a (0.4 mmol), Ni(OAc)2•4H2O (20 mol %), AgNO3 (4.0 equiv), Na2CO3 
(4.0 equiv) in DMA (2 mL) for 30 min. at 130 °C under a N2 atmosphere.
 b
Benzamide 
1a-d7 (0.2 mmol), heteroaromatic carboxylate 4a (0.4 mmol), Ni(OAc)2•4H2O (20 mol 
%), AgNO3 (4.0 equiv), Na2CO3 (4.0 equiv) in DMA (2 mL) for 30 min. at 130 °C under 
a N2 atmosphere. 
c1
H NMR yield with 1,3,5-trimethoxybenzene as an internal standard. 
  We found that Na2CO3 promotes a SNAr-type cyclization following the oxidative 
decarboxylative coupling. From our ODC reaction reported above (Chapter 2), we 
prepared 2'-fluoro-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide (3r) and 
heated the compound at 170 C in the presence of Na2CO3 to mimic our benzoate 
reaction conditions to see if the compound would undergo cyclization. To our delight, 
compound 3r underwent a SNAr cyclization to generate the desired product (5k) in 
quantitative yield (Scheme 21). This type of cyclization has been seen before in other 
reactions.
65
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Scheme 21. Base promoted cyclization by SNAr.
a 
 
a
Reaction conditions:
 
2'-fluoro-3-methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-
carboxamide 3r (0.2 mmol) and Na2CO3 (4.0 equiv) in DMA (2 mL) for 24 h at 170 °C 
under a N2 atmosphere. 
b1
H NMR yield with 1,3,5-trimethoxybenzene as an internal 
standard. 
3.2.4.  Proposed Reaction Mechanism of the Sequential Oxidative Decarboxylative 
(Hetero)Arylation and Cyclization Reaction 
  Based on the results above, we proposed a pathway for this new catalytic 
transformation that follows closely with that proposed for the Ni-catalyzed ODC reaction 
(Scheme 22). The catalyst undergoes ligand exchange with the amide and then CH 
activation to form the nickel(II) metallacycle B. Transmetallation of the aryl fragment to 
the nickel(II) metallacycle with concomitant oxidation of nickel(II) to nickel(III) to form 
intermediate C. After reductive elimination of the high-valent nickel(III) intermediate to 
from the new CC bond resulting in complex D. The desired product is then formed by 
SNAr cyclization.                       
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Scheme 22. Proposed reaction mechanism of the sequential oxidative decarboxylative 
(hetero)arylation and cyclization reaction. 
 
3.3. Conclusion 
  In conclusion, we have developed a new method for the synthesis of heterocycle-
containing phenanthridinones via an oxidative decarboxylative annulation reaction. This 
new method was not only effective for the coupling of heteroaromatic carboxylates but 
also ortho-fluoro benzoates. This new method could allow for the synthesis of a library of 
heterocycle-containing phenanthridinones with biological properties. 
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3.4. Experimental  
General Considerations. All manipulations were performed using standard Schlenk or 
glovebox techniques under a nitrogen atmosphere. All solvents (including dry DMA) 
were purchased from Alfa-Aesar, Fisher, or Cambridge Isotope Laboratories (deuterated 
solvents) and used as received. All other reagents were purchased from Maybridge, 
Oakwood, Acros, Alfa-Aesar, Astatech, Strem and CDN Isotopes and used without 
further purification. All NMR spectra were recorded at ambient temperature on an 
Agilent 400 MHz or JEOL 400 MHz (
1
H, 400 MHz; 
13
C{
1
H}, 100 MHz; 
19
F, 376 MHz) 
spectrometer. Chemical shifts are referenced to the residual solvent signals (CDCl3: 7.26 
ppm (
1
H) and 77.2 ppm (
13
C), DMSO-d6: 2.50 ppm (
1
H) and 39.5 ppm (
13
C)).45 High 
resolution mass spectra were obtained on a Thermofisher Scientific Q Exactive Mass 
Spectrometer. IR spectra were recorded on a PerkinElmer (Spectrum 100) FT-IR 
spectrometer. Column chromatography was performed using Silicycle Silica Flash P60 
silica gel. 
Optimization of the Oxidative Decarboxylative Annulation Reaction 
Representative Procedure for the Optimization of the Oxidative Decarboxylative 
Annulation Reaction. An oven-dried 50 mL Schlenk tube with a stirring bar was 
charged with 2-fluoronicotinic acid 4a (42.3 mg, 0.300 mmol), sodium carbonate (31.7 
mg, 0.300 mmol), and dry DMA (1 mL). The reaction vessel was placed in a pre-heated 
oil bath and stirred for 0.5 h at 110 °C. The solvent was removed under reduced pressure 
until dry. 2-Methyl-N-(quinolin-8-yl) benzamide 1a (52.4 mg, 0.200 mmol), 
Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), Ag2CO3 (110 mg, 0.400 mmol), Na2CO3 (84 mg, 
0.80 mmol) were added and the tube was evacuated and backfilled with nitrogen three 
times after which dry DMA (2 mL) was added via syringe. The reaction mixture was 
stirred at 130 °C for 24 h. Upon completion, the reaction tube was cooled to room 
temperature. The solution was diluted with dichloromethane (30 mL) and filtered through 
a pad of celite. The celite was then washed with dichloromethane (2 x 30 mL). The 
solvent was concentrated by rotary evaporation (to ~2 mL) and the remaining solvent was 
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removed under vacuum. A 1,3,5-trimethoxybenzene (5.00 mg) NMR standard was added 
to the residue and the crude mixture was dissolved in CDCl3 for 
1
H NMR analysis. 
Optimization of the Precatalyst
a
 
 
entry pre-catalyst yield 5a (%)
b 
1 NiBr2•H2O 3 
2 Ni(HCO2)2•2H2O 6 
3
 
Ni(acac)2 4 
4 NiI2 9 
5 NiCO3•2Ni(OH)2•H2O 1 
6 Ni(OTf)2 3 
7 NiF2 1 
8 NiCl2 5 
9
 
Ni(OAc)2•4H2O 63 
10
c
 Ni(OAc)2•4H2O  6 
11
d 
Ni(OAc)2•4H2O  57 
12 none 0 
a
Reaction conditions: 1a (0.200 mmol), 4a (0.300 mmol) in DMA (2 mL). 
b1
H NMR 
yield determined from integration using 1,3,5-trimethoxybenzene as an internal standard. 
c
10 mol% 
d
30 mol% 
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Optimization of the Oxidant
a 
 
entry oxidant yield 5a (%)
b 
1 Ag
2
CO
3
 63 
2
c AgNO
3  72 
3
c AgOAc  51 
4
c
 AgOPiv  63 
5
f Ag
3
PO
4
 35 
6 Ag
2
O 18 
7 oxone 0 
8 O
2
 (1 atm) 0 
9
d AgNO
3  56 
10
e AgNO
3  62 
11 none 0 
a
Reaction conditions: 1a (0.200 mmol), 4a (0.300 mmol) in DMA (2 mL). 
b1
H NMR 
yield determined from integration using 1,3,5-trimethoxybenzene as an internal standard. 
c 
Ag (4.0 equiv) 
d
3.0 equiv 
e
5.0 equiv 
f d
1.3 equiv Ag3PO4 (4.0 equiv of Ag) 
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Optimization of the Solvent
a
 
 
entry solvent yield 5a (%)
b 
1 DMA 72 
2 DMF 52 
3
 NMP 63 
4 DMSO 10 
5 PhCH3 0 
6 MeCN 0 
7
c DMA 38 
8
d DMA 73 
a
Reaction conditions: 1a (0.200 mmol), 4a (0.300 mmol) in solvent (2 mL). 
b1
H NMR 
yield determined from integration using 1,3,5-trimethoxybenzene as an internal standard. 
c
1 mL 
d
3 mL 
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Optimization of the Base
a
 
 
entry base yield 5a (%)
b 
1 Li2CO3 53 
2 Na2CO3 72 
3
 K2CO3 18 
4 NaOAc 40 
5 pyridine 47 
6 none 29 
a
Reaction conditions: 1a (0.200 mmol), 4a (0.300 mmol) in DMA (2 mL). 
b1
H NMR 
yield determined from integration using 1,3,5-trimethoxybenzene as an internal standard. 
 
Optimization of the Temperature
a 
 
entry Temperature (°C) yield 5a (%)
b 
1 120 56 
2 130 72 
3
 140 73 
4 150 73 
a
Reaction conditions: 1a (0.200 mmol), 4a (0.300 mmol) in DMA (2 mL). 
b1
H NMR 
yield determined from integration using 1,3,5-trimethoxybenzene as an internal standard. 
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Equivalents of 4a
a 
 
entry 4a yield 5a (%)
b 
1 1.5 equiv 73 
2 2.0 equiv 81 
3 3.0 equiv 81 
a
Reaction conditions: 1a (0.200 mmol), 4a in DMA (200 mL). 
b1
H NMR yield 
determined from integration using 1,3,5-trimethoxybenzene as an internal standard. 
General Procedure for the Oxidative Decarboxylative Annulation Reaction  
Procedure A: An oven-dried 50 mL Schlenk tube with a stirring bar was charged with 
carboxylic acid 4 (0.400 mmol), Na2CO3 (42.3 mg, 0.400 mmol), and dry DMA (1 mL). 
The reaction vessel was placed in a pre-heated oil bath and stirred for 0.5 h at 110 °C. 
The solvent was then removed under reduced pressure until dry and the carboxylate salt 
was used without further purification. The corresponding benzamide 1 (0.200 mmol), 
Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), AgNO3 (136 mg, 0.800 mmol), and Na2CO3 (84 
mg, 0.80 mmol) were added and the tube was evacuated and backfilled with nitrogen 
three times after which dry DMA (2 mL) was added via syringe. The reaction mixture 
was stirred at 130 °C for 24 h. Upon completion, the reaction tube was cooled to room 
temperature. The solution was diluted with dichloromethane (30 mL) and filtered through 
a pad of celite. The celite was then washed with dichloromethane (2 x 30 mL). The 
solvent was removed by rotary evaporation (to ~2 mL) and concentrated under vacuum. 
The resulting residue was purified by silica gel column chromatography (gradient elution, 
dichloromethane:ethyl acetate (19:1, v/v) to (7:1, v/v)), to yield the corresponding 
product. 
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Procedure B: An oven-dried 50 mL Schlenk tube with a stirring bar was charged with 
carboxylic acid 4 (0.400 mmol), Na2CO3 (42.3 mg, 0.400 mmol), and dry DMA (1 mL). 
The reaction vessel was placed in a pre-heated oil bath and stirred for 0.5 h at 110 °C. 
The solvent was then removed under reduced pressure until dry and the carboxylate salt 
was used without further purification. The corresponding benzamide 1 (0.200 mmol), 
Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), AgNO3 (136 mg, 0.800 mmol), and Na2CO3 (84 
mg, 0.80 mmol) were added and the tube was evacuated and backfilled with nitrogen 
three times after which DMA (2 mL) was added via syringe. The reaction mixture was 
stirred at 170 °C for 24 h. Upon completion, the reaction tube was cooled to room 
temperature. The solution was diluted with dichloromethane (30 mL) and filtered through 
a pad of celite, the celite was washed with dichloromethane (2 x 30 mL). The solvent was 
removed by rotary evaporation (to ~2 mL) and concentrated under vacuo. The residue 
was purified by silica gel column chromatography (gradient elution, 
dichloromethane:ethyl acetate (19:1, v/v) to (7:1, v/v)), yielding the corresponding 
product. 
 
Procedure C: An oven-dried 50 mL Schlenk tube with a stirring bar was charged with 
carboxylic acid 4 (0.400 mmol), Na2CO3 (42.3 mg, 0.400 mmol), and dry DMA (1 mL). 
The reaction vessel was placed in a pre-heated oil bath and stirred for 0.5 h at 110 °C. 
The solvent was removed under reduced pressure until dry and the carboxylate salt was 
used without further purification. The corresponding benzamide 1 (0.200 mmol), 
Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), AgNO3 (136 mg, 0.800 mmol), Na2CO3 (84 mg, 
0.80 mmol) were added and the tube was evacuated and backfilled with nitrogen three 
times after which DMA (2 mL) was added via syringe. The reaction mixture was stirred 
at 130 °C for 8h then 170 C for 16h. Upon completion, the reaction tube was cooled to 
room temperature. The solution was diluted with dichloromethane (30 mL) and filtered 
through a pad of celite, the celite was washed with dichloromethane (2 x 30 mL). The 
solvent was removed by rotary evaporation (to ~2 mL) and concentrated under vacuo. 
The residue was purified by silica gel column chromatography (gradient elution, 
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dichloromethane:ethyl acetate (19:1, v/v) to (7:1, v/v)), yielding the corresponding 
product. 
 
Procedure for the 1 mmol Scale Oxidative Decarboxylative Annulation Reaction.  
An oven-dried 100 mL Schlenk tube with a stirring bar was charged with 2-
fluoronicotinic acid 4a (282 mg, 2.00 mmol), Na2CO3 (212 mg, 2.00 mmol), and dry 
DMA (5 mL). The reaction vessel was placed in a pre-heated oil bath and stirred for 0.5 h 
at 110 °C. The solvent was removed under reduced pressure until dry and the carboxylate 
salt was used without further purification. The corresponding 2-methyl-N-(quinolin-8-yl) 
benzamide 1a (262 mg, 1.00 mmol), Ni(OAc)2•4H2O (49.7 mg, 0.20 mmol), AgNO3 (679 
mg, 4.00 mmol), Na2CO3 (424 mg, 4.00 mmol) were added and the tube was evacuated 
and backfilled with nitrogen three times after which DMA (10 mL) was added via 
syringe. The reaction mixture was stirred at 130 °C for 24 h. Upon completion, the 
reaction tube was cooled to room temperature. The solution was diluted with 
dichloromethane (50 mL) and filtered through a pad of celite, the celite was washed with 
dichloromethane (4 x 50 mL). The solvent was removed by rotary evaporation (to ~10 
mL) and concentrated under vacuo. The residue was purified by silica gel column 
chromatography (gradient elution, dichloromethane:ethyl acetate (19:1, v/v) to (7:1, 
v/v)), yielding 253 mg (0.75 mmol) of the corresponding product in 75% yield.  
Challenging Carboxylates 
Heteroaromatic carboxylates that do not undergo decarboxylative arylation and 
cyclization under the standard reaction conditions.  
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Mechanistic Studies 
Control Reactions with Radical Scavengers.  
An oven-dried 50 mL Schlenk tube with a stirring bar was charged with 2-fluoronicotinic 
acid 4a (56.4 mg, 0.400 mmol), sodium carbonate (42.3 mg, 0.400 mmol), and dry DMA 
(1 mL). The reaction vessel was placed in a pre-heated oil bath and stirred for 0.5 h at 
110 °C. The solvent was removed under reduced pressure until dry and the resulting 
carboxylate salt was used without further purification. 2-methyl-N-(quinolin-8-yl) 
benzamide 1a (52.4 mg, 0.200 mmol), Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), AgNO3 
(136 mg, 0.800 mmol), Na2CO3 (84 mg, 0.80 mmol), and either TEMPO (31.2 mg, 0.200 
mmol) or DHA (36.0, 0.200 mmol) were added. The tube was evacuated and backfilled 
with nitrogen three times after which DMA (2 mL) was added via syringe. The reaction 
mixture was stirred at 130 °C for 24 h. Upon completion, the reaction tube was cooled to 
room temperature. The solution was diluted with dichloromethane (30 mL) and filtered 
through a pad of celite. The celite was then washed with dichloromethane (2 x 30 mL). 
The solvent was concentrated by rotary evaporation (to ~2 mL) and the remaining solvent 
was removed under vacuum. A 1,3,5-trimethoxybenzene (5.00 mg) NMR standard was 
added to the residue and the crude mixture was dissolved in CDCl3 for 
1
H NMR analysis. 
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 Control Reactions with Radical Scavengers
a
  
 
entry radical scavenger (1 equiv) yield 5a (%)
b 
1 none 81 
2 TEMPO 74 
3 DHA 78 
a
Reaction conditions: 1a (0.200 mmol), 4a (0.400 mmol) in DMA (2 mL). 
b1
H NMR 
yield with 1,3,5-trimethoxybenzene as an internal standard. 
 
Kinetic Isotope Effect Experiments 
 
Procedure for the Intermolecular Competition Experiment. An oven-dried 50 mL 
Schlenk tube with a stirring bar was charged with 2-fluoronicotinic acid 4a (56.4 mg, 
0.400 mmol), sodium carbonate (42.3 mg, 0.400 mmol), and dry DMA (1 mL). The 
reaction vessel was placed in a pre-heated oil bath and stirred for 0.5 h at 110 °C. The 
solvent was removed under vacuum until dry and the resulting carboxylate salt was used 
without further purification. 1a (26.2 mg, 0.100 mmol), 6-(methyl-d3)-N-8-quinolinyl-
benzamide-2,3,4,5-d4  1a-d7 (26.9 mg, 0.100 mmol), Ni(OAc)2•4H2O (9.9 mg, 0.040 
mmol), AgNO3 (136 mg, 0.800 mmol), Na2CO3 (84 mg, 0.80 mmol) were added, the tube 
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was evacuated and backfilled with nitrogen three times after which DMA (2 mL) was 
added via syringe. The reaction mixture was stirred at 130 °C for 30 minutes. Upon 
completion, the reaction tube was cooled to room temperature. The solution was diluted 
with dichloromethane (30 mL) and filtered through a pad of celite. The celite was then 
washed with dichloromethane (2 x 30 mL). The solvent was concentrated by rotary 
evaporation (to ~2 mL) and the remaining solvent was removed under vacuum. The 
resulting residue was purified by silica gel column chromatography 
(dichloromethane:ethyl acetate (19:1, v/v) to (7:1, v/v)), yielding the corresponding 
product as a mixture of 5a and 5a-d6 in 16% and 4% yields respectively (as determined 
by 
1
H NMR spectroscopy), giving a KIE of 4.5. 
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Isotopic Exchange Experiment 
 
Procedure for the Isotopic Exchange Experiment. An oven-dried 50 mL Schlenk tube 
with a stirring bar was charged with 2-fluoronicotinic acid 4a (56.4 mg, 0.400 mmol), 
sodium carbonate (42.3 mg, 0.400 mmol), and dry DMA (1 mL). The reaction vessel was 
placed in a pre-heated oil bath and stirred for 0.5 h at 110 °C. The solvent was removed 
under reduced pressure until dry and the resulting carboxylate salt was used without 
further purification. 1a-d7 (53.8 mg, 0.200mmol), Ni(OAc)2•4H2O (9.9 mg, 0.040 mmol), 
AgNO3 (136 mg, 0.800 mmol), and Na2CO3 (84 mg, 0.80 mmol) were added, the tube 
was evacuated and backfilled with nitrogen three times after which DMA (2 mL) was 
added via syringe. The reaction mixture was stirred at 130 °C for 30 minutes. Upon 
completion, the reaction tube was cooled to room temperature. The solution was diluted 
with dichloromethane (30 mL) and filtered through a pad of celite. The celite was then 
washed with dichloromethane (2 x 30 mL). The solvent was concentrated by rotary 
evaporation (to ~2 mL) and the remaining solvent removed under vacuum. The residue 
was purified by silica gel column chromatography (gradient elution, hexanes:ethyl 
acetate (9:1, v/v) to (4:1, v/v)), yielding the corresponding product. The extent of proton 
incorporation was determined to be 0.01H, less than 1%, by 
1
H NMR spectroscopy. 
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General Procedure for the Synthesis of (Hetero)Aryl Benzamides (1) 
Procedure A: Synthesis from the Acid Chloride. A 100 mL two-neck round bottom 
flask was charged with 8-aminoquinoline (1.44 g, 10.0 mmol), Et3N (1.53 mL, 11.0 
mmol), and methylene chloride (20 mL) under a N2 atmosphere. The corresponding acid 
chloride (12.0 mmol) was added dropwise at room temperature over 10 minutes. The 
mixture was stirred for 6 h at room temperature. The reaction was quenched with 10 mL 
of saturated NaHCO3 and extracted with methylene chloride (3 x 25 mL). The combined 
organic layer was washed with brine (15 mL) and dried over anhydrous Na2SO4 and 
filtered. The solvent was removed under reduced pressure and the residue was purified 
via silica gel column chromatography (gradient elution, hexanes : ethyl acetate (15:1, v/v) 
to (1:1, v/v)). 
Procedure B: Synthesis from the carboxylic acid. A 50 mL two-neck round bottom 
flask was charged with the corresponding carboxylic acid (1.70 mmol), anhydrous N,N-
dimethylformamide (2 drops), and methylene chloride (2 mL) under a N2 atmosphere at 0 
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°C. Oxalyl chloride (0.17 mL, 2.00 mmol) was then added dropwise and the reaction 
mixture was allowed to stir for 3 h at room temperature. The solvent was removed under 
reduced pressure and the resulting acid chloride was used without further purification. A 
100 mL two-neck round bottom flask was charged with 8-aminoquinoline (255 mg, 1.70 
mmol), Et3N (0.278 mL, 2.00 mmol), and methylene chloride (10 mL) under a N2 
atmosphere at 0 °C. The corresponding acid chloride was added dropwise to the reaction 
and stirred for 3 h. The reaction was quenched with 5 mL of saturated NaHCO3 and 
extracted with methylene chloride three times (3 x 25 mL). The combined organic layer 
was washed with brine (15 mL) and dried over anhydrous Na2SO4 and filtered. The 
solvent was removed under reduced pressure and the residue was purified via silica gel 
column chromatography (gradient elution, hexanes : ethyl acetate (19:1, v/v) to (9:1, 
v/v)). 
Base Promoted Cyclization Reaction 
 
An oven-dried 50 mL Schlenk tube with a stirring bar was charged with 2'-fluoro-3-
methyl-N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide
66
 (71.2 mg, 0.200 mmol) and 
Na2CO3 (84 mg, 0.80 mmol). The tube was evacuated and backfilled with nitrogen three 
times after which DMA (2 mL) was added via syringe. The reaction mixture was stirred 
at 170 °C for 24 h. Upon completion, the reaction tube was cooled to room temperature. 
The solution was diluted with dichloromethane (30 mL) and filtered through a pad of 
celite, the celite was washed with dichloromethane (2 x 30 mL). The solvent was 
concentrated by rotary evaporation (to ~2 mL) and the remaining solvent was removed 
under vacuum. Then 1,3,5-trimethoxybenzene (5.00 mg) was added to the residue and the 
crude mixture was dissolved in CDCl3 for analysis by 
1
H NMR spectroscopy.  
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General Procedures for the Synthesis of Fluorinated Carboxylic Acids (4) 
Procedure A:Synthesis from Silver(II) Fluoride  
 
Synthesis of methyl esters. A 50 mL two-neck round bottom flask was charged with the 
corresponding carboxylic acid (3.62 mmol), N,N-dimethylformamide (3-4 drops), and 
methylene chloride (4 mL) under a N2 atmosphere at 0 °C. Oxalyl chloride (0.32 mL, 3.8 
mmol) was then added dropwise and the reaction mixture was allowed to stir for 3 h at 
room temperature after removal of the ice bath. The solvent was removed under reduced 
pressure and anhydrous methanol was then added to the resulting crude acid chloride. 
Triethylamine (0.55 mL, 4.00 mmol) was added dropwise to the mixture and the reaction 
was allowed to stir for 3 h. The reaction was quenched with saturated NaHCO3 (5 mL) 
and extracted with dichloromethane (3 x 20 mL). The combined organic layers were 
washed with brine (10 mL) and dried over anhydrous Na2SO4 and filtered. The solvent 
was removed under reduced pressure and the residue was purified via silica gel column 
chromatography (gradient elution, hexanes : ethyl acetate (19:1, v/v) to (9:1, v/v) or 
(gradient elution, hexanes : dichloromethane (15:1, v/v) to (1:1, v/v). 
 
Fluorination of heteroaryl methyl esters. The title compounds were prepared according 
to a literature procedure.
67
 In a N2 filled glovebox, the pyridine substrate (1.00 mmol) and 
anhydrous MeCN (20 mL) were combined in an oven-dried round bottom flask. While 
rapidly stirring, AgF2 (438 mg, 3.00 mmol) was added at once. The round bottom flask 
was capped with a rubber septum and stirred for 1 hour. The reaction mixture was then 
removed from the glovebox and poured into a separatory funnel containing 40 mL of 
saturated aqueous NaHCO3 and the mixture extracted with Et2O (2 x 30 mL). The 
organic layer was washed with brine (40 mL) and dried over anhydrous Na2SO4 and 
filtered. The solvent was removed under reduced pressure and the residue was purified 
via silica gel column chromatography. 
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Hydrolysis of fluorinated heteroaryl methyl esters. A 100 mL round bottom flask was 
charged with the fluorinated heteroaryl methyl ester (1.0 mmol), THF/EtOH/H2O (1:1:1, 
2 mL/2 mL/2 mL), and KOH (4 equiv). The mixture was monitored by TLC until all 
starting material was consumed. The reaction was acidified with HCl (2 N) until a pH of 
2 was achieved. The reaction mixture was poured into a separatory funnel and extracted 
with ethyl acetate (3 x 50 mL) and dried over anhydrous Na2SO4 and filtered. The solvent 
was removed under reduced pressure and the resulting acid was used without further 
purification.  
 
Procedure B: Synthesis from Lithiation and Fluorination with NFSI 
 
Fluorination of 2-thiophenecarboxylic acid substrates. The title compounds were 
prepared following a procedure modified from the literature.
68
 To a pre-cooled (-78 C) 
solution of 2-thiophenecarboxylic acid substrate (5.61 mmol) in anhydrous THF (25 mL) 
was added n-BuLi (4.93 mL, 12.3 mmol) dropwise. After the reaction stirred for 30 
minutes, a solution of N-fluorobenzenesulfonimide (NFSI, 2.65 g, 8.41 mmol) in 
anhydrous THF (22 mL) was added dropwise at -78 C. The solution was stirred at -78C 
for 5 hours and then warmed slowly and allowed to stir at room temperature overnight. 
The reaction was quenched with 6 N HCl (3 mL) at 0 C. The reaction mixture was 
poured into a separatory funnel and extracted with ethyl acetate (3 x 75 mL) and dried 
over anhydrous Na2SO4. The solvent was removed under reduced pressure. The crude 
solid was then dissolved in a mixture of a minimum amount of water (~150mL) and 
NaOH (1.2 equiv). The aqueous layer was poured into a separatory funnel and washed 
with dichloromethane until all residual NFSI was removed. The aqueous layer was then 
acidified with HCl (2 N) until a pH of 2 was achieved. The reaction mixture was poured 
into a separatory funnel and extracted with ethyl acetate (3 x 75 mL) and dried over 
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anhydrous Na2SO4 and filtered. The solvent was removed under reduced pressure to yield 
the crude fluorinated thiophenecarboxylic acid which was used as described below 
without further purification. 
 
Methylation of 2-thiophenecarboxylic acid substrates. To an oven-dried round bottom 
flask was charged the crude fluorinated thiophenecarboxylic acid, K2CO3(1.07 g, 7.74 
mmol), anhydrous DMF (10 mL), and methyl iodide (0.70 mL, 11.2 mmol). The reaction 
mixture was stirred at room temperature for 22 hours. After completion, saturated 
ammonium chloride (15 mL) was added and the resulting mixture was extracted with 
ethyl acetate (3 x 50 mL). The organic phase was washed with water (100 mL) and brine 
(20 mL), dried over anhydrous Na2SO4, filtered, and the solvent was removed under 
reduced pressure. The residue was purified via silica gel column chromatography to give 
the corresponding methyl ester. 
 
Hydrolysis of fluorinated methyl 2-thiophenecarboxylate. A 100 mL round bottom 
flask was charged with the fluorinated methyl 2-thiophenecarboxylate (2.0 mmol), 
THF/EtOH/H2O (1:1:1, 4 mL/4 mL/4 mL)), and KOH (4 equiv). The mixture was 
monitored by TLC until all starting material was consumed. The reaction was acidified  
with HCl (2 N) until a pH of 2 was achieved. The reaction mixture was poured into a 
separatory funnel and extracted with ethyl acetate (3 x 50 mL) and dried over anhydrous 
Na2SO4 and filtered. The solvent was removed under reduced pressure and used without 
further purification.  
 
Procedure C: Synthesis from Lithiation and Carboxylation 
 
Carboxylation of 2-fluoro-5-methylpyridine: The title compound was prepared 
following a modification of a literature synthesis.
69 
A 2.5 M solution of n-butyl lithium in 
hexanes (2.28 mL, 5.70 mmol) was added dropwise to a solution of freshly distilled 
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diisopropylamine (0.80 mL, 5.70 mmol) in THF (10 mL) at -78 C. After complete 
addition, the mixture was allowed to warm to 0 C and stir at this temperature for 10 
minutes. The solution was then cooled back down to -78 C and a solution of 2-fluoro-5-
methylpyridine (0.59 mL, 5.70 mmol) in THF (1.85 mL) was added dropwise. The 
reaction mixture was stirred at -78 C for 2 hours and then quenched with freshly made 
dry ice (~1 brick). The reaction mixture was allowed to warm to room temperature and 
was then acidified with HCl (2 N) until a pH of 2 was achieved and extracted with ethyl 
acetate (3 x 50 mL). The organic phase was washed with brine (20 mL) and dried over 
anhydrous Na2SO4, filtered, and the solvent was removed under reduced pressure. 
 
 
 
  Perspective view of the molecular structure of the C22H15N3O (5a) with the atom 
labeling scheme for the non-hydrogen atoms. Thermal ellipsoids are scaled to enclose 
50% probability. 
 
Description of the X-ray Structural Analysis of C22H15N3O (5a). 
  A colorless rectangular crystal of C22H15N3O (5a) was covered in a polybutene oil 
(Sigma-Aldrich) and placed on the end of a MiTeGen loop. The sample was cooled to 
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100 K with an Oxford Cryostream 700 system and optically aligned on a Bruker AXS D8 
Venture fixed-chi X-ray diffractometer equipped with a Triumph monochromator, a Mo 
Kα radiation source ( = 0.71073 Å), and a PHOTON 100 CMOS detector. Three sets of 
12 frames each were collected using the omega scan method with a 10 s exposure time. 
Integration of these frames followed by reflection indexing and least-squares refinement 
produced a crystal orientation matrix for the monoclinic crystal lattice that was used for 
the structural analysis.  
Data collection consisted of the measurement of a total of 246 frames in two runs 
using omega scans with the detector held at 5.00 cm from the crystal. Frame scan 
parameters are summarized in Table 1 below: 
Data collection details for C22H15N3O (5a). 
 
Run 2θ ω φ  Scan Width (º) Frames Exposure 
Time (sec) 
1 17.45 -164.74 -217.75 54.78 1.50 123 40.00 
2 17.45 -164.74 45.40 54.78 1.50 123 40.00 
 
The APEX3 software program (version 2016.9-0)100 was used for diffractometer control, 
preliminary frame scans, indexing, orientation matrix calculations, least-squares 
refinement of cell parameters, and the data collection. The frames were integrated with 
the Bruker SAINT software package using a narrow-frame algorithm. The integration of 
the data using a monoclinic unit cell yielded a total of 14343 reflections to a maximum θ 
angle of 27.50° (0.77 Å resolution), of which 3597 were independent (average 
redundancy 3.987, completeness = 99.8%, Rint = 3.31%, Rsig = 3.09%) and 2792 
(77.62%) were greater than 2σ(F2). The final cell constants of a = 13.4326(7) Å, b = 
7.3348(4) Å, c = 17.1068(9) Å, β = 111.9152(15)°, volume = 1563.66(14) Å3, are based 
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upon the refinement of the XYZ-centroids of 6729 reflections above 20 σ(I) with 6.445° 
< 2θ < 60.15°. Data were corrected for absorption effects using the Multi-Scan method 
(SADABS). The ratio of minimum to maximum apparent transmission was 0.809. The 
calculated minimum and maximum transmission coefficients (based on crystal size) are 
0.962 and 0.992. 
The structure was solved by direct methods and difference Fourier analysis using the 
programs provided by SHELXL-2014/7.101 Idealized positions for the hydrogen atoms 
were included as fixed contributions using a riding model with isotropic temperature 
factors set at 1.2 (aromatic hydrogens) or 1.5 times (methyl hydrogens) that of the 
adjacent carbon atom.  The positions of the methyl hydrogen atoms were optimized by 
a rigid rotating group refinement with idealized angles.  Full-matrix least-squares 
refinement, based upon the minimization of  wi |Fo
2
 - Fc
2
|
2
, with weighting wi
-1
 = 
[2(Fo
2
) + (0.0524 P)
2
 + 0.7107 P], where P = (Max (Fo
2
, 0) + 2 Fc
2
)/3.101 The final 
anisotropic full-matrix least-squares refinement on F
2
 with 236 variables converged at 
R1 = 3.99%, for the 2792 observed data with I>2σ(I) and wR2 = 11.05% for all data.  
The value of the goodness-of-fit was 1.019.102 The linear absorption coefficient, atomic 
scattering factors, and anomalous dispersion corrections were calculated from values 
found in the International Tables of X-ray Crystallography.103 
 
Crystal data for C22H15N3O (5a). 
Ident. code jh43cms 
Chemical form. C22H15N3O 
Formula wght. 337.37 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.086 x 0.277 x 0.432 mm 
Crystal system monoclinic 
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Space group P21/c (No. 14) 
Unit cell a = 13.4326(7) Å α = 90° 
 b = 7.3348(4) Å β = 111.9152(15)° 
 c = 17.1068(9) Å γ = 90° 
Volume, Å
3
 1563.66(14)  
Z  4 
Density (calc) 1.433 g/cm
3
 
Abs. coefficient 0.090 mm
-1
 
F(000) 704 
 
Data collection and structure refinement for C22H15N3O (5a). 
Theta range  3.06 to 27.50° 
Index ranges -17 ≤ h ≤ 17, -9 ≤ k ≤ 8, -17 ≤ l ≤ 22 
Reflections  14343 
Independent refls 3597 [R(int) = 0.0331] 
Coverage  99.8% 
Absorption correction multi-scan 
Max. and min. trans. 0.992 and 0.962 
Refinement method Full-matrix least-squares on F
2
 
Refinement program SHELXL-2014/7 (Sheldrick, 2014) 
Data / restraints / 
parameters 
3597 / 0 / 236 
Goodness-of-fit on F
2
 1.019 
Final R indices 
2792 data; 
I>2σ(I) 
R1 = 0.0399, wR2 = 0.0986 
 all data R1 = 0.0576, wR2 = 0.1105 
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Largest diff. peak and 
hole 
0.325 and -0.256 e
-
/Å
3
 
 
 
Atomic coordinates and equivalent isotropic atomic displacement parameters (Å
2
) 
for C22H15N3O (5a). U(eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
 
 x/a y/b z/c U(eq) 
O1 0.13435(8) 0.87131(16) 0.22197(6) 0.0267(3) 
N1 0.21961(8) 0.76163(16) 0.14127(7) 0.0147(2) 
N2 0.31986(9) 0.66240(16) 0.06551(7) 0.0184(3) 
N3 0.27078(9) 0.45464(16) 0.24227(7) 0.0181(3) 
C1 0.22280(10) 0.70165(18) 0.06493(8) 0.0148(3) 
C2 0.32566(12) 0.6120(2) 0.99213(9) 0.0208(3) 
C3 0.23747(12) 0.5973(2) 0.91781(9) 0.0217(3) 
C4 0.13755(12) 0.63391(19) 0.91951(9) 0.0200(3) 
C5 0.12687(11) 0.68863(18) 0.99396(8) 0.0154(3) 
C6 0.02538(10) 0.73730(18) 0.00170(8) 0.0154(3) 
C7 0.92732(11) 0.71797(19) 0.93335(9) 0.0192(3) 
C8 0.83324(11) 0.7707(2) 0.94140(9) 0.0217(3) 
C9 0.83429(11) 0.84533(19) 0.01598(9) 0.0209(3) 
C10 0.92885(11) 0.86398(19) 0.08593(8) 0.0176(3) 
C11 0.02545(10) 0.80637(18) 0.07850(8) 0.0157(3) 
C12 0.12732(11) 0.81760(19) 0.15249(8) 0.0166(3) 
C13 0.92210(12) 0.9441(2) 0.16473(9) 0.0240(3) 
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 x/a y/b z/c U(eq) 
C14 0.31676(10) 0.75799(19) 0.21557(8) 0.0150(3) 
C15 0.38375(11) 0.9038(2) 0.23626(8) 0.0182(3) 
C16 0.47808(11) 0.9018(2) 0.31006(9) 0.0203(3) 
C17 0.50156(11) 0.7527(2) 0.36117(8) 0.0192(3) 
C18 0.43384(11) 0.59807(19) 0.34117(8) 0.0169(3) 
C19 0.45540(12) 0.4381(2) 0.39002(9) 0.0223(3) 
C20 0.38625(12) 0.2948(2) 0.36578(9) 0.0248(3) 
C21 0.29503(12) 0.3093(2) 0.29094(9) 0.0220(3) 
C22 0.33916(10) 0.59981(19) 0.26677(8) 0.0151(3) 
 
Interatomic distances (Å) for C22H15N3O (5a). 
O1-C12 1.2219(16) N1-C12 1.3855(17) 
N1-C1 1.3939(16) N1-C14 1.4426(16) 
N2-C1 1.3315(17) N2-C2 1.3385(17) 
N3-C21 1.3167(18) N3-C22 1.3660(18) 
C1-C5 1.4056(18) C2-C3 1.381(2) 
C3-C4 1.380(2) C4-C5 1.3930(19) 
C5-C6 1.4623(19) C6-C7 1.4044(18) 
C6-C11 1.4079(19) C7-C8 1.377(2) 
C8-C9 1.383(2) C9-C10 1.3890(19) 
C10-C11 1.4147(19) C10-C13 1.504(2) 
C11-C12 1.4792(18) C14-C15 1.357(2) 
C14-C22 1.4168(19) C15-C16 1.4162(19) 
C16-C17 1.362(2) C17-C18 1.414(2) 
C18-C19 1.406(2) C18-C22 1.4244(18) 
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C19-C20 1.361(2) C20-C21 1.407(2) 
    
Bond angles (°) for C22H15N3O (5a).  
C12-N1-C1 124.42(11) C12-N1-C14 116.45(10) 
C1-N1-C14 119.05(11) C1-N2-C2 116.89(11) 
C21-N3-C22 117.24(12) N2-C1-N1 115.71(11) 
N2-C1-C5 124.83(12) N1-C1-C5 119.46(12) 
N2-C2-C3 123.69(13) C4-C3-C2 118.19(13) 
C3-C4-C5 120.56(13) C4-C5-C1 115.80(12) 
C4-C5-C6 124.81(12) C1-C5-C6 119.37(12) 
C7-C6-C11 119.15(12) C7-C6-C5 121.09(12) 
C11-C6-C5 119.76(11) C8-C7-C6 119.93(13) 
C7-C8-C9 120.64(13) C8-C9-C10 121.65(13) 
C9-C10-C11 117.89(13) C9-C10-C13 117.96(13) 
C11-C10-C13 124.15(12) C6-C11-C10 120.67(12) 
C6-C11-C12 119.78(12) C10-C11-C12 119.55(12) 
O1-C12-N1 118.81(12) O1-C12-C11 124.14(12) 
N1-C12-C11 117.05(11) C15-C14-C22 121.14(12) 
C15-C14-N1 120.59(12) C22-C14-N1 118.26(12) 
C14-C15-C16 120.64(13) C17-C16-C15 119.79(13) 
C16-C17-C18 120.99(12) C19-C18-C17 123.65(12) 
C19-C18-C22 117.10(13) C17-C18-C22 119.24(12) 
C20-C19-C18 119.83(13) C19-C20-C21 118.84(14) 
N3-C21-C20 124.22(14) N3-C22-C14 119.03(12) 
N3-C22-C18 122.76(12) C14-C22-C18 118.20(12) 
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Anisotropic atomic displacement parameters (Å
2
) for C22H15N3O (5a).  
The anisotropic atomic displacement factor exponent takes the form: -2π2[ 
h
2
 a
*2
 U11 + ... + 2 h k a
*
 b
*
 U12]. 
 U11 U22 U33 U23 U13 U12 
O1 0.0199(5) 0.0430(7) 0.0154(5) -0.0053(5) 0.0044(4) 0.0042(5) 
N1 0.0130(5) 0.0176(6) 0.0110(5) 0.0010(4) 0.0015(4) 0.0010(4) 
N2 0.0179(6) 0.0206(6) 0.0156(6) -0.0006(5) 0.0049(5) 0.0017(5) 
N3 0.0182(6) 0.0191(6) 0.0168(6) -0.0019(5) 0.0062(5) -0.0006(5) 
C1 0.0181(6) 0.0121(6) 0.0135(6) 0.0016(5) 0.0052(5) 0.0005(5) 
C2 0.0211(7) 0.0236(7) 0.0185(7) -0.0005(6) 0.0083(6) 0.0036(6) 
C3 0.0289(8) 0.0218(7) 0.0140(7) -0.0013(5) 0.0075(6) 0.0048(6) 
C4 0.0238(7) 0.0173(7) 0.0133(6) -0.0003(5) 0.0007(5) 0.0016(6) 
C5 0.0181(6) 0.0124(6) 0.0130(6) 0.0018(5) 0.0027(5) 0.0001(5) 
C6 0.0168(6) 0.0107(6) 0.0155(6) 0.0030(5) 0.0022(5) 0.0006(5) 
C7 0.0216(7) 0.0151(7) 0.0158(6) 0.0005(5) 0.0013(5) -0.0017(6) 
C8 0.0162(6) 0.0190(7) 0.0216(7) 0.0027(6) -0.0023(5) -0.0016(6) 
C9 0.0150(6) 0.0188(7) 0.0271(8) 0.0047(6) 0.0058(6) 0.0007(6) 
C10 0.0167(6) 0.0150(6) 0.0205(7) 0.0045(5) 0.0061(5) 0.0003(5) 
C11 0.0154(6) 0.0141(6) 0.0148(6) 0.0034(5) 0.0024(5) -0.0006(5) 
C12 0.0165(6) 0.0175(7) 0.0151(6) 0.0010(5) 0.0049(5) 0.0001(5) 
C13 0.0187(7) 0.0307(8) 0.0229(7) 0.0034(6) 0.0083(6) 0.0044(6) 
C14 0.0130(6) 0.0212(7) 0.0103(6) -0.0017(5) 0.0039(5) 0.0019(5) 
C15 0.0192(7) 0.0202(7) 0.0155(6) -0.0001(5) 0.0069(5) 0.0001(6) 
C16 0.0166(7) 0.0247(7) 0.0203(7) -0.0063(6) 0.0076(6) -0.0043(6) 
C17 0.0134(6) 0.0283(8) 0.0133(6) -0.0047(6) 0.0019(5) 0.0013(6) 
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 U11 U22 U33 U23 U13 U12 
C18 0.0157(6) 0.0227(7) 0.0125(6) -0.0019(5) 0.0054(5) 0.0041(6) 
C19 0.0209(7) 0.0292(8) 0.0149(7) 0.0001(6) 0.0045(5) 0.0083(6) 
C20 0.0319(8) 0.0212(7) 0.0224(7) 0.0057(6) 0.0115(6) 0.0070(6) 
C21 0.0248(7) 0.0196(7) 0.0236(7) -0.0006(6) 0.0115(6) 0.0003(6) 
C22 0.0150(6) 0.0187(7) 0.0120(6) -0.0017(5) 0.0056(5) 0.0018(5) 
 
 
Hydrogen atom coordinates and isotropic atomic displacement parameters (Å
2
)      
for C22H15N3O (5a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x/a y/b z/c U(eq) 
H2 0.3943 0.5848 -0.0089 0.025 
H3 0.2454 0.5629 -0.1331 0.026 
H4 0.0755 0.6217 -0.1305 0.024 
H7 -0.0741 0.6685 -0.1184 0.023 
H8 -0.2330 0.7558 -0.1047 0.026 
H9 -0.2313 0.8848 0.0194 0.025 
H13A -0.1504 0.9916 0.1524 0.036 
H13B -0.0257 1.0434 0.1850 0.036 
H13C -0.0620 0.8495 0.2081 0.036 
H15 0.3672 1.0083 0.2009 0.022 
H16 0.5248 1.0041 0.3239 0.024 
H17 0.5644 0.7526 0.4110 0.023 
H19 0.5181 0.4301 0.4398 0.027 
H20 0.3993 0.1869 0.3988 0.03 
H21 0.2479 0.2077 0.2745 0.026 
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Characterization of (Hetero)Aryl Benzamides (1) 
 
2,4-dimethyl-N-(quinolin-8-yl)benzamide (1q). The title compound was synthesized 
following General Procedure B. 
1
H NMR (400 MHz, CDCl3): δ = 10.22 (s, 1H), 8.94 (dd, 
J = 7.5, 1.5 Hz, 1H), 8.77 (dd, J = 4.2, 1.7 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.65 – 
7.57 (m, 2H), 7.54 (dd, J = 8.3, 1.5 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 7.18 – 7.09 
(m, 2H), 2.59 (s, 3H), 2.39 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 168.22, 
148.25, 140.55, 138.65, 136.88, 136.35, 134.91, 133.76, 132.25, 128.03, 127.46, 127.45, 
126.69, 121.66, 121.66, 116.42, 21.37, 20.34. The spectral data are consistent with those 
reported in the literature.
70
 
 
 
4-methoxy-2-methyl-N-(quinolin-8-yl)benzamide (1r). The title compound was 
synthesized following General Procedure B. 
1
H NMR (400 MHz, CDCl3): δ = 10.21 (s, 
1H), 8.92 (dd, J = 7.5, 1.5 Hz, 1H), 8.79 (dd, J = 4.2, 1.7 Hz, 1H), 8.18 (dd, J = 8.3, 1.7 
Hz, 1H), 7.72 – 7.67 (m, 1H), 7.59 (dd, J = 8.3, 7.5 Hz, 1H), 7.54 (dd, J = 8.3, 1.5 Hz, 
1H), 7.46 (dd, J = 8.2, 4.2 Hz, 1H), 6.88 – 6.81 (m, 2H), 3.87 (s, 3H), 2.62 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 167.82, 161.10, 148.26, 139.47, 138.69, 136.41, 
135.01, 129.33, 129.04, 128.07, 127.50, 121.69, 121.57, 117.01, 116.38, 111.12, 55.39, 
20.91. The spectral data are consistent with those reported in the literature.
70
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4-chloro-2-methyl-N-(quinolin-8-yl)benzamide (1s). The title compound was 
synthesized following General Procedure B. 
1
H NMR (400 MHz, CDCl3): δ = 10.19 (s, 
1H), 8.91 (dd, J = 7.3, 1.7 Hz, 1H), 8.78 (dd, J = 4.2, 1.7 Hz, 1H), 8.19 (dd, J = 8.3, 1.7 
Hz, 1H), 7.66 – 7.54 (m, 3H), 7.47 (dd, J = 8.3, 4.2 Hz, 1H), 7.33 – 7.28 (m, 2H), 2.59 (s, 
3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 167.10, 148.38, 138.90, 138.57, 136.44, 
136.15, 134.99, 134.55, 131.33, 128.69, 128.03, 127.42, 126.21, 122.03, 121.78, 116.60, 
20.21. The spectral data are consistent with those reported in the literature.
70
 
 
 
2,3-dimethyl-N-(quinolin-8-yl)benzamide (1u). The title compound was synthesized 
following General Procedure B. 
1
H NMR (400 MHz, CDCl3): δ = 10.13 (s, 1H), 8.96 (dd, 
J = 7.5, 1.5 Hz, 1H), 8.76 (dd, J = 4.2, 1.7 Hz, 1H), 8.18 (dd, J = 8.3, 1.7 Hz, 1H), 7.65 – 
7.53 (m, 2H), 7.51 – 7.42 (m, 2H), 7.29 (d, J = 7.0 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 2.46 
(s, 3H), 2.36 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 168.97, 148.22, 138.51, 
138.10, 137.57, 136.28, 134.74, 134.56, 131.55, 127.95, 127.34, 125.70, 124.71, 121.77, 
121.63, 116.46, 20.36, 16.50. The spectral data are consistent with those reported in the 
literature.
71
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3-methoxy-2-methyl-N-(quinolin-8-yl)benzamide (1t). The title compound was 
synthesized following General Procedure B. 
1
H NMR (400 MHz, CDCl3): δ = 10.15 (s, 
1H), 8.95 (dd, J = 7.6, 1.5 Hz, 1H), 8.76 (dd, J = 4.2, 1.7 Hz, 1H), 8.18 (dd, J = 8.3, 1.7 
Hz, 1H), 7.65 – 7.51 (m, 2H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 7.34 – 7.22 (m, 2H), 6.98 
(dd, J = 7.9, 1.5 Hz, 1H), 3.89 (s, 3H), 2.43 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 
= 168.28, 158.23, 148.29, 138.58, 138.43, 136.35, 134.73, 128.01, 127.41, 126.84, 
125.17, 121.84, 121.70, 119.12, 116.53, 111.81, 55.75, 12.88. The spectral data are 
consistent with those reported in the literature.
71 
 
 
 
3-chloro-2-methyl-N-(quinolin-8-yl)benzamide (1v). The title compound was 
synthesized following General Procedure B as a white solid in 58% yield (293 mg, 0.98 
mmol), mp = 161  – 163 C. 1H NMR (400 MHz, CDCl3): δ = 10.14 (s, 1H), 8.93 (dd, J = 
7.2, 1.8 Hz, 1H), 8.77 (dd, J = 4.2, 1.7 Hz, 1H), 8.19 (dd, J = 8.3, 1.7 Hz, 1H), 7.66 – 
7.42 (m, 5H), 7.26 (t, J = 7.8 Hz, 1H), 2.59 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ 
= 167.45, 148.42, 139.12, 138.56, 136.46, 136.09, 134.47, 134.43, 131.03, 128.05, 
127.42, 127.07, 125.53, 122.19, 121.82, 116.74, 17.29. FTIR (ATR, cm
-1
): 3359, 3061, 
1674, 1527, 1486, 1427, 1382, 1329, 788, 663. HRMS (ESI-MS) m/z calcd for 
C17H14ClN2O [M + H]
+
 297.0794 found 297.0793.
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3-methyl-N-(quinolin-8-yl)pyridine-4-carboxamide (1x). The title compound was 
synthesized following General Procedure B. 
1
H NMR (400 MHz, CDCl3): δ = 10.27 (s, 
1H), 8.91 (dd, J = 6.3, 2.7 Hz, 1H), 8.80 (dd, J = 4.2, 1.7 Hz, 1H), 8.62 (d, J = 1.0 Hz, 
2H), 8.20 (dd, J = 8.3, 1.7 Hz, 1H), 7.66 – 7.57 (m, 2H), 7.54 (d, J = 5.0 Hz, 1H), 7.48 
(dd, J = 8.3, 4.2 Hz, 1H), 2.59 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 165.70, 
152.53, 148.52, 148.06, 143.03, 138.52, 136.49, 134.11, 130.84, 128.02, 127.36, 122.47, 
121.90, 120.73, 116.86, 17.05. The spectral data are consistent with those reported in the 
literature.
70
 
 
Characterization of ortho-Fluoro Heteroaromatic Carboxylic Acids (4) 
 
2-fluoro-6-methylpyridine-3-carboxylic acid (4b). The title compound was synthesized 
following Procedure A for the Synthesis of Fluorinated Carboxylic Acids as a white solid 
in 91 % yield, mp = 182 – 184 C. 1H NMR (400 MHz, DMSO-d6): δ = 13.40 (s, 1H), 
8.25 (dd, J = 9.9, 7.7 Hz, 1H), 7.30 (dd, J = 7.8, 1.8 Hz, 1H), 2.47 (s, 3H).
 13
C{
1
H} NMR 
(100 MHz, DMSO-d6): δ = 164.08 (d, J = 7.7 Hz), 161.91 (d, J = 15.1 Hz), 160.26 (d, J = 
245.6 Hz), 143.58 (d, J = 1.8 Hz), 121.43 (d, J = 4.6 Hz), 110.92 (d, J = 24.8 Hz), 23.56. 
19
F NMR (376 MHz, DMSO-d6): δ = -64.43 (d, J = 10.0 Hz). FTIR (ATR, cm
-1
): 2918, 
2592, 1725, 1616, 1478, 1243, 1215, 1083, 779, 726. HRMS (ESI-MS) m/z calcd for 
C7H7FNO2 [M + H]
+
 156.0460 found 156.0458. 
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2-fluoro-6-methoxypyridine-3-carboxylic acid (4c). The title compound was 
synthesized following Procedure A for the Synthesis of Fluorinated Carboxylic Acids as 
a white solid in 33% yield, mp = 210 – 212 C. 1H NMR (400 MHz, DMSO-d6): δ = 
13.18 (s, 1H), 8.24 (dd, J = 9.8, 8.4 Hz, 1H), 6.81 (dd, J = 8.4, 1.0 Hz, 1H), 3.88 (s, 3H). 
13
C{
1
H} NMR (100 MHz, DMSO-d6): δ = 165.18 (d, J = 14.5 Hz), 163.87 (d, J = 7.6 
Hz), 160.67 (d, J = 251.0 Hz), 145.45 (d, J = 1.9 Hz), 107.79 (d, J = 5.1 Hz), 105.27 (d, J 
= 22.4 Hz), 54.60. 
19
F NMR (376 MHz, DMSO-d6): δ -63.13 (d, J = 9.8 Hz). FTIR 
(ATR, cm
-1
): 2962, 2571, 1670, 1610, 1499, 1412, 1399, 1303, 1144, 1017, 930, 847, 
789. HRMS (ESI-MS) m/z calcd forC7H7FNO3 [M + H]
+
 172.0409 found 172.0406. 
 
2-fluoroquinoline-3-carboxylic acid (4h). The title compound was synthesized 
following Procedure A at 50 C for Synthesis of Fluorinated Carboxylic Acids as a white 
solid in 73% yield, mp = 258 – 260 C. 1H NMR (400 MHz, DMSO-d6): δ = 13.65 (s, 
1H), 9.12 (d, J = 9.8 Hz, 1H), 8.23 (d, J = 8.1 Hz, 1H), 7.92 (dd, J = 4.5, 1.1 Hz, 2H), 
7.70 (dt, J = 8.2, 3.9 Hz, 1H). 
13
C{
1
H} NMR (100 MHz, DMSO-d6): δ = 163.91 (d, J = 
7.5 Hz), 157.75 (d, J = 247.6 Hz), 146.19 (d, J = 17.5 Hz), 145.72 (d, J = 4.0 Hz), 
133.03, 129.30, 127.10 (d, J = 1.5 Hz), 127.00 (d, J = 2.3 Hz), 126.14 (d, J = 2.3 Hz), 
114.43 (d, J = 30.8 Hz). 
19
F NMR (376 MHz, DMSO-d6): δ = -56.49 (d, J = 9.5 Hz). 
FTIR (ATR, cm
-1
): 2971, 2585, 1695, 1620, 1601, 1472, 1417, 1264, 1078, 915, 788, 
750. HRMS (ESI-MS) m/z calcd for C10H7FNO2 [M + H]
+
 192.0460 found 192.0458. 
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3-fluoro-1-benzothiophene-2-carboxylic acid (4i). The title compound was synthesized 
following Procedure B for Synthesis of Fluorinated Carboxylic Acids as a white solid in 
83 %, mp = 250 – 252 C. 1H NMR (400 MHz, DMSO-d6): δ = 13.71 (s, 1H), 8.03 (d, J 
= 8.2 Hz, 1H), 7.88 (dd, J = 8.1, 0.6 Hz, 1H), 7.60 (td, J = 8.3, 7.1, 1.3 Hz, 1H), 7.52 (td, 
J = 8.1, 7.1, 1.0 Hz, 1H). 
13
C{
1
H} NMR (100 MHz, DMSO-d6): δ = 161.74 (d, J = 3.2 
Hz), 152.66 (d, J = 279.2 Hz), 136.14 (d, J = 8.6 Hz), 128.64, 128.41 (d, J = 22.5 Hz), 
125.63, 123.70 (d, J = 1.4 Hz), 121.46 (d, J = 1.8 Hz), 112.95 (d, J = 8.9 Hz). 
19
F NMR 
(376 MHz, DMSO-d6): δ = -121.02. FTIR (ATR, cm
-1
): 2805, 2569, 1663, 1599, 1574, 
1537, 1446, 1369, 1289, 1043, 900, 755, 729. HRMS (ESI-MS) m/z calcd for C9H6FO2S 
[M + H]
+
 197.0072 found 197.0071. 
 
 
3-fluoro-5-(4-fluorophenyl)thiophene-2-carboxylic acid (4j). The title compound was 
synthesized following Procedure B for Synthesis of Fluorinated Carboxylic Acids as a 
white solid in 85% yield, mp = 248 – 250 C. 1H NMR (400 MHz, DMSO-d6): δ = 13.34 
(s, 1H), 7.82 – 7.73 (m, 2H), 7.55 (s, 1H), 7.34 – 7.23 (m, 2H). 13C{1H} NMR (100 MHz, 
DMSO-d6): δ = 162.81 (d, J = 247.9 Hz), 160.98 (d, J = 3.1 Hz), 158.78 (d, J = 273.3 
Hz), 145.25 (d, J = 9.8 Hz), 128.69 (d, J = 3.2 Hz), 127.73 (d, J = 8.6 Hz), 116.30 (d, J = 
22.1 Hz), 115.14 (d, J = 25.9 Hz), 112.00 (d, J = 9.9 Hz). 
19
F NMR (376 MHz, DMSO-
d6): δ = -111.40 (tt, J = 8.7, 5.2 Hz), -112.89. FTIR (ATR, cm
-1
): 3096, 2550, 1650, 1598, 
1560, 1459, 1442, 1295, 1227, 1161, 1041, 933, 823, 809, 762, 716. HRMS (ESI-MS) 
m/z calcd for C11H7F2O2S [M + H]
+
 241.0134 found 241.0143. 
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2-fluoro-5-methylpyridine-3-carboxylic acid (4f). The title compound was synthesized 
following Procedure C for Synthesis of Fluorinated Carboxylic Acids as a white solid in 
79% yield, mp = 178 – 180 C. 1H NMR (400 MHz, DMSO-d6): δ = 13.47 (s, 1H), 8.19 – 
8.08 (m, 2H), 2.28 (s, 3H). 
13
C{
1
H} NMR (100 MHz, DMSO-d6): δ = 164.22 (d, J = 7.6 
Hz), 159.49 (d, J = 243.5 Hz), 150.88 (d, J = 15.2 Hz), 143.51 (d, J = 1.6 Hz), 131.67 (d, 
J = 5.1 Hz), 113.42 (d, J = 25.7 Hz), 16.70. 
19
F NMR (376 MHz, DMSO-d6): δ = -69.68 
(d, J = 9.0 Hz). FTIR (ATR, cm
-1
): 2852, 2610, 1681, 1605, 1463, 1312, 1209, 1113, 906, 
789, 748. HRMS (ESI-MS) m/z calcd for C7H7FNO2 [M + H]
+
 156.0460 found 156.0458.  
 
Characterization of Oxidative Decarboxylative Annulation Products (5) 
 
7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5a). The title 
compound was synthesized following the General Procedure A as an off-white solid in 
80% yield (53.9 mg, 0.16 mmol), mp = 271 – 273 C. 1H NMR (400 MHz, CDCl3): δ = 
8.75 (dd, J = 4.1, 1.5 Hz, 1H), 8.54 (dd, J = 8.0, 1.6 Hz, 1H), 8.27 – 8.17 (m, 3H), 7.98 
(dt, J = 7.6, 3.8 Hz, 1H), 7.79 – 7.73 (m, 2H), 7.66 (t, J = 7.8 Hz, 1H), 7.43 (d, J = 7.5 
Hz, 1H), 7.38 (dd, J = 8.3, 4.2 Hz, 1H), 7.12 (dd, J = 7.9, 4.7 Hz, 1H), 2.92 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.71, 150.89, 150.36, 148.85, 144.82, 143.58, 
136.59, 136.49, 134.45, 132.58, 132.14, 131.66, 130.39, 129.69, 128.87, 126.72, 124.70, 
121.67, 120.29, 118.21, 114.86, 24.50. FTIR (ATR, cm
-1
): 3030, 2972, 1660, 1584, 1499, 
  99 
1473, 1394, 1288, 825, 773. HRMS (ESI-MS) m/z calcd for C22H16N3O [M + H]
+
 
338.1293 found 338.1291. 
 
 
3,7-dimethyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5b). The title 
compound was synthesized following the General Procedure A and a light brown solid in 
67% yield (47.0 mg, 0.13 mmol), mp = 256 – 258 C. 1H NMR (400 MHz, CDCl3): δ = 
8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.39 (d, J = 8.0 Hz, 1H), 8.23 (dd, J = 8.4, 1.7 Hz, 1H), 
8.15 (d, J = 8 Hz, 1H), 7.98 – 7.92 (m, 1H), 7.76 – 7.69 (m, 2H), 7.67 – 7.61 (m, 1H), 
7.41 – 7.34 (m, 2H), 6.97 (d, J = 8.2 Hz, 1H), 2.91 (s, 3H), 2.19 (s, 3H). 13C{1H} NMR 
(100 MHz, CDCl3): δ = 163.90, 158.34, 150.71, 149.67, 145.07, 143.51, 136.85, 136.34, 
134.79, 132.01, 131.93, 131.73, 130.56, 129.53, 128.42, 126.54, 124.43, 121.45, 119.99, 
118.06, 111.94, 24.58, 24.54. FTIR (ATR, cm
-1
): 3049, 2921, 1651, 1592, 1497, 1460, 
1383, 1297, 821, 786.  HRMS (ESI-MS) m/z calcd for C23H18N3O [M + H]
+
 352.1449 
found 352.1450. 
 
 
3-methoxy-7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5c). 
The title compound was synthesized following the General Procedure A as an ochre solid 
in 36% yield (26.4 mg, 0.07 mmol), mp = 204 – 206 C. 1H NMR (400 MHz, CDCl3): δ 
= 8.77 (dd, J = 4.2, 1.7 Hz, 1H), 8.40 (d, J = 8.6 Hz, 1H), 8.23 (dd, J = 8.3, 1.7 Hz, 1H), 
8.06 (dd, J = 8.1, 1.1 Hz, 1H), 7.94 (dd, J = 7.9, 1.8 Hz, 1H), 7.78 – 7.67 (m, 2H), 7.66 – 
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7.59 (m, 1H), 7.38 (dd, J = 8.3, 4.2 Hz, 1H), 7.33 (dd, J = 7.4, 1.9 Hz, 1H), 6.57 (d, J = 
8.6 Hz, 1H), 3.12 (s, 3H), 2.92 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.98, 
163.01, 150.79, 148.48, 145.00, 143.57, 136.66, 136.23, 135.21, 134.62, 132.12, 130.97, 
130.37, 129.38, 128.45, 126.46, 123.61, 121.46, 119.54, 107.74, 105.60, 53.00, 24.56. 
FTIR (ATR, cm
-1
): 3048, 2923, 1651, 1592, 1498, 1461, 1346, 1295, 1257, 1111, 824, 
784. HRMS (ESI-MS) m/z calcd for C23H18N3O2 [M + H]
+
 368.1399 found 368.1397. 
 
3-fluoro-7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5d). The 
title compound was synthesized following the General Procedure A as a white solid in 
29% yield (20.6 mg, 0.05 mmol), mp = 336 – 338 C. 1H NMR (400 MHz, CDCl3): δ = 
8.74 (dd, J = 4.2, 1.7 Hz, 1H), 8.63 (t, 1H), 8.25 (dd, J = 8.3, 1.7 Hz, 1H), 8.12 (d, J = 8.1 
Hz, 1H), 8.02 – 7.96 (m, 1H), 7.77 – 7.66 (m, 3H), 7.45 – 7.37 (m, 2H), 6.76 (dd, J = 8.5, 
3.1 Hz, 1H), 2.90 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.71, 162.14 (d, J = 
241.9 Hz), 150.97, 149.00, 144.70, 143.87, 136.94 (d, J = 8.8 Hz), 136.49, 135.67, 
134.03, 132.40 (d, J = 10.4 Hz), 130.39, 129.72, 129.14, 126.67, 124.24, 121.75, 120.10, 
112.37 (d, J = 4.6 Hz), 103.69, 103.31, 24.49. 
19
F NMR (376 MHz, CDCl3): δ = -65.85 
(dd, J = 7.6, 3.0 Hz). FTIR (ATR, cm
-1
): 3050, 2923, 1652, 1588, 1498, 1454, 1292, 
1224, 823, 798, 786. HRMS (ESI-MS) m/z calcd for C22H15FN3O [M + H]
+
 356.1199 
found 356.1198. 
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3-chloro-7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5e). The 
title compound was synthesized following the General Procedure A as a white solid in 
27% (20.0 mg, 0.05 mmol), mp = 326 – 328 C. 1H NMR (400 MHz, CDCl3): δ = 8.74 
(dd, J = 4.4, 1.6 Hz, 1H), 8.47 (d, J = 8.2 Hz, 1H), 8.25 (dd, J = 8.4, 1.7 Hz, 1H), 8.14 (d, 
J = 8.2 Hz, 1H), 8.01 – 7.96 (m, 1H), 7.77 – 7.71 (m, 2H), 7.69 (t, J = 7.8 Hz, 1H), 7.45 
(d, J = 7.5 Hz, 1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 2.90 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.53, 150.90, 149.93, 144.72, 143.88, 136.47, 
135.79, 134.10, 133.83, 132.81, 132.40, 130.48, 129.65, 129.00, 126.63, 124.59, 121.68, 
120.32, 118.48, 113.48, 24.48. FTIR (ATR, cm
-1
): 3093, 2924, 1661, 1599, 1579, 1498, 
1439, 1391, 1286, 1128, 1076, 867, 816, 788. HRMS (ESI-MS) m/z calcd for 
C22H15ClN3O [M + H]
+
 372.0903 found 372.0900. 
 
 
2-bromo-7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5s). The 
title compound was synthesized following the General Procedure A. White solid in 40% ( 
33.3 mg, 0.08 mmol), mp = 294 – 296 C. 1H NMR (400 MHz, CDCl3): δ = 8.74 (dd, J = 
4.2, 1.7 Hz, 1H), 8.65 (d, J = 2.2 Hz, 1H), 8.25 (dd, J = 8.3, 1.7 Hz, 1H), 8.21 (d, J = 2.2 
Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 7.99 (dt, J = 7.4, 3.7 Hz, 1H), 7.78 – 7.67 (m, 3H), 
7.47 (d, J = 7.4 Hz, 1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 2.90 (s, 3H). 
13
C{
1
H} NMR (100 
MHz, CDCl3): δ = 163.41, 151.03, 149.35, 148.99, 144.70, 143.91, 136.52, 136.11, 
133.85, 133.35, 133.27, 132.40, 130.31, 129.71, 129.10, 126.71, 124.87, 121.80, 120.48, 
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116.48, 113.69, 24.45. FTIR (ATR, cm
-1
): 3048, 2928, 1665, 1597, 1499, 1465, 1388, 
1288, 964, 827, 795, 689. HRMS (ESI-MS) m/z calcd for C22H15BrN3O [M + H]
+
 
416.0398 found 416.0396. 
 
 
2,7-dimethyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5f). The title 
compound was synthesized following the General Procedure A as a light brown solid in 
70% yield (49.2 mg, 0.14 mmol), mp = 276 – 278 C. 1H NMR (400 MHz, CDCl3): δ = 
8.76 (dd, J = 4.1, 1.5 Hz, 1H), 8.37 – 8.32 (m, 1H), 8.24 (dd, J = 8.3, 1.5 Hz, 1H), 8.19 
(d, J = 8.1 Hz, 1H), 8.07 – 8.02 (m, 1H), 7.98 (dd, J = 6.8, 2.8 Hz, 1H), 7.79 – 7.72 (m, 
2H), 7.64 (t, J = 7.8 Hz, 1H), 7.44 – 7.35 (m, 2H), 2.92 (s, 3H), 2.36 (s, 3H). 13C{1H} 
NMR (100 MHz, CDCl3): δ = 163.63, 150.87, 149.29, 148.54, 144.88, 143.51, 136.69, 
136.46, 134.39, 132.43, 131.99, 131.93, 130.40, 129.68, 128.81, 127.36, 126.70, 124.74, 
121.62, 120.24, 114.28, 24.52, 18.06. FTIR (ATR, cm
-1
): 3050, 2920, 1652, 1599, 1479, 
1301, 805, 782. HRMS (ESI-MS) m/z calcd for C23H18N3O [M + H]
+
 352.1449 found 
352.1450. 
 
 
 
8-methyl-6-(quinolin-8-yl)-6,7-dihydro-5,6-diazatetraphen-7-one (5h). The title 
compound was synthesized following the General Procedure A as a white solid in 51% 
yield (39.5 mg, 0.10 mmol), mp = 332 – 334 C. 1H NMR (400 MHz, CDCl3): δ = 8.99 
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(s, 1H), 8.71 (dd, J = 4.2, 1.7 Hz, 1H), 8.38 (d, J = 8.0 Hz, 1H), 8.26 (dd, J = 8.3, 1.7 Hz, 
1H), 8.01 (dd, J = 7.9, 1.8 Hz, 1H), 7.88 (dd, J = 8.1, 1.3 Hz, 1H), 7.83 – 7.74 (m, 2H), 
7.70 (t, J = 7.8 Hz, 1H), 7.53 – 7.43 (m, 3H), 7.41 – 7.34 (m, 2H), 2.92 (s, 3H). 13C{1H} 
NMR (100 MHz, CDCl3): δ = 164.11, 150.80, 149.81, 147.20, 145.02, 143.81, 136.86, 
136.41, 134.33, 133.01, 132.27, 131.62, 130.69, 130.18, 129.67, 128.59, 128.37, 127.91, 
126.68, 125.29, 124.95, 124.67, 121.55, 120.66, 115.99, 24.54. FTIR (ATR, cm
-1
): 3049, 
2923, 1652, 1599, 1499, 1280, 881, 803. HRMS (ESI-MS) m/z calcd for C26H18N3O [M 
+ H]
+
 388.1449 found 388.1450. 
 
 
8-methyl-6-(quinolin-8-yl)-6H,7H-benzothieno[3,2-c]isoquinolin-7-one (5i). The title 
compound was synthesized following the General Procedure C as a yellow solid in 44% 
yield (34.5 mg, 0.08 mmol), mp = 240 – 242 C. 1H NMR (400 MHz, CDCl3): δ = 8.78 
(dd, J = 4.2, 1.7 Hz, 1H), 8.30 (dd, J = 8.4, 1.7 Hz, 1H), 8.12 (dd, J = 8.2, 1.4 Hz, 1H), 
7.88 (dd, J = 7.3, 1.4 Hz, 1H), 7.82 – 7.73 (m, 2H), 7.70 (d, J = 7.7 Hz, 1H), 7.62 (t, J = 
7.7 Hz, 1H), 7.41 (dd, J = 8.3, 4.2 Hz, 1H), 7.34 (d, J = 7.3 Hz, 1H), 7.15 (ddd, J = 8.1, 
7.1, 1.0 Hz, 1H), 6.73 (ddd, J = 8.4, 7.1, 1.1 Hz, 1H), 5.68 (dd, J = 8.0, 1.0 Hz, 1H, 2.94 
(s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.73, 151.61, 145.05, 143.58, 138.36, 
137.37, 136.31, 134.87, 133.71, 132.34, 130.86, 130.46, 129.68, 129.45, 126.65, 125.25, 
124.04, 123.15, 123.01, 122.48, 122.10, 121.75, 117.75, 24.12. FTIR (ATR, cm
-1
): 3067, 
2922, 1645, 1597, 1497, 1388, 1294, 905, 814, 727. HRMS (ESI-MS) m/z calcd for 
C25H17N2OS [M + H]
+
 393.1061 found 393.1061. 
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2-(4-fluorophenyl)-6-methyl-4-(quinolin-8-yl)-4H,5H-thieno[3,2-c]isoquinolin-5-one 
(5j). The title compound was synthesized following the General Procedure B as a yellow 
solid in 23% yield (20.1 mg, 0.04 mmol), mp = 250 – 252 C. 1H NMR (400 MHz, 
CDCl3): δ = 8.87 (dd, J = 4.2, 1.7 Hz, 1H), 8.28 (dd, J = 8.3, 1.8 Hz, 1H), 8.03 (dd, J = 
8.2, 1.5 Hz, 1H), 7.84 (dd, J = 7.3, 1.5 Hz, 1H), 7.75 (dd, J = 8.2, 7.3 Hz, 1H), 7.62 (dd, J 
= 8.0, 1.4 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 7.41 – 7.36 
(m, 2H), 7.26 (dt, J = 7.3, 1.1 Hz, 1H), 7.02 – 6.93 (m, 2H), 6.22 (s, 1H), 2.90 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.05, 162.65 (d, J = 248.0 Hz), 151.49, 144.31, 
143.75, 142.20, 141.40, 137.04, 136.31, 134.69, 132.24, 130.13, 130.03, 129.87 (d, J = 
3.4 Hz), 129.74, 129.41, 127.51 (d, J = 8.1 Hz), 126.66, 122.44, 122.01, 120.57, 116.72, 
115.83 (d, J = 22.0 Hz), 114.18, 24.20. 
19
F NMR (376 MHz, CDCl3): δ = -112.96 – -
113.13 (m). FTIR (ATR, cm
-1
): 3067, 2920, 1640, 1598, 1492, 1228, 882, 818, 787. 
HRMS (ESI-MS) m/z calcd for C27H18FN2OS [M + H]
+
 437.1123 found 437.1124. 
 
 
7-methyl-5-(quinolin-8-yl)-5,6-dihydrophenanthridin-6-one (5j). The title compound 
was synthesized following the General Procedure B as an off white solid in 68% (45.8 
mg, 0.13 mmol). 
1
H NMR (400 MHz, CDCl3): δ = 8.81 (dd, J = 4.2, 1.6 Hz, 1H), 8.36 – 
8.24 (m, 3H), 8.02 (dd, J = 7.3, 2.4 Hz, 1H), 7.82 – 7.73 (m, 2H), 7.65 (t, J = 7.8 Hz, 1H), 
7.41 (dt, J = 8.6, 4.4 Hz, 2H), 7.18 (dtd, J = 19.0, 7.3, 1.4 Hz, 2H), 6.41 (dd, J = 8.1, 1.5 
Hz, 1H), 2.95 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 162.87, 151.40, 144.73, 
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143.18, 139.70, 136.70, 136.41, 136.05, 131.94, 131.80, 130.76, 129.93, 129.25, 128.96, 
126.94, 124.51, 123.49, 122.20, 121.98, 120.25, 119.32, 116.51, 24.64. The spectral data 
are consistent with those reported in the literature.
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2-fluoro-7-methyl-5-(quinolin-8-yl)-5,6-dihydrophenanthridin-6-one (5k). The title 
compound was synthesized following the General Procedure B as an ochre solid in 62% 
yield (43.8 mg, 0.12 mmol), mp = 237 – 239 C. 1H NMR (400 MHz, CDCl3): δ = 8.81 
(dd, J = 4.2, 1.7 Hz, 1H), 8.28 (dd, J = 8.3, 1.7 Hz, 1H), 8.15 (d, J = 8.2 Hz, 1H), 8.06 – 
8.00 (m, 1H), 7.96 (dd, J = 10.2, 2.8 Hz, 1H), 7.79 – 7.73 (m, 2H), 7.67 (t, J = 7.8 Hz, 
1H), 7.43 (dd, J = 8.3, 4.3 Hz, 2H), 6.87 (ddd, J = 9.3, 7.6, 2.8 Hz, 1H), 6.34 (dd, J = 9.2, 
4.9 Hz, 1H), 2.92 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 162.57, 158.48 (d, J = 
240.3 Hz), 151.54, 144.70, 143.48, 136.62, 136.51, 136.21 (d, J = 1.8 Hz), 135.19 (d, J = 
2.8 Hz), 132.52, 132.10, 130.83, 130.04, 129.46, 127.03, 124.75, 122.12, 120.61 (d, J = 
7.7 Hz), 120.51, 118.03 (d, J = 8.2 Hz), 116.42 (d, J = 23.6 Hz), 109.39 (d, J = 24.1 Hz), 
24.60. 
19
F NMR (376 MHz, CDCl3): δ = -121.35 (ddd, J = 10.2, 7.5, 4.8 Hz). FTIR 
(ATR, cm
-1
): 3073, 2924, 1652, 1592, 1481, 1396, 1303, 1205, 961, 828, 799, 758. 
HRMS (ESI-MS) m/z calcd for C23H16FN2O [M + H]
+
 355.1246 found 355.1245. 
 
 
2,7-dimethyl-5-(quinolin-8-yl)-5,6-dihydrophenanthridin-6-one (5l). The title 
compound was synthesized following the General Procedure B as a light brown solid in 
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56% yield (39.2 mg, 0.11 mmol). 
1
H NMR (400 MHz, CDCl3): δ = 8.81 (dd, J = 4.1, 1.5 
Hz, 1H), 8.32 – 8.24 (m, 2H), 8.12 (s, 1H), 8.01 (dd, J = 6.4, 3.3 Hz, 1H), 7.79 – 7.72 (m, 
2H), 7.65 (t, J = 7.8 Hz, 1H), 7.45 – 7.36 (m, 2H), 6.97 (dd, J = 8.5, 1.7 Hz, 1H), 6.28 (d, 
J = 8.5 Hz, 1H), 2.93 (s, 3H), 2.42 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 
162.82, 151.44, 144.81, 143.25, 137.72, 136.89, 136.44, 136.05, 131.86, 131.73, 131.51, 
130.81, 130.09, 129.97, 129.21, 126.98, 124.64, 123.61, 121.98, 120.24, 119.16, 116.44, 
24.70, 21.17. The spectral data are consistent with those reported in the literature.
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3-bromo-7-methyl-5-(quinolin-8-yl)-5,6-dihydrophenanthridin-6-one (5m). The title 
compound was synthesized following the General Procedure B as an off white solid in 
36% yield (29.7 mg, 0.07 mmol), mp = 253 – 255 C. 1H NMR (400 MHz, CDCl3): δ = 
8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.29 (dd, J = 8.3, 1.7 Hz, 1H), 8.20 (d, J = 8.2 Hz, 1H), 
8.15 (d, J = 8.7 Hz, 1H), 8.04 (dd, J = 7.3, 2.4 Hz, 1H), 7.80 – 7.72 (m, 2H), 7.65 (t, J = 
7.8 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 7.40 (d, J = 7.4 Hz, 1H), 7.31 (dd, J = 8.7, 1.9 
Hz, 1H), 6.53 (d, J = 1.9 Hz, 1H), 2.89 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 
162.73, 151.63, 144.57, 143.49, 140.77, 136.59, 136.09, 135.45, 132.25, 132.24, 130.77, 
130.09, 129.72, 127.04, 125.40, 125.02, 124.42, 123.03, 122.23, 120.22, 119.11, 118.43, 
24.60. FTIR (ATR, cm
-1
): 3060, 2921, 1651, 1594, 1499, 1464, 1387, 1301, 802, 783, 
685. HRMS (ESI-MS) m/z calcd for C23H16BrN2O [M + H]
+
 415.0445 found 415.0447. 
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3-fluoro-7-methyl-5-(quinolin-8-yl)-5,6-dihydrophenanthridin-6-one (5n). The title 
compound was synthesized following the General Procedure B as an off white solid in 
68% ( 48.7 mg, 0.13 mmol), mp = 233 – 235 C. 1H NMR (400 MHz, CDCl3): δ = 8.81 
(dd, J = 4.2, 1.7 Hz, 1H), 8.32 – 8.23 (m, 2H), 8.16 (d, J = 8.2 Hz, 1H), 8.08 – 8.00 (m, 
1H), 7.79 – 7.74 (m, 2H), 7.64 (t, J = 7.8 Hz, 1H), 7.44 (dd, J = 8.3, 4.2 Hz, 1H), 7.37 (d, 
J = 7.4 Hz, 1H), 6.91 (ddd, J = 9.0, 7.9, 2.6 Hz, 1H), 6.08 (dd, J = 10.8, 2.6 Hz, 1H), 2.91 
(s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.04 (d, J = 246.9 Hz), 162.99, 151.56, 
144.49, 143.38, 141.22 (d, J = 10.7 Hz), 136.55, 136.28, 135.65, 132.21, 131.64, 130.69, 
130.06, 129.63, 127.00, 125.48 (d, J = 9.8 Hz), 123.89 (d, J = 1.2 Hz), 122.17, 120.12, 
115.85 (d, J = 2.5 Hz), 109.89 (d, J = 22.6 Hz), 103.29 (d, J = 26.9 Hz), 24.60. 
19
F NMR 
(376 MHz, CDCl3): δ = -111.14 – -111.28 (m). FTIR (ATR, cm
-1
): 3067, 2967, 1654, 
1598, 1459, 1388, 1301, 1144, 823, 784. HRMS (ESI-MS) m/z calcd for C23H16FN2O [M 
+ H]
+
 355.1246 found 355.1246. 
 
 
 
 
 
 
3,7-dimethyl-5-(quinolin-8-yl)-5,6-dihydrophenanthridin-6-one (5o). The title 
compound was synthesized following the General Procedure B as a light brown solid in 
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50% yield ( 35.1 mg, 0.10 mmol), mp = 218 – 220 C. 1H NMR (400 MHz, CDCl3): δ = 
8.82 (dd, J = 4.2, 1.7 Hz, 1H), 8.28 (dd, J = 8.3, 1.7 Hz, 1H), 8.24 (d, J = 8.2 Hz, 1H), 
8.19 (d, J = 8.3 Hz, 1H), 8.07 – 7.98 (m, 1H), 7.82 – 7.73 (m, 2H), 7.63 (t, J = 7.8 Hz, 
1H), 7.43 (dd, J = 8.3, 4.2 Hz, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.02 (d, J = 8 Hz, 1H), 6.18 
(s, 1H), 2.91 (s, 3H), 2.15 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.08, 151.50, 
144.87, 143.21, 139.75, 139.34, 136.89, 136.49, 136.27, 131.94, 131.36, 130.82, 129.98, 
129.26, 127.00, 124.18, 123.61, 123.47, 122.03, 120.05, 117.02, 116.64, 24.67, 21.70. 
FTIR (ATR, cm
-1
): 3067, 2920, 1646, 1598, 1498, 1462, 1390, 1300, 822, 788. HRMS 
(ESI-MS) m/z calcd for C24H19N2O [M + H]
+
 351.1497 found 351.1498. 
 
 
7,9-dimethyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5q): The title 
compound was synthesized following the General Procedure A as a merlot solid in 75% 
yield (53.2 mg, 0.15 mmol), mp = 294 – 296 C.  1H NMR (400 MHz, CDCl3): δ = 8.75 
(dd, J = 4.2, 1.7 Hz, 1H), 8.52 (dd, J = 8.1, 1.7 Hz, 1H), 8.23 (dd, J = 8.3, 1.7 Hz, 1H), 
8.19 (dd, J = 4.6, 1.7 Hz, 1H), 8.00 – 7.94 (m, 2H), 7.79 – 7.70 (m, 2H), 7.37 (dd, J = 8.3, 
4.2 Hz, 1H), 7.25 (s, 1H), 7.09 (dd, J = 8.0, 4.7 Hz, 1H), 2.88 (s, 3H), 2.52 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.70, 150.88, 150.50, 148.69, 144.90, 143.36, 
142.54, 136.70, 136.45, 134.48, 133.90, 131.59, 130.42, 129.67, 128.81, 126.70, 122.38, 
121.64, 120.47, 118.09, 114.83, 24.31, 21.94. FTIR (ATR, cm
-1
): 3050, 2922, 1645, 
1598, 1499, 1464, 1392, 1300, 823, 789. HRMS (ESI-MS) m/z calcd for C23H18N3O [M 
+ H]
+
 352.1449 found 352.1447. 
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9-methoxy-7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5r). 
The title compound was synthesized following the General Procedure A as a merlot solid 
in 71% yield ( 52.2 mg, 0.14 mmol), mp = 303 – 305 C. 1H NMR (400 MHz, CDCl3): δ 
= 8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.48 (dd, J = 8.0, 1.6 Hz, 1H), 8.27 – 8.19 (m, 2H), 7.97 
(dt, J = 7.4, 3.7 Hz, 1H), 7.77 – 7.71 (m, 2H), 7.59 (d, J = 2.5 Hz, 1H), 7.38 (dd, J = 8.3, 
4.2 Hz, 1H), 7.11 (dd, J = 8.0, 4.7 Hz, 1H), 6.99 (d, J = 1.9 Hz, 1H), 3.99 (s, 3H), 2.88 (s, 
3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.41, 162.11, 150.92, 150.67, 149.06, 
146.13, 144.97, 136.71, 136.57, 136.49, 131.71, 130.50, 129.70, 128.82, 126.73, 121.65, 
119.56, 118.57, 118.00, 114.71, 103.70, 55.61, 24.80. FTIR (ATR, cm
-1
): 3004, 2921, 
1652, 1601, 1500, 1452, 1399, 1306, 1291, 1166, 1049, 814, 784. HRMS (ESI-MS) m/z 
calcd for C23H18N3O2 [M + H]
+
 368.1399 found 368.1396. 
 
 
9-chloro-7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5s). The 
title compound was synthesized following the General Procedure A as a terra cotta solid 
in 63% yield (46.6 mg, 0.12 mmol), mp = 284 – 286 C. 1H NMR (400 MHz, CDCl3): δ 
= 8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.45 (dd, J = 8.1, 1.7 Hz, 1H), 8.27 – 8.20 (m, 2H), 8.15 
(d, J= 2.0 Hz,1H), 7.99 (dd, J = 6.4, 3.3 Hz, 1H), 7.78 – 7.71 (m, 2H), 7.43 – 7.35 (m, 
2H), 7.11 (dd, J = 8.0, 4.7 Hz, 1H), 2.89 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 
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163.04, 150.93, 150.47, 149.54, 145.81, 144.69, 138.59, 136.50, 136.25, 135.98, 132.30, 
131.85, 130.34, 129.67, 128.99, 126.68, 123.12, 121.73, 120.14, 118.38, 113.81, 24.35. 
FTIR (ATR, cm
-1
): 3067, 2923, 1661, 1592, 1501, 1470, 1396, 1300, 825, 783, 760. 
HRMS (ESI-MS) m/z calcd for C22H15ClN3O [M + H]
+
 372.0903 found 372.0903. 
 
 
8-methoxy-7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5t). 
The title compound was synthesized following the General Procedure A as an off white 
solid in 54% yield (40.0 mg, 0.10 mmol), mp = 337 – 339 C. 1H NMR (400 MHz, 
CDCl3): δ = 8.74 (dd, J = 4.2, 1.8 Hz, 1H), 8.48 (dd, J = 8.0, 1.7 Hz, 1H), 8.24 (dd, J = 
8.3, 1.7 Hz, 1H), 8.20 (d, J = 8.9 Hz, 1H), 8.16 (dd, J = 4.7, 1.6 Hz, 1H), 8.00 – 7.95 (m, 
1H), 7.77 – 7.71 (m, 2H), 7.43 – 7.35 (m, 2H), 7.12 (dd, J = 7.9, 4.7 Hz, 1H), 3.97 (s, 
3H), 2.82 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.85, 158.47, 150.96, 149.80, 
147.78, 144.92, 136.87, 136.49, 131.47, 130.72, 130.42, 129.71, 128.84, 127.17, 126.74, 
125.75, 121.67, 120.82, 118.22, 115.93, 115.13, 56.49, 13.90. FTIR (ATR, cm
-1
): 3012, 
2936, 1655, 1594, 1495, 1452, 1030, 1274, 1163, 1069, 827, 789. HRMS (ESI-MS) m/z 
calcd for C23H18N3O2 [M + H]
+
 368.1399 found 368.1397. 
 
 
7,8-dimethyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5u). The title 
compound was synthesized following the General Procedure A as an off white solid in 
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70% yield (49.0 mg, 0.13 mmol), mp = 329 – 331 C. 1H NMR (400 MHz, CDCl3): δ = 
8.74 (dd, J = 4.2, 1.7 Hz, 1H), 8.52 (dd, J = 8.0, 1.6 Hz, 1H), 8.24 (dd, J = 8.3, 1.6 Hz, 
1H), 8.19 (dd, J = 4.7, 1.6 Hz, 1H), 8.11 (d, J = 8.3 Hz, 1H), 8.02 – 7.95 (m, 1H), 7.78 – 
7.72 (m, 2H), 7.61 (d, J = 8.2 Hz, 1H), 7.38 (dd, J = 8.3, 4.2 Hz, 1H), 7.12 (dd, J = 7.9, 
4.7 Hz, 1H), 2.86 (s, 3H), 2.48 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 164.05, 
150.89, 150.15, 148.42, 141.75, 138.88, 136.87, 136.55, 136.53, 134.56, 132.47, 131.25, 
130.43, 129.70, 128.82, 126.75, 124.71, 121.66, 119.47, 118.16, 115.03, 21.58, 18.53. 
FTIR (ATR, cm
-1
): 3010, 2970, 1651, 1587, 1497, 1385, 1299, 829, 791. HRMS (ESI-
MS) m/z calcd for C23H18N3O [M + H]
+
 352.1449 found 352.1447. 
 
 
 
 
8-chloro-7-methyl-5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5v). The 
title compound was synthesized following the General Procedure A as a dark brown solid 
in 31% yield (22.9 mg, 0.06 mmol), mp = 344 – 346 C. 1H NMR (400 MHz, CDCl3): δ 
= 8.73 (dd, J = 4.1, 1.8 Hz, 1H), 8.52 (dd, J = 8.0, 1.7 Hz, 1H), 8.29 – 8.21 (m, 2H), 8.15 
(d, J = 8.7 Hz, 1H), 7.99 (dt, J = 7.3, 3.7 Hz, 1H), 7.82 (d, J = 8.7 Hz, 1H), 7.78 – 7.72 
(m, 2H), 7.39 (dd, J = 8.3, 4.2 Hz, 1H), 7.17 (dd, J = 8.0, 4.6 Hz, 1H), 3.01 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 163.04, 151.02, 150.26, 149.27, 144.72, 140.95, 
136.88, 136.54, 136.47, 133.59, 133.28, 131.63, 130.30, 129.73, 129.04, 126.73, 126.24, 
121.78, 120.87, 118.45, 114.25, 19.34. FTIR (ATR, cm
-1
): 3050, 2999, 1652, 1587, 1499, 
1451, 1369, 1300, 811, 786, 707. HRMS (ESI-MS) m/z calcd for C22H15ClN3O [M + H]
+
 
372.0903 found 372.0900. 
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5-(quinolin-8-yl)-5H,6H-benzo[c]1,8-naphthyridin-6-one (5w). The title compound 
was synthesized following the General Procedure A as a light red solid in 48% yield 
(31.3 mg, 0.09 mmol), mp = 262 – 264 C. 1H NMR (400 MHz, CDCl3): δ = 8.74 (dd, J 
= 4.1, 1.8 Hz, 1H), 8.61 – 8.56 (m, 2H), 8.32 (dd, J = 8.3, 1.3 Hz, 1H), 8.29 – 8.23 (m, 
2H), 8.00 (dd, J = 7.1, 2.5 Hz, 1H), 7.87 – 7.81 (m, 1H), 7.80 – 7.72 (m, 2H), 7.69 – 7.63 
(m, 1H), 7.38 (dd, J = 8.3, 4.2 Hz, 1H), 7.19 (dd, J = 7.8, 4.6 Hz, 1H). 
13
C{
1
H} NMR 
(100 MHz, CDCl3): δ = 162.94, 150.99, 150.39, 148.94, 144.77, 136.47, 136.16, 133.16, 
132.99, 131.41, 130.36, 129.64, 129.51, 129.08, 128.85, 126.64, 126.37, 122.08, 121.70, 
118.52, 114.88. FTIR (ATR, cm
-1
): 3032, 2999, 1652, 1587, 1499, 1451, 1369, 1300, 
811, 785. HRMS (ESI-MS) m/z calcd for C21H14N3O [M + H]
+
 324.1136 found 
324.1133. 
 
 
 
 
4-methyl-6-(quinolin-8-yl)-5H,6H-pyrido[4,3-c]1,8-naphthyridin-5-one (5x). The title 
compound was synthesized following the General Procedure A as a terra cotta solid in 
61% yield (41.4 mg, 0.12 mmol), mp = 335 – 337 C. 1H NMR (400 MHz, CDCl3): δ = 
9.61 (s, 1H), 8.73 (dd, J = 4.3, 1.6 Hz, 1H), 8.71 – 8.65 (m, 2H), 8.31 – 8.23 (m, 2H), 
8.04 – 7.97 (m, 1H), 7.80 – 7.72 (m, 2H), 7.41 (dd, J = 8.3, 4.1 Hz, 1H), 7.22 (dd, J = 7.8, 
4.6 Hz, 1H), 2.87 (s, 3H). 
13
C{
1
H} NMR (100 MHz, CDCl3): δ = 162.62, 151.78, 151.08, 
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150.61, 149.83, 144.54, 143.97, 136.55, 135.83, 135.33, 131.30, 130.20, 129.72, 129.67, 
129.26, 127.83, 126.70, 121.88, 118.84, 112.92, 20.25. FTIR (ATR, cm
-1
): 3048, 2956, 
1659, 1593, 1448, 1407, 1298, 827, 786. HRMS (ESI-MS) m/z calcd for C21H15N4O [M 
+ H]
+
 339.1245 found 339.1243. 
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C h a p t e r  4 :  S y n t h e t i c  R o u t e s  t o  a  P o s s i b l e  
N i c k e l ( I I )  M e t a l l a c y c l e :  D e n i t r o g e n a t i o n  a n d  
D e c a r b o n y l a t i o n  
4.1. Overview 
  
  Nickel complexes have been widely employed as catalyst in CC and C-heteroatom 
bond transformations in traditional cross-coupling reactions.1 While nickel has 
experienced a revival as an economical and complementary alternative to palladium-
catalyzed methods in recent years, the mechanism of nickel-catalyzed reactions are not 
fully understood. However, many of these reactions involve a proposed Ni(II) 
metallacycle complex to result from CH activation41,72 allowing the proposed Ni(II) 
metallacycle to react with a coupling partner through either a two electron or single 
electron pathway.
73
 Despite the ubiquity of these proposed species in catalytic cycles, 
such a complex has not yet been isolated or shown to be catalytically relevant.  
  In the revival of nickel catalysis, many groups have begun to isolate and study elusive 
Ni(III) and Ni(IV) dialkyl/aryl complexes. Mirica and Sanford demonstrated that a 
cleverly designed tetradentate or tridentate nitrogen donor ligand could be used to 
stabilize an isolable Ni(III) or Ni(IV) dialkyl/aryl complex.
74
 More recently, the Love 
group has reported a Ni(II) metallacycle from sp
3
 CH activation of a urea moiety 
(Scheme 23).
75
 The urea moiety was needed in order to stabilize the Ni(II) metallacycle. 
In addition, the Love group also showed the metallacycle would react with a small set of 
coupling partners, but in low yields (20 – 48%). Unfortunately, this urea moiety has not 
been shown to be catalytically relevant.  
 
Scheme 23. Ni(II)-mediated sp
3
 CH activation of a tertiary urea moiety. 
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  We have recently proposed a Ni(II) metallacycle in our oxidative decarboxylative 
(hetero)arylation and annulation reactions above in chapters 2 and 3.
66,76
 Under our 
reaction conditions, we proposed the Ni(II) metallacycle intermediate to undergo 
transmetallation with a silver(I)-aryl and concomitant oxidation to form the desired 
product. However, in order to study our proposed reaction, we first had to isolate the 
Ni(II) intermediate. We then hypothesized the desired metallacycle could be isolated 
through either denitrogenation or decarbonylation. 
  Similar to decarboxylative coupling reactions discussed above, decarbonylation 
reactions represent another approach in creating a metalC bond. This involves the 
insertion of a transition-metal into an aroyl compound and extruding carbon monoxide. 
One of the first reported transition-metal mediated decarbonylations was reported from 
Eschinazi.
77
 Eschinazi found that aldehydes undergo decarbonylation in the presence of 
palladium. Later, Tsuji and Ohno reported the decarbonylation of primary or aryl 
aldehydes and acyl halides by stoichiometric amounts of Wilkinson’s catalyst 
(RhCl(PPh3)3) (Scheme 24).
78
 Since then, decarbonylation has been utilized in  other 
functional groups including carboxylic acids
79
, esters
80
, anhydrides
81
, phthalimides
82
, and 
unstrained ketones.
83
 
 
Scheme 24. First reported transition-metal-mediated decarbonylation. 
  More recently, nickel-catalyzed decarbonylative annulations of phthalimides have been 
reported. In 2008, Matsubara and Kurahashi postulated that a Ni(0) with electron-rich 
phosphines would oxidatively add to the CN bond thereby creating a CNiN species 
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after decarbonylation and allowing a variety of unsaturated alkynes to undergo 
insertion.
84
 There have also been reports of a directed nickel-catalyzed decarbonylation of 
unstrained ketones from Xu and Wei.
85
 Where they found N-pyrimidinyl 2-benzoyl 
indole as their model substrate would undergo decarbonylation to form a biaryl in the 
presence of Ni(COD)2 with a NHC and Cs2CO3 in dioxane. In addition, the directing 
group did not shut down the Ni-catalyst due to heterocyclic poisoning (Scheme 25).  
 
Scheme 25. Ni-catalyzed decarbonylation of unstrained ketones and phthalimides. 
  On the other hand, transition-metal catalyzed denitrogenative functionalization of 
triazole rings has attracted attention as an alternative to traditional synthesis for the 
construction of heterocyclic compounds. Early pioneering work from Gevorgyan
86
 and 
Fokin
87
 in Rh-catalyzed transannulation of triazoles with nitriles and alkynes highlighted 
this utility. Murakami and co-workers were the first to report a nickel-catalyzed 
denitrogenative annulation of 1,2,3-benzotriazin-4(3H)-ones with various unsaturated 
compounds.
88
 They discovered when using Ni(COD)2 in combination with a phosphine 
ligand, Ni(COD)2 inserted into the NN bond thereby producing dinitrogen and an 
azanickelacycle. This was later confirmed by adding stoichiometric amounts of 
Ni(COD)2 and Dppbenz to N-toyl-1,2,3-benzotriazine-4(3H)-one to afford an isolable 
five-membered azanickelacycle (Scheme 26).
89
 Other groups have also reported 
annulation reactions with alkenes,
90
 isocyanides,
91
 benzynes,
92
 and cross-coupling with 
boronic acids.
93
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Scheme 26. Formation of a five-membered azanickelacycle by denitrogenation. 
  Since Ni(0) has been shown to insert in to the CN bond of phthalimide and the NN 
of triazole rings we hypothesized we would be able to synthesize the Ni(II) metallacycle 
from 3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one or 2-(quinolin-8-yl)-2,3-
dihydro-1H-isoindole-1,3-dione in the presence of a Ni(0) source (Scheme 27). Access to 
the targeted metallacycle would allow us to probe our proposed reaction mechanism, 
discussed earlier in Chapters 2 and 3. 
 
Scheme 27. Proposed synthesis of a Ni(II) metallacycle from phthalimide or 1,2,3-
benzotriazine. 
4.2. Results 
 
4.2.1. Synthesis of 1,2,3-Benzotriazine Derivative and Attempted Denitrogenation 
for Ni(II) Metallacycle 
  Since triazoles have been reported to undergo denitrogenation in the presence of 
Ni(COD)2, we set out to synthesize a 1,2,3-benzotriazine linked quinoline in hopes of 
isolating the proposed Ni(II) metallacycle. The 2-nitro-N-(quinolin-8-yl)benzamide was 
synthesized from a modified reported procedure.
94
 2-nitrobenzoyl chloride and 8-
aminoquinoline were allowed to stir overnight, providing 67% yield after purification.
95
 
The corresponding 2-nitro-N-(quinolin-8-yl)benzamide was then reduced using a 
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Béchamp reduction to afford the corresponding 2-amino-N-(quinolin-8-yl)benzamide. 
The substituted 2-aminobenazide product then afforded the desired annulation product 
from a reported procedure (Scheme 28).
96
 
 
Scheme 28. Synthesis of 3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one from 8-
aminoquinoline and 2-nitrobenzoyl chloride. 
  The reaction of 3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one (6a) was 
treated with equimolar amounts of Ni(COD)2 and a ligand in THF at room temperature 
causing the solution to turn dark brown. After stirring for 3 h, the mixture was 
concentrated down to minimum amount of THF. The reaction mixture was then 
precipitated out of solution into pentane dropwise producing a dark brown solid. The 
solid was then dried under high vacuum for 2 h. 
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Table 4.1. Attempted synthesis of a Ni(II) metallacycle by denitrogenation
a 
 
entry Ligand Yield 7a (%) Yield 8a (%) 
1 PPh3 0 74 
2 MeCN 0 44 
3 Dppbenz 0 63 
4 none 0 71 
a
Isolated yields. Reaction conditions: 6a (0.2 mmol), Ni(COD)2 (0.2 mmol), ligand (0.2 
mmol) in THF (8 mL). 
  Ni(COD)2 was treated with 6a with in order to obtain the Ni(II) metallacycle complex. 
Characterization of the isolated products (Table 4.1, entry 1-4) showed the same 
diamagnetic 
1
H NMR spectrum when ligands or no ligands were added. The 
1
H NMR 
spectrum of 8a shows eight inequivalent aryl resonances adding up to ten protons. The 
13
C{
1
H} NMR spectrum shows fifteen different aryl resonances and one carbonyl 
resonance. The carbonyl resonance at δ 167.0 is indicative of a typical six-membered 
azanickel metallacycle.
97
 Recrystallization of the reaction mixture from CH2Cl2/Hexane 
afforded complex 8a as dark brown crystals. The structure of 8a was established by 
single-crystal X-ray analysis to contain a square planar Ni(II) dimeric molecule in a 
bowl-shaped structure [(C16H10N4O)Ni]2 (Figure 2).  
O 
N N 
N 
N 
O 
N N 
Ni 
-  N 2 
THF,  rt,  3  h 
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8a 
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Figure 2. Perspective view of the molecular structure of [(C16H10N4O)Ni]2 (8a) with the 
atom labeling scheme for the non-hydrogen atoms. The thermal ellipsoids are 
scaled to enclose 50% probability.  
  Intrigued by the formation of the six-membered azanickelacycle 8a, we explored the 
reactivity of the complex with our first reported ODC reaction conditions (Scheme 29). 
When 20 mol% of complex 8a was substituted in place of Ni(OAc)2•4H2O, we 
discovered the ODC product 3z and 3z’ were formed with almost identical yields from 
our reported work. Likewise, when a stoichiometric amount of 8a was used, we noticed 
the diarylated ODC product 3z’ was formed in higher yields than 3z. This could be due to 
slow protonation of the NiN bond allowing a second CH activation to take place. 
Surprised by these data, complex 8a could be undergoing a denitrogenation forming a 
NiC bond.  
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Scheme 29. Reactivity of complex 8a under the nickel-catalyzed oxidative 
decarboxylative (hetero)arylation reaction conditions.
 
 
Reaction conditions: 
a
Azanickelacycle 8a (0.040 mmol), 1a (0.16 mmol), heteroaromatic 
carboxylate 2a (0.60 mmol), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), and PivOH (1.5 
equiv) in DMA (2 mL) for 24 h at 110 °C under a N2 atmosphere.
 b
Azanickelacycle 8a 
(0.20 mmol), Heteroaromatic carboxylate 2a (0.60 mmol), Ag2CO3 (2.0 equiv), Na2CO3 
(4.0 equiv), and PivOH (1.5 equiv) in DMA (2 mL) for 24 h at 110 °C under a N2 
atmosphere. 
c1
H NMR yield with 1,3,5-trimethoxybenzene as an internal standard. 
  We hypothesized heating complex 8a in different solvents would force 8a to undergo 
denitrogenation, thereby creating the five-membered azanickelacycle. Heating of 
complex 8a in DCM-d2, MeCN-d3, THF-d8, or DMSO-d6 showed no change in the 
starting material by 
1
H NMR spectroscopy. Heating of 8a in anhydrous DMA at 140 C 
for 1 h led to a complex mixture of products. Upon switching the solvent to anhydrous 
DMF-d7, we were able to see complex 8a was converted to a new species. Heating of the 
six-membered azanickelacycle 8a (red box outline), at 140 C for 1 h led to formation of 
a new unknown product (Figure 3). Heating of the reaction over time and increasing 
temperature led to the formation of new unknown products. However, over time, there 
was a decrease in yield of the new product from 62 % to 37 %. Attempts to isolate the 
unknown product after 1 h were unsuccessful.  
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Figure 3. Heating of 8a in DMF-d7: Reaction conditions: 8a (0.015 mmol) in DMF-d7 
(0.90 mL) with 1,3,5-trimethoxybenzene as an internal standard at 140 C to 160 C. 
4.2.2. Synthesis of the Ni(II) Metallacycle by Decarbonylation of Phthalimides 
  To obtain the desired five-membered azanickelacycle, we then tried a different 
synthetic route, decarbonylation of phthalimides. The 2-(quinolin-8-yl)-2,3-dihydro-1H-
isoindole-1,3-dione was synthesized from a reported procedure.
98
 Phthalic anhydride and 
8-aminoquinoline were refluxed in acetic acid for 2 h, providing 79% yield of 9a 
following recrystallization (Scheme 30). The phthalimide was found to be soluble in 
THF, MeCN, and PhCH3 allowing for potential synthesis of the desired Ni(II) 
metallacycle. 
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Scheme 30. Synthesis of 2-(quinolin-8-yl)-2,3-dihydro-1H-isoindole-1,3-dione (9a) from 
8-aminoquinoline and phthalic anhydride. 
  The reaction of 2-(quinolin-8-yl)-2,3-dihydro-1H-isoindole-1,3-dione (9a) was treated 
with equimolar amounts of Ni(COD)2 in THF at room temperature. Coordination of the 
phthalimide to nickel is signaled by a change in color in the solution from clear to dark 
red. After stirring for 3 h, the mixture produced a light red precipitate that was filtered out 
of solution in (Scheme 31). The 
1
H NMR spectrum of 10a shows eight inequivalent aryl 
resonances adding up to ten protons. The 
13
C{
1
H} NMR spectrum shows fifteen different 
aryl resonances and two carbonyl resonance. The carbonyl resonance at δ 167.23 is 
indicative of a typical six-membered Ni(II) metallacycle while the second carbonyl 
resonance at δ 268.82 is from insertion of Ni(COD)2 into the (O)CN bond.
99
 
Scheme 31. Synthesis of an azaacylNi(II) complex (10a) from insertion of nickel into the 
phthalimide CN bond.a 
 
a
Isolated yields. Reaction conditions: 9a (1.0 mmol), Ni(COD)2 (1.0 mmol) in THF (27 
mL). 
  Complex 10a was tested under our nickel-catalyzed ODC reaction conditions to see if 
it had similar reactivity as complex 8a (Scheme 32). When 20 mol% of complex 10a was 
substituted in place of Ni(OAc)2•4H2O, we found the ODC products 3z and 3z’ were 
formed in 37% and 21% yields. When a stoichiometric amount of complex 10a was used, 
there was a higher yield of the monoarylation ODC product 3z in 28% than the 
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diarylation ODC product 3z’ in 11% yield. While complex 10a shows reactivity under 
our reaction conditions, we were surprised to see differences in yields of 3z and 3z’ 
between complex 8a and 10a.  
Scheme 32. Reactivity of azaacylNi(II) complex 10a under the nickel-catalyzed 
oxidative decarboxylative (hetero)arylation reaction conditions. 
 
Reaction conditions: 
a
Azanickelacycle 10a (0.040 mmol), 1a (0.16 mmol), 
heteroaromatic carboxylate 2a (0.60 mmol), Ag2CO3 (2.0 equiv), Na2CO3 (4.0 equiv), 
and PivOH (1.5 equiv) in DMA (2 mL) for 24 h at 110 °C under a N2 atmosphere.
 
b
Azanickelacycle 10a (0.20 mmol), heteroaromatic carboxylate 2a (0.60 mmol), Ag2CO3 
(2.0 equiv), Na2CO3 (4.0 equiv), and PivOH (1.5 equiv) in DMA (2 mL) for 24 h at 110 
°C under a N2 atmosphere. 
c1
H NMR yield with 1,3,5-trimethoxybenzene as an internal 
standard. 
  With the azaacylNi(II) complex 10a in hand, we hypothesized the metallacycle would 
undergo decarbonylation at an elevated temperature. Heating complex 10a in MeCN, 
dioxane, DMC, or THF led to decomposition with no formation of the desired product 
11a. However, when complex 10a was heated in PhCH3, the solution turned from bright 
red to light yellow (see experimental below). Crystallization of the reaction mixture after 
heating afforded complex 11a as bright yellow parallelepiped crystals (Scheme 33).  
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Scheme 33. Decarbonylation of the azaacylNi(II) metallacycle 10a to complex 11a. 
  The 
1
H NMR spectrum of 11a shows nine inequivalent aryl resonances adding up to 
ten protons. The 
13
C{
1
H} NMR spectrum shows fifteen different aryl resonances and one 
carbonyl resonance. The carbonyl resonance at δ 186.96 is indicative of a typical five-
membered azanickel metallacycle.89 The reaction mixture was allowed to cool to room 
temperature after heating affording complex 11a as bright yellow crystals. FTIR of 
complex 11a showed a characteristic carbonyl stretch at 2063 cm
-1
. The structure of 11a 
was established by single-crystal X-ray analysis to contain a square planar Ni(II) 
molecule (Figure 4) 
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Figure 4.  Perspective view of the molecular structure of (C16H10N2O)Ni(CO) (11a) with 
the atom labeling scheme for the non-hydrogen atoms. The thermal ellipsoids 
are scaled to enclose 50% probability. 
 
  After isolation of the new Ni(II) metallacycle, we wanted to probe our proposed 
catalytic cycle. We hypothesized in the previous chapters that silver is likely responsible 
for the decarboxylation step generating a well-defined silver aryl in solution, which then 
reactions with a nickel(II) metallacycle. To explore the possibility of such pathway, we 
conducted an experiment where complex 11a was treated with equimolar amounts of 
(2‐nitrophenyl)silver(I) in DMA (Scheme 34). The initial reaction solution turned from 
orange/yellow to dark when the (2‐nitrophenyl)silver(I) solution was added dropwise. 
The reaction was allowed to stir for 1 h at room temperature. After extraction of the 
reaction mixture, we were excited to see 13a was formed in 46% yield by 
1
H NMR 
spectroscopy. When two equivalents of 12a were added, the yield of 13a increased to 
68% (Scheme 34, entry 2). This transformation could be going through a transmetalation 
of the aryl fragment from Ag to Ni followed by concomitant oxidation of the nickel 
center to thereby generation the new CC bond. This data suggest there could be 
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cooperation between both nickel and silver allowing for the remarkable efficiency and 
selectivity of our catalyst system as mentioned previously. 
Scheme 34. Arylation of complex 11a with silver(I)-aryl for CC bond formation.a 
 
entry (12a) Equivalence yield (13a)
b 
1 1.0  46% 
2 2.0  68% 
a
Reaction conditions:  11a (0.025 mmol), 12a (0.025 mmol or 0.050 mmol), in DMA (2 
mL) for 1 h at room temperature under a N2 atmosphere.
 b1
H NMR yield with 1,3,5-
trimethoxybenzene as an internal standard.
 
4.3. Conclusion 
  In conclusion, we have synthesized a catalytically relevant five-membered 
azanickelacycle by decarbonylation of an azaacylNi(II) complex (10a). The attempted 
denitrogenation of 3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one (6a) afforded 
an interesting nickel metallacycle dimer, that showed reactivity under our earlier reported 
reaction conditions. Ultimately, the five-membered Ni(II) complex (11a) showed 
reactivity with (2‐nitrophenyl)silver(I) to form the arylated product (13a). These findings 
support that both metals are needed to form the desired ODC product. 
 
 
 
 
 
 
 
 
  128 
 
4.4. Experimental 
 
  General Considerations. All manipulations were performed using standard Schlenk 
or glovebox techniques under a nitrogen atmosphere. All solvents (including dry DMA) 
were purchased from Alfa-Aesar and Fisher and used as received. All other reagents were 
purchased from Maybridge, Oakwood, Acros, Alfa-Aesar, and Strem and used without 
further purification. All NMR spectra were recorded at ambient temperature on an 
Agilent 400 MHz or JEOL 400 MHz (
1
H, 400 MHz; 
13
C{
1
H}, 100 MHz) spectrometer. 
Chemical shifts are referenced to the residual solvent signals (CDCl3: 7.26 ppm (
1
H) and 
77.2 ppm (
13
C), DMSO-d6: 2.50 ppm (
1
H) and 39.5 ppm (
13
C), CD2Cl2: 5.32 ppm (
1
H) 
and 54.0 ppm (
13
C)).45 IR spectra were recorded on a PerkinElmer (Spectrum 100) FT-IR 
spectrometer. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, 
GA. Column chromatography was performed using Silicycle Silica Flash P60 silica gel.  
Synthesis of 3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one (6a). 
  Amide bond formation. A 100 mL two-neck round bottom flask was charged with 8-
aminoquinoline (1.44 g, 10.0 mmol), Et3N (1.56 mL, 12.0 mmol), and methylene chloride 
(20 mL) under a N2 atmosphere. The corresponding 2-nitrobenzoyl chloride (1.58 mL, 
12.0 mmol) was added dropwise at room temperature over 10 minutes. The mixture was 
stirred overnight at room temperature. The reaction was quenched with 10 mL of 
saturated NaHCO3 and extracted with methylene chloride (3 x 25 mL). The combined 
organic layer was washed with brine (15 mL) and dried over anhydrous Na2SO4. The 
solvent was removed under reduced pressure and the residue was purified via silica gel 
column chromatography (gradient elution, hexanes : ethyl acetate (5:1, v/v) to (1:1, v/v)) 
yielding 2-nitro-N-(quinolin-8-yl)benzamide. 
 
Reduction of 2-nitro-N-(quinolin-8-yl)benzamide. A 50 mL round bottom flask was 
charged with water (5 mL), iron powder (10.0 mmol, 558 mg), and concentrated HCl (1.5 
drops) were added to a solution of 2-nitro-N-(quinolin-8-yl)benzamide (1.00 mmol, 293 
mg) in THF (15 mL). The mixture was refluxed for 3 h. Upon completion, the reaction 
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mixture was allowed to cool to room temperature, diluted with brine (25 mL) and filtered 
through a pad of celite. The filtrate was extracted with ethyl acetate (3 x 25 mL) and 
dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the 
residue was purified via silica gel column chromatography (gradient elution, hexanes : 
ethyl acetate (19:1, v/v) to (10:1, v/v)) yielding 2-amino-N-(quinolin-8-yl)benzamide. 
 
Annulation of 2-amino-N-(quinolin-8-yl)benzamide. A oven dried Schlenk tube (50 
mL) was charged with 2-amino-N-(quinolin-8-yl)benzamide (3.00 mmol, 790 mg), TBAI 
(0.15 mmol, 55.4 mg), tert-butyl nitrite (9.00 mmol, 1.07 mL), and MeCN (30 mL). The 
Schlenk tube was sealed with a rubber septum and placed in a pre-heated oil bath at 60 
C for 12 h. The solution was cooled to room temperature and solvent was removed 
under reduced pressure. The residue was purified via silica gel column chromatography 
(gradient elution, hexanes : ethyl acetate (1:1, v/v) to (1:2, v/v)) yielding 
3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one (6a) in 50% (1.50 mmol, 417 
mg). 
 
 
3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one (6a). 1H NMR (400 MHz, 
DMSO-d6) δ 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.57 (dd, J = 8.4, 1.7 Hz, 1H), 8.35 (dddd, J 
= 8.0, 4.7, 1.4, 0.6 Hz, 2H), 8.27 (dd, J = 8.3, 1.4 Hz, 1H), 8.20 (ddd, J = 8.1, 7.3, 1.4 Hz, 
1H), 8.13 (dd, J = 7.3, 1.4 Hz, 1H), 8.03 (ddd, J = 8.0, 7.3, 1.2 Hz, 1H), 7.86 (dd, J = 8.3, 
7.3 Hz, 1H), 7.66 (dd, J = 8.3, 4.2 Hz, 1H). 
13
C{
1
H} NMR (100 MHz, DMSO-d6) δ 
155.13, 151.50, 143.57, 143.21, 136.55, 136.17, 135.83, 133.41, 130.39, 129.35, 128.64, 
128.32, 126.40, 124.94, 122.42, 119.94. The spectral data is consistent with literature.28 
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[(C16H10N4O)Ni]2 (8a). In a glovebox filled with N2. A mixture of 
3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one (54.8 mg, 0.200 mmol) was added 
to a 20 mL vial and dissolved in THF (4 mL). In another 20 mL vial, Ni(COD)2 (55.0 mg, 
0.200 mmol) and ligand (0.200 mmol) was dissolved in THF (4 mL). The solution of 
Ni(COD)2 was added dropwise to the vial containing  
3‐(quinolin‐8‐yl)‐3,4‐dihydro‐1,2,3‐benzotriazin‐4‐one and THF over 5 minutes. The 
solution was allowed to stir for 3 h at room temperature. The volume was then reduced to 
~1.5 mL and added dropwise to hexanes (~100 mL) to precipitate out a dark brown solid. 
The solid was then dried under vacuum to give 47.2 mg (0.142 mmol, 71%). 
1
H NMR 
(400 MHz, CD2Cl2) δ 9.17 (dd, J = 7.9, 1.1 Hz, 2H), 8.30 (dd, J = 8.3, 1.5 Hz, 2H), 8.25 
(dd, J = 7.9, 1.5 Hz, 2H), 7.60 (t, J = 8.0 Hz, 2H), 7.56 – 7.47 (m, 4H), 7.44 – 7.33 (m, 
4H), 7.27 (dd, J = 8.2, 5.1 Hz, 2H), 6.78 (dd, J = 7.9, 1.2 Hz, 2H). 
13
C{
1
H} NMR (100 
MHz, CD2Cl2) δ 167.03, 151.78, 149.18, 147.96, 144.85, 139.86, 131.53, 130.92, 130.56, 
130.12, 130.08, 129.27, 122.84, 121.85, 119.71, 119.14. 
 
Heating of [(C16H10N4O)Ni]2 (8a) in J. Young NMR tube. In a glovebox filled with N2. 
A J. Young NMR tube was charged with azanickelacycle 8a (5.0 mg, 0.015 mmol), 
1,3,5-trimethoxybenzene (1.3 mg, 0.0077 mmol), and DMF-d7 (0.90 mL). The J. Young 
NMR tube was taken out of the glovebox and placed in a preheated oil bath at 140 C. 
The reaction was monitored by 
1
H NMR every hour. After 4 h, the oil bath was heated to 
160 C and monitored by 1H NMR every hour.  
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  Perspective view of the molecular structure of [(C16H10N4O)Ni]2 (8a) with the atom 
labeling scheme for the non-hydrogen atoms. The thermal ellipsoids are scaled to enclose 
50% probability. The Ni(1)···Ni(2) interatomic distance is 3.285 Å. The acute dihedral 
angle between the plane containing atoms Ni(1), N(1), N(2), N3), N(8) and the plane 
containing atoms Ni(2), N(4), N5), N(6), N(7) is 77.2º. 
  
Description of the X-ray Structural Analysis of [(C16H10N4O)Ni]2·CH2Cl2  (8a) 
  A dark brown parallelepiped crystal of [(C16H10N4O)Ni]2·CH2Cl2 (8a) was coated in 
polybutene oil (Sigma-Aldrich) and placed on the end of a MiTeGen loop. The sample 
was cooled to 100 K with an Oxford Cryostream 700 system and optically aligned on a 
Bruker AXS D8 Venture fixed-chi X-ray diffractometer equipped with a Triumph 
monochromator, a Mo Kα radiation source ( = 0.71073 Å), and a PHOTON 100 CMOS 
detector. Three sets of 12 frames each were collected using the omega scan method with 
a 10 second exposure time. Integration of these frames followed by reflection indexing 
and least-squares refinement produced a crystal orientation matrix for the monoclinic 
crystal lattice that was used for the structural analysis.  
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  Data collection consisted of the measurement of a total of 1056 frames in four runs 
using omega scans with the detector held at 5.00 cm from the crystal. Frame scan 
parameters are summarized below: 
Data collection details for [(C16H10N4O)Ni]2·CH2Cl2 (8a). 
Run 2θ ω φ  Scan Width (º) Frames Exposure 
Time (sec) 
1 11.01 -171.48 144.00 54.74 0.70 264 60.00 
2 11.01 -171.48 72.00 54.74 0.70 264 60.00 
3 11.01 -171.48 -144.00 54.74 0.70 264 60.00 
4 11.01 -171.48 0.00 54.74 0.70 264 60.00 
 
  The APEX3 software program (version 2016.9-0)
100
 was used for diffractometer 
control, preliminary frame scans, indexing, orientation matrix calculations, least-squares 
refinement of cell parameters, and the data collection. The frames were integrated with 
the Bruker SAINT software package using a narrow-frame algorithm. The integration of 
the data using a monoclinic unit cell yielded a total of 58425 reflections to a maximum θ 
angle of 27.98° (0.76 Å resolution), of which 7038 were independent (average 
redundancy 8.301, completeness = 98.4%, Rint = 6.17%, Rsig = 4.35%) and 5358 
(76.13%) were greater than 2σ(F2). The final cell constants of a = 12.1353(10) Å, b = 
24.815(2) Å, c = 10.1263(9) Å, β = 103.132(2)°, volume = 2969.7(4) Å3, are based upon 
the refinement of the XYZ-centroids of 9287 reflections above 20 σ(I) with 6.174° < 2θ < 
54.87°. Data were corrected for absorption effects using the multi-scan method 
(SADABS). The ratio of minimum to maximum apparent transmission was 0.850. The 
calculated minimum and maximum transmission coefficients (based on crystal size) are 
0.437 and 0.922. 
  The structure was solved by direct methods and difference Fourier analyses using the 
programs provided by SHELXL-2014/7.
101
 Idealized positions for the methylene and 
aromatic hydrogen atoms were included as fixed contributions using a riding model with 
isotropic temperature factors set at 1.2 times that of the adjacent carbon atom. Full-matrix 
least-squares refinement, based upon the minimization of wi |Fo
2
 - Fc
2
|
2
, with weighting 
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wi
-1
 = [2(Fo
2
) + (0.0203 P)
2
 + 2.9372 P], where P = (Max (Fo
2
, 0) + 2 Fc
2
)/3.
2
  The final 
anisotropic full-matrix least-squares refinement on F
2
 with 424 variables converged at R1 
= 3.06 % for the 5358 data with I>2σ(I) and wR2 = 5.58 % for all data. The goodness-of-
fit was 1.016.
102
   
  A correction for secondary extinction was not applied. The largest peak in the final 
difference electron density synthesis was 0.399 e
-
/Å
3
 and the largest hole was -0.545 e
-
/Å
3
 with an RMS deviation of 0.079 e
-
/Å
3
. The linear absorption coefficient, atomic 
scattering factors, and anomalous dispersion corrections were calculated from values 
found in the International Tables of X-ray Crystallography.
103
 
Crystal data for [(C16H10N4O)Ni]2·CH2Cl2 (8a). 
Ident. code jh53cms 
Chem. form. C33H22Cl2N8Ni2O2 
Mol. weight 750.90 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.055 x 0.111 x 0.663 mm 
Cryst. type monoclinic 
Space group P21/c (No. 14) 
Unit cell  a = 12.1353(10) Å α = 90° 
 b = 24.815(2) Å β = 103.132(2)° 
 c = 10.1263(9) Å γ = 90° 
Volume, Å
3
 2969.7(4)   
Z  4 
Density 
(calc) 
1.679 g/cm
3
 
Abs. coeff. 1.497 mm
-1
 
F(000) 1528 
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Data collection and structure refinement for [(C16H10N4O)Ni]2·CH2Cl2 (8a). 
Theta range  2.88 to 27.98° 
Index ranges -15 ≤ h ≤ 15, -32 ≤ k ≤ 32, -13 ≤ l ≤ 13 
Reflections  58425 
Independent refls 7038 [R(int) = 0.0617] 
Coverage  98.4% 
Abs. correction multi-scan 
Max./ min. trans. 0.922 and 0.437 
Refinement method Full-matrix least-squares on F
2
 
Ref.  program SHELXL-2014/7 (Sheldrick, 2014) 
Data / restrs / 
parms 
7038 / 0 / 424 
GOF on F
2
 1.016 
Final R indices 
5358 data; 
I>2σ(I) 
R1 = 0.0306, wR2 = 0.0587 
 all data R1 = 0.0558, wR2 = 0.0655 
Largest diff. peak 
and hole 
0.399 and -0.545 e
-
/Å
3
 
 
Atomic coordinates and equivalent isotropic atomic displacement parameters (Å
2
) 
for [(C16H10N4O)Ni]2·CH2Cl2 (8a).  U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 x/a y/b z/c U(eq) 
Ni1 0.48714(2) 0.20781(2) 0.38695(3) 0.01089(7) 
Ni2 0.21247(2) 0.18842(2) 0.29789(3) 0.01136(7) 
O1 0.63111(13) 0.34317(6) 0.26545(15) 0.0183(3) 
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 x/a y/b z/c U(eq) 
O2 0.05756(13) 0.04119(6) 0.24573(16) 0.0232(4) 
N1 0.59986(14) 0.15761(7) 0.36212(17) 0.0134(4) 
N2 0.56869(14) 0.25817(6) 0.30274(17) 0.0120(4) 
N3 0.37741(14) 0.25818(6) 0.40015(17) 0.0113(3) 
N4 0.27252(14) 0.25286(7) 0.36729(17) 0.0128(4) 
N5 0.11739(14) 0.22296(7) 0.14396(17) 0.0133(4) 
N6 0.13645(14) 0.12434(7) 0.22252(18) 0.0130(4) 
N7 0.31233(14) 0.15094(6) 0.43374(17) 0.0121(4) 
N8 0.41704(14) 0.15655(7) 0.46962(17) 0.0133(4) 
C1 0.61749(18) 0.10772(8) 0.4094(2) 0.0173(5) 
C2 0.69670(19) 0.07351(9) 0.3707(2) 0.0227(5) 
C3 0.75627(19) 0.09119(9) 0.2793(2) 0.0203(5) 
C4 0.73955(18) 0.14411(8) 0.2266(2) 0.0161(4) 
C5 0.79267(18) 0.16575(9) 0.1272(2) 0.0172(5) 
C6 0.77024(18) 0.21788(9) 0.0860(2) 0.0175(5) 
C7 0.69883(17) 0.25184(8) 0.1413(2) 0.0142(4) 
C8 0.64308(17) 0.23187(8) 0.2360(2) 0.0126(4) 
C9 0.66175(17) 0.17688(8) 0.2744(2) 0.0132(4) 
C10 0.57337(17) 0.31253(8) 0.3178(2) 0.0130(4) 
C11 0.50696(17) 0.33581(8) 0.4138(2) 0.0121(4) 
C12 0.53571(18) 0.38774(8) 0.4635(2) 0.0152(4) 
C13 0.48073(18) 0.41252(8) 0.5530(2) 0.0162(4) 
C14 0.39442(18) 0.38582(8) 0.5957(2) 0.0163(4) 
C15 0.36168(17) 0.33496(8) 0.5447(2) 0.0137(4) 
C16 0.41704(17) 0.31082(8) 0.4546(2) 0.0120(4) 
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 x/a y/b z/c U(eq) 
C17 0.10322(18) 0.27529(8) 0.1189(2) 0.0155(4) 
C18 0.03540(18) 0.29448(9) 0.9969(2) 0.0180(5) 
C19 0.98563(18) 0.25885(9) 0.8980(2) 0.0186(5) 
C20 0.00015(17) 0.20288(9) 0.9207(2) 0.0164(4) 
C21 0.95287(18) 0.16230(9) 0.8261(2) 0.0206(5) 
C22 0.97150(18) 0.10920(10) 0.8610(2) 0.0213(5) 
C23 0.03199(17) 0.09301(9) 0.9907(2) 0.0183(5) 
C24 0.07803(17) 0.13135(8) 0.0865(2) 0.0149(4) 
C25 0.06506(16) 0.18645(8) 0.0480(2) 0.0131(4) 
C26 0.11679(17) 0.08050(8) 0.2926(2) 0.0154(4) 
C27 0.16762(17) 0.08165(8) 0.4435(2) 0.0150(4) 
C28 0.11652(19) 0.04896(8) 0.5241(2) 0.0191(5) 
C29 0.15311(19) 0.04724(9) 0.6637(2) 0.0211(5) 
C30 0.2482(2) 0.07672(9) 0.7260(2) 0.0230(5) 
C31 0.30268(19) 0.10861(9) 0.6482(2) 0.0195(5) 
C32 0.26091(17) 0.11193(8) 0.5090(2) 0.0136(4) 
C33 0.7187(2) 0.46528(9) 0.2612(2) 0.0245(5) 
Cl1 0.59581(6) 0.49793(3) 0.16820(7) 0.03478(16) 
Cl2 0.75204(5) 0.48583(2) 0.43372(6) 0.02809(14) 
 
Interatomic distances (Å) for [(C16H10N4O)Ni]2·CH2Cl2 (8a).
 
Ni1-N8 1.8347(17) Ni1-N3 1.8531(17) 
Ni1-N1 1.9086(17) Ni1-N2 1.9109(17) 
Ni2-N4 1.8301(17) Ni2-N7 1.8624(17) 
Ni2-N6 1.9085(16) Ni2-N5 1.9179(17) 
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O1-C10 1.233(2) O2-C26 1.240(2) 
N1-C1 1.327(3) N1-C9 1.373(3) 
N2-C10 1.357(3) N2-C8 1.405(3) 
N3-N4 1.247(2) N3-C16 1.456(2) 
N5-C17 1.327(3) N5-C25 1.374(3) 
N6-C26 1.349(3) N6-C24 1.409(3) 
N7-N8 1.247(2) N7-C32 1.457(3) 
C1-C2 1.404(3) C2-C3 1.370(3) 
C3-C4 1.415(3) C4-C9 1.412(3) 
C4-C5 1.419(3) C5-C6 1.367(3) 
C6-C7 1.413(3) C7-C8 1.384(3) 
C8-C9 1.423(3) C10-C11 1.511(3) 
C11-C16 1.397(3) C11-C12 1.399(3) 
C12-C13 1.385(3) C13-C14 1.389(3) 
C14-C15 1.387(3) C15-C16 1.386(3) 
C17-C18 1.403(3) C18-C19 1.369(3) 
C19-C20 1.412(3) C20-C25 1.409(3) 
C20-C21 1.418(3) C21-C22 1.370(3) 
C22-C23 1.410(3) C23-C24 1.383(3) 
C24-C25 1.421(3) C26-C27 1.513(3) 
C27-C28 1.392(3) C27-C32 1.394(3) 
C28-C29 1.383(3) C29-C30 1.391(3) 
C30-C31 1.386(3) C31-C32 1.388(3) 
C33-Cl1 1.769(2) C33-Cl2 1.776(2) 
 
Bond angles (°) for [(C16H10N4O)Ni]2·CH2Cl2 (8a). 
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N8-Ni1-N3 91.11(7) N8-Ni1-N1 91.61(7) 
N3-Ni1-N1 176.39(7) N8-Ni1-N2 176.23(7) 
N3-Ni1-N2 92.56(7) N1-Ni1-N2 84.77(7) 
N4-Ni2-N7 90.99(7) N4-Ni2-N6 174.70(7) 
N7-Ni2-N6 93.07(7) N4-Ni2-N5 92.02(7) 
N7-Ni2-N5 173.64(7) N6-Ni2-N5 84.29(7) 
C1-N1-C9 119.44(18) C1-N1-Ni1 128.53(15) 
C9-N1-Ni1 111.82(13) C10-N2-C8 120.05(17) 
C10-N2-Ni1 127.76(14) C8-N2-Ni1 111.43(13) 
N4-N3-C16 115.16(16) N4-N3-Ni1 128.01(14) 
C16-N3-Ni1 116.83(13) N3-N4-Ni2 119.21(14) 
C17-N5-C25 119.41(18) C17-N5-Ni2 128.36(15) 
C25-N5-Ni2 112.10(13) C26-N6-C24 120.24(17) 
C26-N6-Ni2 126.06(15) C24-N6-Ni2 112.21(13) 
N8-N7-C32 116.80(17) N8-N7-Ni2 127.46(14) 
C32-N7-Ni2 115.72(13) N7-N8-Ni1 119.45(14) 
N1-C1-C2 121.8(2) C3-C2-C1 119.7(2) 
C2-C3-C4 120.0(2) C9-C4-C3 117.06(19) 
C9-C4-C5 118.19(19) C3-C4-C5 124.7(2) 
C6-C5-C4 118.9(2) C5-C6-C7 122.7(2) 
C8-C7-C6 120.10(19) C7-C8-N2 129.43(19) 
C7-C8-C9 117.39(18) N2-C8-C9 113.18(17) 
N1-C9-C4 121.86(18) N1-C9-C8 115.74(18) 
C4-C9-C8 122.39(19) O1-C10-N2 125.29(19) 
O1-C10-C11 118.64(18) N2-C10-C11 115.96(17) 
C16-C11-C12 116.79(19) C16-C11-C10 125.93(18) 
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C12-C11-C10 117.26(18) C13-C12-C11 121.8(2) 
C12-C13-C14 120.09(19) C15-C14-C13 119.37(19) 
C16-C15-C14 119.86(19) C15-C16-C11 122.04(18) 
C15-C16-N3 117.96(17) C11-C16-N3 119.98(18) 
N5-C17-C18 121.7(2) C19-C18-C17 119.9(2) 
C18-C19-C20 119.9(2) C25-C20-C19 117.17(19) 
C25-C20-C21 117.9(2) C19-C20-C21 124.9(2) 
C22-C21-C20 119.4(2) C21-C22-C23 122.3(2) 
C24-C23-C22 120.0(2) C23-C24-N6 129.3(2) 
C23-C24-C25 117.9(2) N6-C24-C25 112.79(18) 
N5-C25-C20 121.90(19) N5-C25-C24 115.81(18) 
C20-C25-C24 122.27(19) O2-C26-N6 126.1(2) 
O2-C26-C27 117.97(19) N6-C26-C27 115.84(17) 
C28-C27-C32 117.2(2) C28-C27-C26 116.58(19) 
C32-C27-C26 126.21(18) C29-C28-C27 122.3(2) 
C28-C29-C30 119.2(2) C31-C30-C29 119.7(2) 
C30-C31-C32 120.0(2) C31-C32-C27 121.36(19) 
C31-C32-N7 118.01(18) C27-C32-N7 120.50(18) 
Cl1-C33-Cl2 111.59(12)   
 
Anisotropic atomic displacement parameters (Å
2
) for 
[(C16H10N4O)Ni]2·CH2Cl2 (8a). The anisotropic atomic displacement factor 
exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a
*
 b
*
 U12]. 
 U11 U22 U33 U23 U13 U12 
Ni1 0.01075(13) 0.00827(12) 0.01414(14) 0.0004(1) 0.00386(10) -0.0005(1) 
Ni2 0.01095(13) 0.00888(12) 0.01419(14) -0.0003(1) 0.00273(10) -0.0015(1) 
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 U11 U22 U33 U23 U13 U12 
O1 0.0212(8) 0.0122(7) 0.0247(9) 0.0004(6) 0.0120(7) -0.0041(6) 
O2 0.0255(9) 0.0155(8) 0.0276(9) -0.0030(7) 0.0037(7) -0.0093(7) 
N1 0.0125(9) 0.0124(8) 0.0144(9) -0.0011(7) 0.0014(7) -0.0013(7) 
N2 0.0126(9) 0.0107(8) 0.0132(9) 0.0000(7) 0.0042(7) -0.0001(7) 
N3 0.0122(9) 0.0099(8) 0.0122(9) 0.0005(7) 0.0035(7) -0.0012(7) 
N4 0.0125(9) 0.0130(8) 0.0131(9) 0.0005(7) 0.0031(7) -0.0017(7) 
N5 0.0103(9) 0.0147(9) 0.0160(9) 0.0000(7) 0.0052(7) -0.0014(7) 
N6 0.0111(9) 0.0114(8) 0.0165(9) -0.0020(7) 0.0028(7) -0.0014(7) 
N7 0.0140(9) 0.0095(8) 0.0141(9) -0.0020(7) 0.0058(7) -0.0025(7) 
N8 0.0145(9) 0.0119(8) 0.0142(9) -0.0020(7) 0.0049(7) -0.0001(7) 
C1 0.0187(11) 0.0130(10) 0.0200(12) 0.0025(9) 0.0040(9) 0.0007(8) 
C2 0.0244(13) 0.0138(11) 0.0293(13) 0.0011(9) 0.0050(11) 0.0053(9) 
C3 0.0169(11) 0.0162(11) 0.0277(13) -0.0044(9) 0.0048(10) 0.0050(9) 
C4 0.0129(10) 0.0159(10) 0.0185(11) -0.0046(9) 0.0015(9) -0.0010(8) 
C5 0.0118(11) 0.0225(11) 0.0174(11) -0.0062(9) 0.0035(9) -0.0004(9) 
C6 0.0143(11) 0.0235(12) 0.0156(11) -0.0032(9) 0.0052(9) -0.0047(9) 
C7 0.0129(10) 0.0151(10) 0.0139(11) -0.0007(8) 0.0014(9) -0.0025(8) 
C8 0.0099(10) 0.0154(10) 0.0112(10) -0.0035(8) -0.0002(8) -0.0016(8) 
C9 0.0123(10) 0.0144(10) 0.0125(10) -0.0029(8) 0.0021(8) -0.0019(8) 
C10 0.0115(10) 0.0127(9) 0.0139(10) 0.0004(8) 0.0010(8) -0.0007(8) 
C11 0.0121(10) 0.0107(9) 0.0129(10) 0.0025(8) 0.0017(8) 0.0015(8) 
C12 0.0159(11) 0.0105(10) 0.0183(11) 0.0006(8) 0.0018(9) -0.0022(8) 
C13 0.0189(11) 0.0097(10) 0.0188(11) -0.0030(8) 0.0015(9) -0.0006(8) 
C14 0.0181(11) 0.0146(10) 0.0167(11) -0.0023(8) 0.0049(9) 0.0038(8) 
C15 0.0105(10) 0.0144(10) 0.0168(11) 0.0009(8) 0.0046(9) -0.0010(8) 
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 U11 U22 U33 U23 U13 U12 
C16 0.0122(10) 0.0094(9) 0.0135(10) 0.0013(8) 0.0008(8) 0.0000(8) 
C17 0.0134(10) 0.0147(10) 0.0202(11) 0.0004(9) 0.0074(9) -0.0011(8) 
C18 0.0145(11) 0.0190(11) 0.0224(12) 0.0065(9) 0.0082(9) 0.0002(9) 
C19 0.0133(11) 0.0257(12) 0.0181(11) 0.0066(9) 0.0060(9) 0.0018(9) 
C20 0.0093(10) 0.0261(12) 0.0150(11) -0.0001(9) 0.0049(9) -0.0001(9) 
C21 0.0130(11) 0.0328(13) 0.0159(11) -0.0026(10) 0.0029(9) -0.0009(9) 
C22 0.0133(11) 0.0295(13) 0.0207(12) -0.0097(10) 0.0029(9) -0.0030(9) 
C23 0.0112(10) 0.0202(11) 0.0238(12) -0.0058(9) 0.0046(9) -0.0002(9) 
C24 0.0090(10) 0.0185(11) 0.0180(11) -0.0023(9) 0.0047(9) 0.0008(8) 
C25 0.0082(10) 0.0170(10) 0.0156(10) -0.0012(9) 0.0058(8) -0.0003(8) 
C26 0.0117(10) 0.0128(10) 0.0227(12) -0.0022(9) 0.0061(9) -0.0010(8) 
C27 0.0148(11) 0.0106(10) 0.0216(12) -0.0001(8) 0.0083(9) 0.0017(8) 
C28 0.0167(11) 0.0131(10) 0.0287(13) 0.0019(9) 0.0076(10) -0.0021(9) 
C29 0.0267(13) 0.0123(11) 0.0293(13) 0.0046(9) 0.0164(11) 0.0009(9) 
C30 0.0334(14) 0.0188(11) 0.0186(12) 0.0022(9) 0.0099(10) 0.0000(10) 
C31 0.0232(12) 0.0156(11) 0.0198(12) 0.0013(9) 0.0049(10) -0.0032(9) 
C32 0.0155(11) 0.0098(9) 0.0167(11) 0.0009(8) 0.0060(9) -0.0003(8) 
C33 0.0263(13) 0.0151(11) 0.0342(14) -0.0012(10) 0.0111(11) 0.0023(9) 
Cl1 0.0348(4) 0.0289(3) 0.0366(4) -0.0098(3) -0.0002(3) 0.0104(3) 
Cl2 0.0267(3) 0.0210(3) 0.0350(3) -0.0011(2) 0.0038(3) -0.0063(2) 
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Hydrogen atom coordinates and isotropic atomic displacement parameters (Å
2
) for 
[(C16H10N4O)Ni]2·CH2Cl2 (8a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x/a y/b z/c U(eq) 
H1 0.5753 0.0948 0.4713 0.021 
H2 0.7089 0.0383 0.4077 0.027 
H3 0.8088 0.0679 0.2513 0.024 
H5 0.8430 0.1444 0.0898 0.021 
H6 0.8041 0.2318 0.0173 0.021 
H7 0.6890 0.2884 0.1136 0.017 
H12 0.5945 0.4065 0.4352 0.018 
H13 0.5021 0.4478 0.5852 0.019 
H14 0.3581 0.4022 0.6593 0.02 
H15 0.3014 0.3167 0.5714 0.016 
H17 0.1399 0.3004 0.1853 0.019 
H18 0.0240 0.3321 -0.0171 0.022 
H19 -0.0586 0.2718 -0.1857 0.022 
H21 -0.0913 0.1719 -0.2607 0.025 
H22 -0.0574 0.0823 -0.2045 0.026 
H23 0.0411 0.0558 0.0123 0.022 
H28 0.0543 0.0271 0.4816 0.023 
H29 0.1137 0.0262 0.7164 0.025 
H30 0.2757 0.0750 0.8216 0.028 
H31 0.3686 0.1282 0.6902 0.023 
H33A 0.7832 0.4737 0.2198 0.029 
H33B 0.7068 0.4258 0.2564 0.029 
  143 
Synthesis of 2-(quinolin-8-yl)-2,3-dihydro-1H-isoindole-1,3-dione (9a). A round 
bottom flask was charged with phthalic anhydride (0.74 g, 5 mmol) and 8-
aminoquinoline (0.72 g, 5 mmol). Acetic acid (30 mL) was added and the mixture was 
refluxed for 2 hours. The round bottom flask was allowed to cool to room temperature 
and an equal volume of water (30 mL) was added. The mixture was allowed to sit 
overnight and the solid was recovered by filtration. The solid was dried by high vacuum 
to yield 2-(quinolin-8-yl)-2,3-dihydro-1H-isoindole-1,3-dione in 987 mg (3.60 mmol, 72 
%). 
1
H NMR (400 MHz, CDCl3) δ 8.87 (d, J = 4.2 Hz, 1H), 8.24 (dd, J = 8.3, 1.5 Hz, 
1H), 8.04 – 7.94 (m, 3H), 7.81 (ddd, J = 5.4, 3.1, 1.0 Hz, 2H), 7.76 (d, J = 7.3 Hz, 1H), 
7.68 (t, J = 7.7 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 
168.07, 151.05, 144.39, 136.45, 134.30, 132.62, 130.46, 129.88, 129.78, 129.47, 126.33, 
123.99, 122.07. The spectral data is consistent with literature.
98 
 
Synthesis of intermediate (10a). In a N2 filled glovebox, an over dried 20 mL vial with a 
stir bar was charged with phthalimide (9a) (274 mg, 1.00 mmol) and THF (20 mL). In an 
oven dried 100 mL RB flask was charged with THF (15 mL) and Ni(COD)2. Both 
solutions were allowed to stir until starting materials were dissolved. The phthalimide 
containing solution was then added dropwise to the Ni(COD)2 (275 mg, 1.00 mmol) 
solution while stirring vigorously. After complete addition of phthalimide solution, the 
reaction mixture was allowed to stir for 3 h at room temperature. After completion, the 
reaction mixture was filtered in a Buchner funnel with filter paper and washed with Et2O 
(~50 mL). The filtrate was then added to a dried RB flask with Et2O and allowed to sit 
over night to allow any remaining nickel metallacycle to crash out. The filtrate was 
filtered the following morning. The nickel metallacycle was then dried under vacuum for 
2 h yielding 10a in 256 mg as light red solid (0.77 mmol, 77%). 
1
H NMR (400 MHz, 
CD2Cl2) δ 9.08 (d, J = 8.0 Hz, 1H), 8.45 (d, J = 7.9 Hz, 1H), 8.31 (d, J = 9.0 Hz, 1H), 
7.95 (d, J = 4.2 Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.50 – 7.38 (m, 
3H), 7.33 (dd, J = 8.3, 4.9 Hz, 1H). 
13
C{
1
H} NMR (100 MHz, CD2Cl2) δ 268.82, 167.23, 
148.98, 147.47, 143.44, 139.60, 139.55, 138.20, 138.16, 134.01, 131.08, 129.53, 129.00, 
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124.03, 121.90, 120.56, 119.84. FTIR (ATR, cm
-1
): 3041, 1609, 1575, 1557, 1498, 1463, 
1398, 1377, 1338, 1314, 1263, 751. 
 
Synthesis of Ni(II) metallacycle by decarbonylation (11a). In a glovebox filled with 
N2, the nickel metallacycle (10a) (332 mg, 1.00 mmol) was added to an oven dried 40 
mL pressure tube with a stir bar. The PhCH3 (20 ml) was added and the pressure tube was 
closed with a Teflon screw cap. The reaction mixture was then taken out of the glovebox 
and placed in a pre-heated oil bath at 160 C for 2 h. After completion, the reaction 
mixture was taken out of the oil bath and allowed to cool to room temperature. The 
solution was allowed to sit undisturbed for a week while bright yellow crystals formed in 
solution. After the allotted time, the pressure tube was opened and the bright yellow 
crystals were isolated yielding 11a in 33.4 mg (0.100 mmol, 10%). 
1
H NMR (400 MHz, 
CD2Cl2) δ 8.77 (d, J = 7.8 Hz, 1H), 8.55 (d, J = 3.2 Hz, 1H), 8.37 (d, J = 8.4 Hz, 1H), 
7.56 (t, J = 7.9 Hz, 1H), 7.50 (dd, J = 8.3, 4.9 Hz, 1H), 7.43 (d, J = 7.3 Hz, 1H), 7.37 (d, J 
= 8.1 Hz, 1H), 7.23 – 7.16 (m, 1H), 7.12 (dd, J = 4.7, 1.2 Hz, 2H). 13C{1H} NMR (100 
MHz, CD2Cl2) δ 186.96, 150.18, 147.46, 147.02, 146.70, 145.48, 140.29, 137.75, 131.76, 
130.59, 130.01, 128.01, 127.18, 122.45, 119.35, 118.66. FTIR (ATR, cm
-1
): 3050, 2063, 
1634, 1573, 1501, 1466, 1385, 1340, 780. Elemental Analysis: calculated C17H10N2NiO2, 
C: 61.32; H: 3.03; N: 8.41; found, C: 61.37; H: 3.06; N: 8.48. 
 
                             
Before heating complex                       After heating complex      Crystals of complex 11a. 
10a in PhCH3.                                      10a in PhCH3. 
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  Perspective view of the molecular structure of (C16H10N2O)Ni(CO) (11a) with the 
atom labeling scheme for the non-hydrogen atoms. The thermal ellipsoids are scaled to 
enclose 50% probability.  
 
 
Description of the X-ray Structural Analysis of (C16H10N2O)Ni(CO) (11a). 
  A long yellow parallelepiped crystal of (C16H10N2O)Ni(CO) (11a) was coated in 
polybutene oil (Sigma-Aldrich) and placed on the end of a MiTeGen loop. The sample 
was cooled to 100 K with an Oxford Cryostream 700 system and optically aligned on a 
Bruker AXS D8 Venture fixed-chi X-ray diffractometer equipped with a Triumph 
monochromator, a Mo Kα radiation source ( = 0.71073 Å), and a PHOTON 100 CMOS 
detector. Three sets of 12 frames each were collected using the omega scan method with 
a 10 second exposure time. Integration of these frames followed by reflection indexing 
and least-squares refinement produced a crystal orientation matrix for the monoclinic 
crystal lattice that was used for the structural analysis.  
  Data collection consisted of the measurement of a total of 740 frames in four runs 
using omega scans with the detector held at 5.00 cm from the crystal. Frame scan 
parameters are summarized in Table 1 below: 
Data collection details for (C16H10N2O)Ni(CO) (11a). 
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Run 2θ ω φ  Scan Width (º) Frames Exposure 
Time (sec) 
1 16.35 -166.34 -156.00 54.74 1.00 185 60.00 
2 16.35 -166.34 -54.00 54.74 1.00 185 60.00 
3 16.35 -166.34 -105.00 54.74 1.00 185 60.00 
4 16.35 -166.34 153.00 54.74 1.00 185 60.00 
 
  The APEX3 software program (version 2016.9-0)
100
 was used for diffractometer 
control, preliminary frame scans, indexing, orientation matrix calculations, least-squares 
refinement of cell parameters, and the data collection. The frames were integrated with 
the Bruker SAINT software package using a narrow-frame algorithm. The integration of 
the data using a monoclinic unit cell yielded a total of 29130 reflections to a maximum θ 
angle of 30.09° (0.71 Å resolution), of which 3891 were independent (average 
redundancy 7.487, completeness = 99.8%, Rint = 3.05%, Rsig = 1.96%) and 3417 
(87.82%) were greater than 2σ(F2). The final cell constants of a = 10.9298(5) Å, b = 
7.1659(3) Å, c = 17.2345(7) Å, β = 101.0570(10)°, volume = 1324.78(10) Å3, are based 
upon the refinement of the XYZ-centroids of 9902 reflections above 20 σ(I) with 6.174° 
< 2θ < 60.11°. Data were corrected for absorption effects using the multi-scan method 
(SADABS). The ratio of minimum to maximum apparent transmission was 0.859. The 
calculated minimum and maximum transmission coefficients (based on crystal size) are 
0.541 and 0.921. 
 The structure was solved by using the intrinisic phasing routine available in the APEX3 
software100 and refined using the programs provided by SHELXL-2014/7.101 The 
crystallographic asymmetric unit consists of only a molecule of (C16H10N2O)Ni(CO) 
(13a). Idealized positions for the aromatic hydrogen atoms were included as fixed 
contributions using a riding model with isotropic temperature factors set at 1.2 times that 
of the adjacent carbon atom. Full-matrix least-squares refinement, based upon the 
minimization of wi |Fo
2
 - Fc
2
|
2
, with weighting wi
-1
 = [2(Fo
2
) + (0.0254 P)
2
 + 1.0711 P], 
where P = (Max (Fo
2
, 0) + 2 Fc
2
)/3.101 The final anisotropic full-matrix least-squares 
refinement on F
2
 with 199 variables converged at R1 = 2.48 % for the 3417 data with 
I>2σ(I) and wR2 = 6.11 % for all data. The goodness-of-fit was 1.033.101 A correction for 
secondary extinction was not applied. The largest peak in the final difference electron 
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density synthesis was 0.537 e
-
/Å
3
 and the largest hole was -0.290 e
-
/Å
3
 with an RMS 
deviation of 0.063 e
-
/Å
3
. The linear absorption coefficient, atomic scattering factors, and 
anomalous dispersion corrections were calculated from values found in the International 
Tables of X-ray Crystallography.103 
Crystal data for (C16H10N2O)Ni(CO) (11a). 
Ident. code jh54cms 
Chem. form. C17H10N2NiO2 
Mol. weight 332.98 g/mol 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.057 x 0.120 x 0.476 mm 
Cryst. type monoclinic 
Space group P21/c (No. 14) 
Unit cell  a = 10.9298(5) Å α = 90° 
 b = 7.1659(3) Å β = 101.0570(10)° 
 c = 17.2345(7) Å γ = 90° 
Volume, Å
3
 1324.78(10)  
Z  4 
Density 
(calc) 
1.669 g/cm
3
 
Abs. coeff. 1.472 mm
-1
 
F(000) 680 
 
Data collection and structure refinement for (C16H10N2O)Ni(CO) (11a). 
Theta range  3.09 to 30.09° 
Index ranges -15 ≤ h ≤ 15, -10 ≤ k ≤ 10, -22 ≤ l ≤ 24 
Reflections  29130 
Independent refls 3891 [R(int) = 0.0305] 
Coverage  99.8% 
Abs. correction multi-scan 
Max./ min. trans. 0.921 and 0.541 
Refinement method Full-matrix least-squares on F
2
 
Ref.  program SHELXL-2014/7 (Sheldrick, 2014) 
Data / restrs / 
parms 
3891 / 0 / 199 
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GOF on F
2
 1.033 
Final R indices 
3417 data; 
I>2σ(I) 
R1 = 0.0248, wR2 = 0.0586 
 all data R1 = 0.0319, wR2 = 0.0611 
Largest diff. peak 
and hole 
0.537 and -0.290 e
-
/Å
3
 
 
Atomic coordinates and equivalent isotropic atomic displacement parameters (Å
2
) 
for (C16H10N2O)Ni(CO) (11a). U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 x/a y/b z/c U(eq) 
Ni1 0.39088(2) 0.71655(2) 0.50851(2) 0.00949(5) 
O1 0.49582(10) 0.57634(15) 0.30799(6) 0.0178(2) 
O2 0.22921(10) 0.71492(16) 0.62317(7) 0.0227(2) 
N1 0.54072(10) 0.81810(15) 0.57288(6) 0.0102(2) 
N2 0.48904(10) 0.69556(15) 0.43209(6) 0.0104(2) 
C1 0.63842(12) 0.82426(18) 0.53303(7) 0.0102(2) 
C2 0.61147(12) 0.75649(17) 0.45385(7) 0.0103(2) 
C3 0.55955(12) 0.88152(18) 0.64668(8) 0.0126(2) 
C4 0.67458(13) 0.95435(19) 0.68502(8) 0.0148(3) 
C5 0.77259(13) 0.9592(2) 0.64618(8) 0.0157(3) 
C6 0.75693(12) 0.89248(18) 0.56750(8) 0.0126(2) 
C7 0.85140(13) 0.8925(2) 0.52158(9) 0.0164(3) 
C8 0.82440(13) 0.8296(2) 0.44511(9) 0.0164(3) 
C9 0.70522(13) 0.76201(19) 0.41003(8) 0.0137(2) 
C10 0.43969(12) 0.61425(18) 0.36133(7) 0.0119(2) 
C11 0.30521(12) 0.57602(18) 0.35883(8) 0.0121(2) 
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 x/a y/b z/c U(eq) 
C12 0.22833(13) 0.5061(2) 0.29162(8) 0.0171(3) 
C13 0.10260(14) 0.4776(2) 0.29229(9) 0.0222(3) 
C14 0.05619(13) 0.5201(2) 0.35963(10) 0.0220(3) 
C15 0.13410(13) 0.5897(2) 0.42726(9) 0.0169(3) 
C16 0.26083(12) 0.61852(18) 0.42801(8) 0.0126(2) 
C17 0.29259(13) 0.7178(2) 0.57821(8) 0.0148(3) 
 
Interatomic distances (Å) for (C16H10N2O)Ni(CO) (11a).
 
Ni1-C17 1.7584(14) Ni1-N2 1.8574(11) 
Ni1-C16 1.9189(13) Ni1-N1 1.9354(11) 
O1-C10 1.2294(16) O2-C17 1.1344(17) 
N1-C3 1.3290(17) N1-C1 1.3766(16) 
N2-C10 1.3658(17) N2-C2 1.3890(16) 
C1-C6 1.4052(18) C1-C2 1.4250(18) 
C2-C9 1.3852(17) C3-C4 1.4039(19) 
C4-C5 1.368(2) C5-C6 1.4168(19) 
C6-C7 1.4163(19) C7-C8 1.370(2) 
C8-C9 1.4125(19) C10-C11 1.4876(18) 
C11-C12 1.3878(19) C11-C16 1.4041(18) 
C12-C13 1.392(2) C13-C14 1.387(2) 
C14-C15 1.397(2) C15-C16 1.3980(19) 
 
          
Bond angles (°) for (C16H10N2O)Ni(CO) (11a). 
C17-Ni1-N2 175.14(6) C17-Ni1-C16 91.77(6) 
N2-Ni1-C16 84.62(5) C17-Ni1-N1 99.62(6) 
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N2-Ni1-N1 84.06(5) C16-Ni1-N1 168.56(5) 
C3-N1-C1 118.29(11) C3-N1-Ni1 129.48(9) 
C1-N1-Ni1 112.22(8) C10-N2-C2 124.76(11) 
C10-N2-Ni1 119.00(9) C2-N2-Ni1 116.15(8) 
N1-C1-C6 122.72(12) N1-C1-C2 115.41(11) 
C6-C1-C2 121.86(12) C9-C2-N2 129.56(12) 
C9-C2-C1 118.27(12) N2-C2-C1 112.16(11) 
N1-C3-C4 122.54(12) C5-C4-C3 119.57(12) 
C4-C5-C6 119.84(13) C1-C6-C7 118.40(12) 
C1-C6-C5 117.02(12) C7-C6-C5 124.58(13) 
C8-C7-C6 119.45(13) C7-C8-C9 122.37(13) 
C2-C9-C8 119.63(13) O1-C10-N2 126.42(12) 
O1-C10-C11 124.72(12) N2-C10-C11 108.86(11) 
C12-C11-C16 122.32(13) C12-C11-C10 121.83(12) 
C16-C11-C10 115.84(11) C11-C12-C13 119.13(14) 
C14-C13-C12 119.68(14) C13-C14-C15 120.96(14) 
C14-C15-C16 120.32(14) C15-C16-C11 117.59(12) 
C15-C16-Ni1 131.00(11) C11-C16-Ni1 111.39(9) 
O2-C17-Ni1 178.66(13)   
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Anisotropic atomic displacement parameters (Å
2
) for (C16H10N2O)Ni(CO) 
(11a). The anisotropic atomic displacement factor exponent takes the form: -
2π2[ h2 a*2 U11 + ... + 2 h k a
*
 b
*
 U12]. 
 U11 U22 U33 U23 U13 U12 
Ni1 0.00930(8) 0.01046(8) 0.00940(8) -0.00005(6) 0.00354(6) -0.00031(6) 
O1 0.0215(5) 0.0220(5) 0.0112(4) -0.0029(4) 0.0063(4) -0.0029(4) 
O2 0.0223(5) 0.0265(6) 0.0232(5) -0.0018(5) 0.0140(4) -0.0033(5) 
N1 0.0111(5) 0.0088(5) 0.0113(5) 0.0018(4) 0.0036(4) 0.0011(4) 
N2 0.0102(5) 0.0123(5) 0.0092(5) 0.0002(4) 0.0028(4) -0.0007(4) 
C1 0.0114(5) 0.0082(5) 0.0114(6) 0.0016(4) 0.0036(4) 0.0006(4) 
C2 0.0116(5) 0.0088(6) 0.0111(6) 0.0008(4) 0.0038(4) 0.0010(4) 
C3 0.0159(6) 0.0108(6) 0.0113(6) 0.0012(5) 0.0035(5) 0.0018(5) 
C4 0.0203(7) 0.0129(6) 0.0102(6) 0.0002(5) 0.0009(5) -0.0007(5) 
C5 0.0156(6) 0.0145(6) 0.0151(6) 0.0007(5) -0.0015(5) -0.0027(5) 
C6 0.0127(6) 0.0103(6) 0.0145(6) 0.0024(5) 0.0021(5) -0.0002(5) 
C7 0.0116(6) 0.0169(6) 0.0213(7) 0.0013(5) 0.0044(5) -0.0024(5) 
C8 0.0142(6) 0.0159(6) 0.0217(7) 0.0014(5) 0.0097(5) -0.0007(5) 
C9 0.0162(6) 0.0121(6) 0.0144(6) -0.0002(5) 0.0070(5) -0.0008(5) 
C10 0.0152(6) 0.0103(6) 0.0100(5) 0.0015(4) 0.0023(5) 0.0002(5) 
C11 0.0137(6) 0.0092(6) 0.0129(6) 0.0014(5) 0.0012(5) 0.0006(5) 
C12 0.0187(7) 0.0153(6) 0.0153(6) -0.0001(5) -0.0019(5) 0.0007(5) 
C13 0.0182(7) 0.0213(7) 0.0231(7) -0.0024(6) -0.0064(6) 0.0002(6) 
C14 0.0118(6) 0.0208(7) 0.0313(8) -0.0004(6) -0.0011(6) -0.0008(5) 
C15 0.0125(6) 0.0158(6) 0.0224(7) 0.0004(5) 0.0035(5) 0.0006(5) 
C16 0.0129(6) 0.0094(6) 0.0150(6) 0.0012(5) 0.0015(5) 0.0002(5) 
C17 0.0151(6) 0.0128(6) 0.0166(6) -0.0010(5) 0.0030(5) -0.0014(5) 
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 U11 U22 U33 U23 U13 U12 
       
Hydrogen atom coordinates and isotropic atomic displacement parameters (Å
2
) for 
(C16H10N2O)Ni(CO) (11a). 
 
 
 
 
 
 
 
 
Synthesis of (2‐nitrophenyl)silver (12a). The title compound was prepared by following 
literature synthesis.
104
 To a mixture of AgF (269 mg, 2.12 mmol) and anhydrous MeCN 
(20 mL) in a glovebox filled with N2, was added a solution of 5,5-dimethyl-2-(2-
nitrophenyl)-[1,3,2]dioxaborinane (499 mg, 2.12 mmol) in MeCN (20 mL). The reaction 
mixture was stirred at room temperature for 24 h while protected from light with 
aluminum foil. The solid was collected by filtration and washed with diethyl ether (~50 
mL), to yield 316 mg (1.37 mmol, 65%) as a bright yellow solid. 
1
H NMR (400 MHz, 
 x/a y/b z/c U(eq) 
H3 0.4926 0.8774 0.6746 0.015 
H4 0.6843 1.0000 0.7376 0.018 
H5 0.8509 1.0071 0.6719 0.019 
H7 0.9328 0.9358 0.5436 0.02 
H8 0.8881 0.8316 0.4146 0.02 
H9 0.6894 0.7205 0.3567 0.016 
H12 0.2611 0.4780 0.2457 0.021 
H13 0.0488 0.4293 0.2468 0.027 
H14 -0.0298 0.5016 0.3598 0.026 
H15 0.1008 0.6175 0.4730 0.02 
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DMSO-d6) δ 8.03 (dd, J = 8.1, 1.2 Hz, 1H), 7.95 (dd, J = 7.0, 1.7 Hz, 1H), 7.54 (td, J = 
7.1, 1.3 Hz, 1H), 7.40 (td, J = 8.4, 8.0, 1.7 Hz, 1H). 
 
Procedure for (hetero)arylation of complex 11a with silver aryls. To a mixture of 
complex 11a (8.3 mg, 0.025 mmol) and anhydrous DMA (1 mL) in a glovebox filled 
with N2, was added a solution of (2‐nitrophenyl)silver(I) (0.025 mmol or 0.050 mmol) in 
anhydrous DMA (1 mL) dropwise. The mixture was stirred at room temperature for 1 h. 
The reaction mixture was taken out of the glovebox and poured into a 100 mL separatory 
funnel. To the solution, water (25 mL), aqueous HCl (2N, 3 mL) were added and 
extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with 
water (3 x 30 mL) and brine (~15 mL), dried over Na2SO4, filtered, and concentrated 
under vacuum. Then 1,3,5-trimethoxybenzene (2.0 mg) was added to the residue and the 
crude mixture was dissolved in CDCl3 for 
1
H analysis. 
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